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A Introduction 
1 The cell-specific transcription factor HNF4A 
The cell-specific transcription factor hepatocyte nuclear factor 4 alpha (HNF4A, NR2A1) is a 
highly conserved member of the nuclear receptor superfamily (Sladek et al., 1990). Other 
members of subfamily 2, group A (Nuclear Receptors Nomenclature Committee 1999), 
include HNF4B (Holewa et al., 1997), so far exclusively identified in Xenopus, and HNF4G 
present in humans (Drewes et al., 1996) and mice (Taraviras et al., 2000).  
HNF4A consists of six structural domains A-F responsible for specific functions (Fig. 1A). 
The A/B domain is positioned at the N-terminus and includes the transactivation domain 
AF-1 comprised of the N-terminal 24 amino acids (Hadzopoulou-Cladaras et al., 1997; Green 
et al., 1998). The DNA binding domain (DBD, C domain), highly conserved among nuclear 
receptors, consists of two zinc fingers and is linked by the flexible D domain to the large 
hydrophobic ligand binding domain (LBD, E domain). This second highly conserved region 
functions as a ligand binding, homodimerisation and second activation domain (AF-2; Jiang 
and Sladek, 1997; Hadzopoulou-Cladaras et al., 1997). Hence, it is involved in transcriptional 
activation and interactions with other transcription factors and coregulators (Ktistaki and 
Talianidis, 1997). In contrast to the majority of nuclear receptors, the C-terminal F domain of 
HNF4A is unusually long and includes a repressor function that inhibits access of 
coactivators to AF-2, and possibly to other regions (Suaud et al., 1999; Sladek et al., 1999).  
 
HNF4A was long considered an orphan receptor as no activity modulating ligand could be 
identified. The search for ligands caused much controversy. Long-chain fatty acids were 
shown to bind as acyl-CoA thioesters to the LBD of HNF4A and function as transactivational 
agonists or antagonists, depending on their chain length and degree of saturation (Hertz et 
al., 1998). Crystal structures of the LBD of bacterially expressed HNF4A confirmed that the 
ligand-binding pocket is occupied by fatty acids, but excluded acyl-CoAs (Dhe-Paganon et 
al., 2002; Wisely et al., 2002; Duda et al., 2004). Fatty acids were bound firmly and could not 
be exchanged, suggesting that HNF4A is constitutively bound and activated by fatty acids. 
Hence, fatty acids seemed to act more as structural cofactors rather than classical regulatory 
ligands (Benoit et al., 2004). However, in a recent study, mammalian expressed HNF4A was 
shown to be bound to the essential fatty acid linoleic acid (LA; C18:2). Although binding is 
reversible, no effect was observed on the transactivation function of HNF4A (Yuan et al., 
2009). 
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Figure 1: HNF4A gene structure (A) and isoforms (B).  
(A) The six structural (A-F) and functional domains are illustrated above the exon structure (not drawn 
to scale). The P2 and P1 specific exon 1D and 1A are indicated by red and green, respectively. Novel 
exon 1E (P2) is given in pink. Transcriptional termination at a polyadenylation signal (PAS) in intron 8 
(8+) results in an alternative C-terminus (light blue box). Presence of 10 amino acids due to alternative 
splicing at exon 9 is indicated by a black box. The presence and significance of exon 1B is not clearly 
established. (B) The P1 and P2 specific isoforms and their exon structure are listed, excluding 
disputable isoforms HNF4A4/5/6. Abbreviations: Activation function 1 (AF-1); DNA binding domain 
(DBD); non-conserved “hinge” region; multi-functional domain for ligand-binding domain (LBD), 
receptor dimerization and activation function 2 (AF-2); inhibitory “F” domain. (Figure adapted from 
Huang et al., 2009a). 
 
Several other endogenous or external circumstances are known to influence the 
transcriptional activity or expression of HNF4A. These include bile acids (Zhang and Chiang, 
2001), cytokines (Li et al., 2006b), hypoxia (Mazure et al., 2001), diet (Viollet et al., 1997), 
exposure to drugs (Hertz et al., 2001) and nitric oxide (NO; Vossen and Erard, 2002). 
Furthermore, HNF4A function is modulated by phosphorylation (Jiang et al., 1997; Sun et al., 
2007; Gonzalez, 2008) as well as methylation (Barrero and Malik, 2006) and acetylation 
(Soutoglou et al., 2000). Its expression is regulated by a variety of different transcription 
factors that target both promoter and enhancer sequences (Hatzis and Talianidis, 2001; 
Bailly et al., 2009) and is also autoregulated by HNF4A itself (Hatzis and Talianidis, 2001; 
HNF4A1/A2
HNF4A3
HNF4A7/A8
HNF4A9
HNF4A10/A11
HNF4A12
(A)
(B)
A/B               C                 D                      D/E                         F
AF-1                 DBD         hinge        LBD/dimerization
AF-2 inhibitory “F“
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Magenheim et al., 2005; Bailly et al., 2009). Interestingly, HNF4A, HNF1A and HNF1B, which 
have key roles in embryonic development and in mature homeostasis, are part of an 
autoregulatory network in mammalian pancreas, kidney, liver and gut (Ferrer, 2002; Harries 
et al., 2009). However, expression of HNF4A is not dependent on HNF1A in hepatocytes 
(Boj et al., 2001; Ferrer, 2002). Taken together, the versatile interactions of HNF4A with a 
variety of different transcription factors, coregulators and modifying enzymes can cause up- 
and downregulation of HNF4A as well as increased and decreased transcriptional activity 
(Sladek and Seidel, 2001; Kyrmizi et al., 2006; Gonzalez, 2008; Tomaru et al., 2009). 
 
In humans, the HNF4A gene spans about 74 kb on chromosome 20 and comprises at least 
12 exons (Avraham et al., 1992; Drewes et al., 1996; Sladek and Seidel, 2001; Huang et al., 
2009a). Two promoters, P1 and P2, have been identified that drive the expression of at least 
six different splice variants (HNF4A1-A3 and HNF4A7-A9; Fig. 1B). Expression of predicted 
variants HNF4A4-A6 is controversial (Drewes et al., 1996; Huang et al., 2008; Harries et al., 
2008) and therefore not included in Figure 1B. Recently, three new isoforms (HNF4A10-A12) 
were described (Huang et al., 2009a) including exon 1E that was previously not detected. 
The proximal P1 and distal P2 promoter are separated by about 45.5 kb in the human 
HNF4A gene (Thomas et al., 2001). Despite the conserved structure in rodents, the two 
promoters are located approximately 36.6 kb and 40.2 kb apart in rat and mouse, 
respectively (Huang et al., 2009a). AF-1 is exclusively contained in proteins derived from the 
P1 promoter due to the P1 and P2 promoter specific first exon 1A and 1D, respectively. The 
isoform specific differences in the F domain are splice dependent. Importantly, the variant-
specific domain makeup causes functional variations (Sladek et al., 1999; Torres-Padilla et 
al., 2001; Eeckhoute et al., 2003; Briancon and Weiss, 2006). HNF4A2 (P1), used in this 
work contains a 10 amino acid insert in the middle of the F domain in comparison to the 
initially identified HNF4A1 (Sladek et al., 1999). The corresponding isoform HNF4A8 is 
expressed from the P2 promoter and thus lacks AF-1. The use of the two promoters 
including distinct regulatory elements, in a temporal and spatial-specific fashion results in a 
complex regulation of the isoforms and their different physiological roles (Torres-Padilla et 
al., 2001; Kyrmizi et al., 2006; Huang et al., 2008; Harries et al., 2008). The major tissues in 
which the P1 promoter is active includes the adult kidney, liver, stomach and colon as well as 
fetal liver and pancreas. The P2 promoter is predominantly expressed in adult colon, 
pancreas, stomach and small intestine as well as in fetal pancreas and liver (Bolotin et al., 
2010). In other tissues expressing HNF4A the promoter usage has not been established.  
 
HNF4A usually binds as a homodimer (Jiang et al., 1995) to a direct repeat element 
(AGGTCA) with either a one or two nucleotide spacer, designated DR1 or DR2, respectively, 
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in the regulatory sequences of its target genes (Jiang and Sladek, 1997; Ellrott et al., 2002). 
However, HNF4A is predicted to bind to thousands of different variations of the response 
element (Badis et al., 2009). To regulate gene expression, transcriptional coactivators and 
other accessory proteins are recruited by HNF4A. Many sites targeted by HNF4A are also 
bound by other nuclear receptors including COUP transcription factors, RXR and PPARs, 
resulting in the expression of many of the same genes.  
The impact of HNF4A on gene regulation has been elucidated by identifying numerous target 
genes in several tissues involved in various processes such as homeostasis, metabolism, 
immune and stress response, cell structure, apoptosis and cancer. A list of target genes can 
be found at http://www.sladeklab.ucr.edu/hnf43.pdf. In the liver many target genes of HNF4A 
were initially identified by classical techniques such as promoter deletions, gel shifts and 
luciferase assays. Recently genome-wide techniques have been applied to identify more 
than a thousand potential target genes in the liver, but also in other tissues such as kidney 
and pancreas. Expression profiles of HNF4A regulated genes have been determined in 
different human cell lines including HEK293 (embryonic kidney; Lucas et al., 2005; Grigo et 
al., 2008), HuH-7 (hepatocyte; Naiki et al., 2002), HepG2 (hepatocyte; Bolotin et al., 2009), 
HCT116 (colon; Yuan et al., 2009) and in human liver (Boj et al., 2009), as well as in different 
mouse and rat tissues (Garrison et al., 2006; Battle et al., 2006; Waxman and O'Connor, 
2006; Erdmann et al., 2007; Gupta et al., 2007; Ishikawa et al., 2008; Boj et al., 2009; 
Darsigny et al., 2009). ChIP-chip analyses were performed in hepatocytes purified from 
human (Odom et al., 2004; Odom et al., 2006; Odom et al., 2007) and mouse liver (Odom et 
al., 2007), HepG2 cells (Rada-Iglesias et al., 2005; Wallerman et al., 2009), pancreatic islets 
(Odom et al., 2004), the human intestinal cell line CaCo2 (Boyd et al., 2009) and in liver of 
human, mouse, dog, opossum and chicken by ChIP-seq (Schmidt et al., 2010). However, 
which of these genes are directly dependent on HNF4A in vivo and the functional 
significance of this binding, remains to be analyzed.  
 
HNF4A plays an important role in early embryogenesis. This transcription factor is present as 
a maternal component in the Xenopus egg (Holewa et al., 1996) and is detected in the 
primary endoderm of mouse embryos at day 4.5 (Duncan et al., 1994). Its essential function 
in vertebrate development is evident in homozygous knockout mice that die during early 
gastrulation due to dysfunction of the visceral endoderm (Chen et al., 1994; Duncan et al., 
1997). Furthermore, HNF4A is essential in the adult as shown by severe defects in mice 
lacking hepatic Hnf4a expression resulting in death within six weeks (Hayhurst et al., 2001). 
HNF4A is crucial to establish and maintain the heptatocyte phenotype by regulating genes 
involved in the control of lipid homeostasis (Li et al., 2000; Hayhurst et al., 2001; Naiki et al., 
2005) and the liver architecture (Parviz et al., 2003; Battle et al., 2006). In the embryonic 
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liver, HNF4A expression is driven by the P1 and P2 promoter, while in adults, the P1 
promoter is mainly active. Hence, in the adult liver Hnf4a2 is the main isoform besides 
Hnf4a1, while Hnf4a7 and Hnf4a8 are absent (Nakhei et al., 1998; Torres-Padilla et al., 
2001).  
In addition to the liver, where HNF4A (A1) was initially identified (Costa et al., 1989), HNF4A 
function in the pancreas has been quite thoroughly investigated. It is expressed in the 
endocrine and exocrine cells of the pancreas, although at a lower level than in liver (Miquerol 
et al., 1994; Tanaka et al., 2006; Nammo et al., 2008). Hnf4a was described to regulate the 
expression of genes associated with β-cell glucose metabolism and insulin secretion in rat 
insulinoma cells (INS-1; Wang et al., 2000). Location analysis, which combined ChIP with a 
custom DNA microarray containing parts of the promoter regions of 13,000 human genes, 
resulted in the presumption that HNF4A regulates >40% of the active promoters in the islets 
(Odom et al., 2004). The vast majority of genes were not verified in β-cell-specific Hnf4a 
knockout mice. Although there is substantial discrepancy in the different studies concerning 
HNF4A targets genes and HNF4A dependent phenotype, disruption of Hnf4a in β-cells of 
mice causes impaired glucose tolerance due to attenuated glucose-stimulated insulin 
secretion (Gupta et al., 2005; Miura et al., 2006; Gupta et al., 2007). Furthermore, Hnf4a 
seems to be essential for adult β-cell mass expansion upon enhanced metabolic demand 
(Gupta et al., 2007). In humans, transcripts derived from the P1 promoter comprise up to 
23% of total HNF4A expression in fetal pancreas from nine weeks until at least 19-26 weeks 
post-conception (Harries et al., 2008). Hnf4a mRNAs transcribed from both promoters are 
also detected in mouse pancreas during embryonic periods (Kanazawa et al., 2009). Several 
reports constrained HNF4A expression in the adult to the P2 promoter in human and rat 
pancreases (Thomas et al., 2001; Boj et al., 2001; Hansen et al., 2002; Ihara et al., 2005; 
Tanaka et al., 2006). This is in contrast to one study reporting the expression of P1 specific 
isoforms in human adult β-cells (Eeckhoute et al., 2003). 
Despite high expression of HNF4A in selected parts of the kidney, little is known about its 
functions in this organ. In the metanephros of the mouse, Hnf4a is initially detected in the 
epithelial cells of the comma-shaped body, then distributed widely throughout the developing 
nephron and is finally restricted to the proximal tubules (Taraviras et al., 1994; Kanazawa et 
al., 2009). Hnf4a expression in those embryonic periods is driven by both promoters, but 
predominantly by P1 (Kanazawa et al., 2009). In the adult kidney, HNF4A expression is 
observed in the proximal tubules as determined in human kidney tissue specimens 
(Chabardes-Garonne et al., 2003; Tanaka et al., 2006) and verified on protein level (Jiang et 
al., 2003). HNF4A is not detected in the glomerulus, distal and collecting tubular epithelial 
cells of the kidney nor in HEK293 cells (Jiang et al., 2003; Lucas et al., 2005; Tanaka et al., 
2006). In the adult kidney, HNF4A expression is restricted to the P1 promoter in humans, 
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mouse and rat as established on RNA and protein level (Nakhei et al., 1998; Jiang et al., 
2003; Tanaka et al., 2006; Kanazawa et al., 2009).    
2 HNF4A and human diseases  
In humans, no homozygous mutations have been identified in HNF4A, consistent with the 
embryonic lethality in mice (Chen et al., 1994; Ellard and Colclough, 2006). However, 
monoallelic mutations in the HNF4A gene have been directly linked to Maturity Onset 
Diabetes of the Young 1 (MODY1; Yamagata et al., 1996). In addition, a mutation in the 
HNF4A binding site within the HNF1A promoter has been associated with MODY3 (Gragnoli 
et al., 1997). Indirectly, HNF4A is linked to many human diseases via the target genes it 
regulates. Due to the impact on the majority of apolipoproteins in the liver, a role in 
atherosclerosis is suggested (Sladek and Seidel, 2001). Increasing evidence links HNF4A 
misregulation to the pathogenesis of various human cancers (Tanaka et al., 2006). The 
tumor repressive effect is supported by findings that HNF4A inhibits cell proliferation in 
various cell types, including murine hepatocellular carcinoma cells (Lazarevich et al., 2004; 
Yin et al., 2008), endothelial lung and embryonal carcinoma cells (Chiba et al., 2005), 
insulinoma cells (Erdmann et al., 2007) as well as embryonic kidney cells (Lucas et al., 2005; 
Grigo et al., 2008).  
2.1 Diabetes  
The pancreas is comprised of exocrine and endocrine (<5%) parts. The latter consists of the 
islets of Langerhans which includes five cell types: glucagon-producing α-cells, insulin-
producing β-cells, somatostatin-producing δ-cells, ghrelin-producing ε-cells and pancreatic 
polypeptide-producing cells. Heterozygous mutations in the coding sequence of the human 
HNF4A gene or in the P2 promoter lead to MODY1 (Bell et al., 1991; Yamagata et al., 1996; 
Harries et al., 2008), while mice heterozygous for Hnf4a show no signs of diabetes (Stoffel 
and Duncan, 1997). This form of type 2 diabetes mellitus (T2DM) is characterized by an 
autosomal dominant mode of inheritance, early onset around 20 to 40 years of age and 
impaired glucose-stimulated insulin secretion due to pancreatic β-cell dysfunction (Yamagata 
et al., 1996; Ryffel, 2001; Owen and Hattersley, 2001). Infants heterozygous for HNF4A may 
exhibit macrosomia and hypoglycemia at birth, reflecting increased insulin secretion in utero 
and during the neonatal period, respectively (Pearson et al., 2007). However, pancreatic 
β-cells usually produce adequate insulin at first and insulin deficiency is slowly progressive 
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resulting in overt hyperglycemia typically in early adulthood (Hattersley, 1998). The age-
related penetrance varies considerably, but by the age of 55, about 95% of mutation carriers 
have developed diabetes (Frayling et al., 2001). Since many studies exclude a dominant-
negative effect of the mutated HNF4A, but rather imply a loss-of-function mechanism, a 
haploinsufficiency mechanism is discussed (Stoffel and Duncan, 1997; Sladek et al., 1998; 
Navas et al., 1999; Lausen et al., 2000). In accordance with that assumption, are the 
identified mutations in the P2 promoter of HNF4A. The complex regulation of HNF4A via both 
promoters, resulting in various isoforms at different time points in the pancreas has been 
described above. The distinct isoforms give rise to proteins with different properties 
functioning in a unique network. Hence, depending on the location of the mutation, different 
isoforms and subsequent interaction partners are affected, which might at least in part 
explain the differential diabetic phenotype of HNF4A mutation carriers (Harries et al., 2008; 
Harries et al., 2009). Up to date 45 different HNF4A mutations in 190 patients from 58 
families have been identified (Harries et al., 2008). The R154X MODY mutation, which 
results in a truncated protein lacking most of the ligand binding domain (Lindner et al., 1997; 
Laine et al., 2000) is used in this work. Given the large number of genes regulated by 
HNF4A, a pleiotropic phenotype is expected. However, MODY1 patients show only few 
symptoms in other organs (Froguel and Velho, 1999). In some HNF4A mutation carriers low 
levels of triglycerides, lipoprotein(a) and apolipoproteins (AII and CIII) have been noticed,  
indicating a primary hepatic defect (Lehto et al., 1999; Shih et al., 2000).  
 
The common late-onset T2DM is characterized by relative insulin deficiency due to defective 
insulin secretion and/or insulin sensitivity (Martin et al., 1992; DeFronzo et al., 1992; Weyer 
et al., 1999). Although this complex heterogenous disease is considered a polygenic 
disorder, little is known about the responsible genes. Several groups have observed linkage 
of T2DM to chromosome 20q12-q13.1, the region HNF4A is localized in (Zouali et al., 1997; 
Bowden et al., 1997; Ghosh et al., 1999; Klupa et al., 2000; Permutt et al., 2001). Hence, an 
important role for HNF4A in T2DM is suggested (Gupta and Kaestner, 2004), which is 
significantly downregulated in pancreatic islets of patients with T2DM (Gunton et al., 2005). 
One study reported that a deletion of seven base pairs in the proximal promoter, deleting a 
single putative Sp1 binding site, can confer a severe form of T2DM causing renal target 
organ damage (Price et al., 2000). Single nucleotide polymorphisms (SNPs) in the promoter 
area as well as in exon 1-3 of HNF4A were associated with T2DM (Silander et al., 2004; 
Love-Gregory et al., 2004; Damcott et al., 2004). Furthermore, Hnf4a was shown to be 
essential for adult β-cell mass expansion upon increased metabolic demand, the failure of 
which is a hallmark of T2DM (Dickson and Rhodes, 2004; Gupta et al., 2007). In addition 
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there is evidence that loss of Hnf4a in other organs such as liver contribute to the 
progression to T2DM. (Zhu et al., 2003; Gupta et al., 2005).  
 
Recently, microRNAs (miRNAs) were shown to be required during pancreas development by 
conditional Dicer knockout early in pancreas development in mice (Lynn et al., 2007). 
Although severe defects were observed in all pancreatic lineages, the β-cells were reduced 
the most. miRNAs are reported to play significant roles in insulin production, action and 
secretion as well as in diverse parts of glucose and lipid metabolism, indicating a critical role 
in the pathogenesis and progression of diabetes (Tang et al., 2008; Pandey et al., 2009). An 
example is miR-375, which is the most abundant intra-islet miRNA (Bravo-Egana et al., 
2008) and was shown to directly target myotrophin (Mtpn), which inhibits insulin secretion 
and 3'-phosphoinositide-dependent protein kinase-1 (PDK1). miR-375 suppresses glucose-
stimulated insulin secretion in a calcium independent manner, while inhibition of miR-375 
enhanced insulin release (Poy et al., 2004; El Ouaamari A. et al., 2008). Furthermore, a role 
in pancreatic β-cell development is suggested due to decreased total β-cell mass and insulin 
levels in mice with homozygous deletion of miR-375 (Poy et al., 2007). Several other 
miRNAs have been experimentally linked to diabetes (Tang et al., 2008; Pandey et al., 
2009). A few miRNA microarrays have been performed, comparing miRNA expression in 
mouse embryonic pancreas at two different developmental stages (Baroukh et al., 2007), in 
the mouse insulinoma cell line MIN6B1 exposed to fatty acid (palmitate; Lovis et al., 2008) 
and in MIN6 cells in response to changes in glucose concentrations (Tang et al., 2009). 
Although those analyses shed some light on the potential role of miRNAs in diabetes, it is not 
known, whether miRNAs are dysregulated in T2DM or MODY and whether they influence 
HNF4A expression.   
2.2 Cancer  
Hepatocellular carcinoma (HCC) is one of the world´s most common cancers. Even though 
epidermal growth factor (EGF) and transforming growth factor α (TGF- α) seem to play an 
important role (Tonjes et al., 1995), the molecular mechanism underlying HCC progression 
remains obscure. HNF4A is known to be a central regulator of the differentiated hepatocyte 
phenotype (Li et al., 2000; Hayhurst et al., 2001; Parviz et al., 2003). Initially, differences in 
the biologic properties of experimental systems and tumor samples gave rise to conflicting 
reports concerning the role of HNF4A in HCC progression (Stumpf et al., 1995; Flodby et al., 
1995; Kalkuhl et al., 1996; Xu et al., 2001; Choi et al., 2004). However, dysfunction of 
HNF4A due to structural aberrations or modification of upstream regulatory signaling 
cascades, has been associated with the progression of rodent and human HCC and 
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contributes to accelerated cell proliferation, loss of epithelial morphology, dedifferentiation 
and the ability for invasion and metastasis (Lazarevich and Fleishman, 2008). Furthermore, 
re-expression of HNF4A in dedifferentiated hepatoma cells results in partial reversion of the 
malignant phenotype both in vitro and in vivo (Lazarevich et al., 2004; Yin et al., 2008). 
Usually the HNF4A P1 promoter is active in the adult liver and decreased P1 promoter 
expression has been reported in HCC (Tanaka et al., 2006). Recently a switch from P1 to P2 
expression was detected in transgenic livers and HCCs of EGF overexpressing mice and 
human HCCs. The switch to fetal liver programs in HCC is presumed to predispose liver cells 
to malignant transformation prior to loss of HNF4A expression (Niehof and Borlak, 2008).  
 
Renal cell carcinoma (RCC) is a type of kidney cancer that accounts for 3% of all 
malignancies and is classified into different subtypes including clear cell (cc), papillary (p), 
chromophobe (ch) and colleting duct (c) RCC (Kovacs et al., 1997). Those carcinomas are 
associated with distinct molecular alterations and different clinical outcomes. ccRCC is the 
most common and aggressive form in adults, accounting for 70-80% of kidney cancers 
(Jones and Libermann, 2007). The genetics of ccRCC are distinctive, but in most cases 
somatic or germline inactivating mutations in the von Hippel-Lindau (VHL) gene have been 
reported (Kaelin and Maher, 1998; Dalgliesh et al., 2010). Under normal oxygen pressure 
VHL causes the degradation of hypoxia-inducible factors (HIFs). VHL inactivation results in 
accumulation of HIFs which triggers transcription of genes such as VEGF, PDGF-β, TGF-α 
and EPO involved in angiogenesis, cell growth, migration and proliferation (Gnarra et al., 
1993; Calzada and del, 2007; Rathmell and Chen, 2008). However, other molecular factors 
associated with RCC initiation and progression are largely unknown. To gain insight into the 
mechanism of RCC, several microarray analyses have been performed over the years. 
However, there is very little agreement as to which genes are differentially regulated among 
these studies (Lenburg et al., 2003). Those genes repeatedly identified as differentially 
expressed genes in RCC are involved in a broad range of processes such as glycolysis, cell 
adhesion, signal transduction, or nucleotide metabolism (Greenman et al., 2007). However, 
due to the various discrepancies among the studies, genes that failed to be identified multiple 
times might still be essential for RCC progression. Gene specific analyses are needed to 
clarify which factors are indeed associated with RCC. Expression of HNF4A is 4.7 fold 
downregulated in RCC compared to normal tissue (Lenburg et al., 2003). Furthermore, the 
amount and DNA binding activity of HNF4A is reduced in RCC compared to normal tissue 
(Sel et al., 1996). Overexpression of HNF4A in the HEK293 cell line results in a decrease in 
cell proliferation and is accompanied by a failure of cells to grow in an epithelium-like 
monolayer (Lucas et al., 2005). HNF4A dependent microarray analyses in those cells 
revealed several target genes that have been shown to be deregulated in RCC (ACY1, WT1, 
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SELENBP1, COBL, EFHD1, AGXT2L1, ALDH5A1, THEM2, ABCB1, FLJ14146, CSPG2, 
TRIM9 and HEY1; Lucas et al., 2005). HNF4A has been described to function in a network of 
transcription factors including HNF1A and HNF1B that control gene expression in embryonic 
and adult tissues, particularly in liver, pancreas and kidney (Ferrer, 2002; Harries et al., 
2009). Misregulation of HNF1A and HNF1B has been suggested as predisposing factors 
contributing to renal tumors (Sel et al., 1996; Rebouissou et al., 2005). HNF1B is expressed 
along the length of the nephron, whereas HNF1A expression is restricted to the proximal 
tubules comparable to HNF4A. The two most common forms of RCC, ccRCC and pRCC, 
originate from the proximal tubules as well. mRNA expression of HNF1A and HNF4A seems 
to be co-regulated in tumor and non-tumor renal tissue (Rebouissou et al., 2005) and 
disruption of the HNF4A/HNF1A pathway is assumed to be a molecular event contributing to 
renal cell carcinogenesis (Sel et al., 1996). Taken together, loss of HNF4A function might 
contribute to the progression of RCC (Lucas et al., 2005). However, so far no mutation in the 
HNF4A gene has been identified (Lausen et al., 2000; Dalgliesh et al., 2010) that may 
explain the downregulation of HNF4A in RCC. 
 
Various mice with conditional Dicer knockout in different parts of the kidney have been 
generated, revealing a critical role for miRNAs in kidney development and maintenance of 
function (Saal and Harvey, 2009). In addition, several miRNA expression profiles from 
mouse, rat and human kidney, identified an overlap of 73 miRNAs with conserved expression 
in the kidney (Saal and Harvey, 2009). For a few miRNAs a specific target and function have 
been described and some of them have been linked to kidney diseases such as diabetic 
nephropathy and polycystic kidney disease (Saal and Harvey, 2009; Kato et al., 2009). 
miRNA expression profilings in RCC have revealed a large number of miRNAs that are either 
up- or downregulated in the tumors compared to normal tissue (Gottardo et al., 2007; Dutta 
et al., 2007; Kort et al., 2008; Nakada et al., 2008; Jung et al., 2009; Petillo et al., 2009; 
Huang et al., 2009b; Chow et al., 2010; Juan et al., 2010). A recent study set out to identify 
direct mRNA targets of miRNAs dysregulated in RCC (Liu et al., 2010). The method is mainly 
based on the anti-correlation of miRNA/mRNA levels strongly dysregulated in tumor versus 
normal cells of the same patient. Several miRNA/mRNA pairs were identified and the 
reduction of SEMA6A upon pre-miR-141 expression was confirmed by semi-quantitative 
RT-PCR. Another study reported the downregulation of Kallikrein-related peptidase 1 (KLK1) 
protein by miR-224 and a decrease in luciferase activity of a KLK1 reporter upon let-7f 
transfection (White et al., 2010). Even in those two examples where functional assays were 
applied, the specific interaction of the miRNA with the target site in the mRNA was not 
proven. Ago1 is expressed at a low to medium level in most tissues, but particularly high in 
embryonic kidney. In Wilms` tumor, the most frequent renal tumor in children, that lack the 
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Wilms` tumor suppressor gene WT1, Ago1 expression is increased (Carmell et al., 2002). 
Despite good indication for miRNA misregulation in RCC, direct linkage of those miRNAs to 
the corresponding mRNAs with regards to RCC by functional assays is still missing.  
3 Transcriptional and posttranscriptional regulation 
3.1 Promoter regulation by transcription factors 
Transcription is the first step of a process that converts the encoded information from the 
DNA into RNA which is then translated into protein. Gene expression is regulated at several 
steps, but regulation at transcription initiation is most commonly studied (Maston et al., 
2006). A promoter is composed of a core promoter and proximal regulatory elements which 
together usually span less than 1 kb. Distal regulatory elements can include enhancers, 
silencers, insulators, and locus control regions (LCR) which can be spread up to 1 Mb away 
from the promoter. All cis-acting transcriptional regulatory elements are targeted by trans-
acting transcription factors that can either enhance or repress transcription. In case of protein 
coding genes, general transcription factors, required for transcription of almost all genes, 
assemble on the core promoter, direct RNA polymerase II to the transcription start site and 
can cause basal transcription. About 1850 promoter specific transcription factors have been 
discovered that bind to upstream regulatory elements (6-12 bp DNA binding site) and greatly 
enhance transcriptional activity in a spatial and temporal fashion. The numerous transcription 
factors are distinguished from each other by different DNA-binding domains such as zinc 
finger (Laity et al., 2001), helix-turn-helix (Wintjens and Rooman, 1996), basic leucine zipper 
domain (Vinson et al., 2002) and many more (Pabo and Sauer, 1992). Interaction of different 
regulatory elements is achieved by looping out intervening DNA and coactivators often 
provide a link between different proteins without binding to DNA themselves (Maston et al., 
2006). However, transcriptional regulation is even more complex and is influenced by 
chromatin structure and by histone modifications such as methylation and acetylation (Li et 
al., 2007a). Transcriptional elongation, in which the RNA transcript is synthesized, is followed 
by the termination process, when dissociation of the polymerase, DNA template and RNA 
transcript takes place.  
As sequence specific binding of transcription factors to promoters is a critical component of 
transcriptional control, sequence variations in the target site may alter or abolish the binding 
capacity (Kadonaga, 2004). Disruption of the normal process of gene expression, 
subsequently increases or decreases the amount of mRNA and thus protein (Cooper, 2002). 
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Mutations in transcription factor binding sites likely underlie a substantial component of the 
phenotypic variability within and across species (Wray, 2007). Furthermore, several 
mutations in the different transcriptional regulatory elements have been linked to human 
diseases (Maston et al., 2006) such as β-thalassemia (Hardison et al., 2002), Bernard-
Soulier syndrome (Ludlow et al., 1996) and pyruvate kinase deficiency (Manco et al., 2000; 
van et al., 2003). In hemophila B (Crossley and Brownlee, 1990; Reijnen et al., 1992; Carew 
et al., 2000) and MODY3 (Gragnoli et al., 1997), the mutations are in part located within 
HNF4A binding sites. Despite the known impact of promoter mutations on gene expression, 
promoter analysis is not a regular part of DNA diagnostics and of a total of 85,558 registered 
mutations in the Human Gene Mutation Database (HGMD) only 1.6% are regulatory 
(Stenson et al., 2009). The majority of those regulatory mutations are located between 
nucleotides +50 and -500 from the transcription start site (de Vooght et al., 2009). In addition, 
59% of functional SNPs were identified in the first 500 nucleotides upstream of the 
transcription start site in human promoters (Rockman and Wray, 2002). Sequence variations 
identified in the HNF4A P2 promoter that are linked to MODY1 have so far been located in 
close vicinity to the transcription start site as well. The first identified HNF4A promoter 
mutation was a heterozygous -146T>C substitution that impairs binding and attenuates the 
transactivation potential of the β-cell-specific transcription factor insulin promoter factor-1 
(IPF-1; Thomas et al., 2001; Hansen et al., 2002). The second mutation causing reduced 
HNF4A activation is located within the HNF1 binding sites at position -181G>A and impairs 
binding of the transcription factor HNF1A (Hansen et al., 2002). Further artificial mutations in 
various transcription factor target sites in the regulatory elements of HNF4A have been 
shown to interfere with gene expression, but have not yet been identified in any diseases 
(Bailly et al., 2009). In other cases, rare variants in the P2 promoter of patients have either 
not correlated with diabetes and/or failed to cause an impaired function in vitro (Mitchell et 
al., 2002; Vaxillaire et al., 2005). It is known that effects of promoter mutations are often 
subtle and difficult to detect (de Vooght et al., 2009). Interestingly, a -192C>G mutation in the 
HNF4A P2 promoter is linked to diabetes in several families as revealed by two independent 
studies and was even shown to disrupt binding of an unidentified protein in vitro (Ek et al., 
2006; Raeder et al., 2006b). However, reporter gene assays did not confirm an effect of this 
mutation in vitro.  
3.2 3’UTR regulation by RNA-binding proteins 
Transcription is intimately linked to processing of pre-mRNA (Proudfoot et al., 2002; 
Rosonina et al., 2006; Moore and Proudfoot, 2009). In human cells, the polyadenylation 
machinery that recognizes and processes poly(A) sites has been shown to involve about 90 
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protein factors (Shi et al., 2009). Both upstream (e.g., PAS) and downstream (e.g., U-rich 
and GU-rich) elements surrounding a poly(A) site are critical for mRNA polyadenylation (Hu 
et al., 2005; Nunes et al., 2010). The length of the poly(A) is species specific and in 
mammals about 150-250 nucleotides long (Brown and Sachs, 1998). About half of the genes 
in mammals contain multiple poly(A) sites that produce transcript variants with different 
3’UTRs or coding regions if the poly(A) site is located within an alternative intron (Tian et al., 
2005). The length of 3’UTRs varies a lot within a species, ranging from several nucleotides to 
a few thousand and is on average about one thousand nucleotides long (Mignone et al., 
2002). Alternative 3’UTRs are usually about two fold longer than constitutive regions and 
contain more cis-elements (Ji et al., 2009). Hence, variant 3’UTRs have been shown to alter 
mRNA metabolism depending on the different cis-elements located in the corresponding 
3’UTR (Majoros and Ohler, 2007; Ji et al., 2009; Mayr and Bartel, 2009). Although 
posttranscriptional regulation was long neglected in research in contrast to transcriptional 
control, it has become evident that the former process is equally as important for normal cell 
function and that its dysfunction is linked to the pathogenesis of many diseases (Danckwardt 
et al., 2008; Chatterjee and Pal, 2009). Eukaryotic 3’UTRs contain several types of repeats 
including short interspersed repetitive elements (SINEs), long interspersed repetitive 
elements (LINEs), minisatellites and microsatellites (Mignone et al., 2002). In general there 
are two main classes, regulatory proteins (Moore, 2005) and miRNAs (Bartel, 2009; Inui et 
al., 2010) that target cis-elements and mediate the 3’UTR dependent control of mRNA 
localization, stability, translation and even transcriptional initiation (Pesole et al., 2000; 
Chatterjee and Pal, 2009; Thomas et al., 2010). 
 
Localization of mRNAs to different subcellular regions allows for a spatial and temporal 
specific regulation of protein expression due to local stimuli (Martin and Ephrussi, 2009; 
Meignin and Davis, 2010). Furthermore, translation of localized mRNAs is more efficient than 
transporting each protein one by one to a specific region. Several localized mRNAs have 
been reported in various species and processes such as bicoid, oskar and nanos mRNAs in 
Drosophila (Johnstone and Lasko, 2001) and VegT in Xenopus (King et al., 2005). In 
addition, localization of several mRNAs has been identified during brain development (Lin 
and Holt, 2007), but also in the mature brain (Martin and Zukin, 2006). Localization is 
determined by the sequence of cis-acting elements located mainly in the 3’UTR of mRNAs 
(Oleynikov and Singer, 1998; Martin and Ephrussi, 2009). Those elements ranging in length 
from five to several hundred nucleotides are often repeated and a combination of unique 
elements mediates different functions in mRNA localization (Macdonald et al., 1993; Lewis et 
al., 2004; Martin and Ephrussi, 2009). Although, no clear consensus motif has been 
established yet, bioinformatic analysis suggests that repeats of CAC motifs may be important 
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(Betley et al., 2002). RNA-binding proteins targeting those elements seem to be loaded on 
the mRNA already during transcription and nuclear mRNA processing and often function 
both in localization and translational regulation (Martin and Ephrussi, 2009). mRNAs are 
transported together with RNA-binding proteins within large RNA transport particles by motor 
proteins along cytoskeletal elements (Oleynikov and Singer, 1998; Meignin and Davis, 2010). 
During delivery, mRNAs are often translationally silenced in part through the association with 
eukaryotic translation initiation factor-4G and get re-activated appropriately (Besse and 
Ephrussi, 2008). 
 
The control of mRNA stability is crucial, since changes in mRNA turnover alters the 
abundance of the corresponding protein. Hence, mRNAs of early-response-genes have half-
lives of 5 to 30 minutes, whereas other mRNAs (e.g., β-globin) are stable for several hours or 
even days (Laroia et al., 1999). The most common cis-acting elements are the highly 
conserved AU-rich elements (AREs) that have been identified in mRNAs of functionally 
diverse proteins (Chen and Shyu, 1995; Khabar, 2005; Halees et al., 2008). AREs differ in 
their sequence feature, but are divided broadly into three classes: (1) 1-3 copies of AUUUA 
motifs including nearby U-rich region or U stretch; (2) minimum of two overlapping copies of 
the nonamer UUAUUUA(U/A)(U/A) in a U-rich region; (3) lacks a core AUUUA sequence but 
has a U-rich region (Chen and Shyu, 1995; Chen et al., 2006). Several ARE-binding proteins 
(AREBPs) have been identified (e.g., AUF1 and HuR) that can either promote or inhibit the 
degradation of mRNAs containing AREs in their 3’UTR in response to various stimuli such as 
development, stress and proliferation (Khabar, 2005; Barreau et al., 2006; Glisovic et al., 
2008). Various other elements have been described to impact the stability of its mRNAs such 
as cytosine- or pyrimidine-rich elements, AG-rich elements and iron-responsive elements 
(IREs; Chen et al., 2006).  
 
Translational regulation provides a rapid mechanism to control gene expression and is often 
linked to mRNA localization. Such a dual role is described for the zipcode binding protein 1 
(ZBP1) on β-actin mRNA. The block of translational initiation is assumed to be abolished 
upon phosphorylation of ZBP1 which leads to a decreased binding affinity to β-actin mRNA 
(Hüttelmaier et al 2005). AREs and AREBPs also seem to play a minor role in the 
translational control of some genes. T-cell intracellular antigen 1 (TIA-1) is a translational 
repressor known to target AREs located in the tumor necrosis factor-α (TNFA) and 
cyclooxygenase 2 (COX2) 3’UTRs (Piecyk et al., 2000; Dixon et al., 2003). 
Immunoprecipitation experiments identified a 30-37 nucleotide long motif in TIA-1 targeted 
mRNAs that is highly U-rich in the 5’ segment and AU-rich in the 3’ stem (Lopez, et al., 
2005). 
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3.3 Regulation by miRNAs 
The first miRNA gene (lin-4) was described in Caenorhabditis elegans 17 years ago (Lee et 
al., 1993; Wightman et al., 1993). Since then, miRNA research has been extensive, resulting 
in 15,632 mature miRNAs entries across 133 virus, plant and animal species in the records 
of miRBase (http://www.microrna.sanger.ac.uk, V 15.0 April 2010). The 940 discovered 
human miRNAs seem to play a crucial role in posttranscriptional gene regulation of almost 
every process investigated including development, cell proliferation, differentiation, 
apoptosis, signaling pathways, metabolism and life span (Kloosterman and Plasterk, 2006).  
 
 
 
Figure 2: Biogenesis and mechanism of action of miRNAs.  
The primary miRNA transcript (pri-miRNA) is generated mainly by RNA polymerase II (RNA Pol II). 
After cleavage, the precursor miRNA (pre-miRNA) is exported into the cytoplasm and processed by 
Dicer. The mature miRNA is loaded into the RNA-induced silencing complex (RISC) together with 
Argonaute (Ago) proteins and functions mostly by inhibiting gene expression. For a detailed 
description of miRNA biogenesis and function refer to text. (Figure from Winter et al., 2009). 
 
miRNAs are 20-25 nucleotide-long noncoding RNAs (ncRNAs) that are mainly described to 
modulate gene expression by base-pairing to partially complementary sequences in the 
3’UTR of its target mRNAs. Their genes can be monocistronic or expressed as clusters of 
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miRNAs from within one locus (polycistronic; Lagos-Quintana et al., 2001; Zeng, 2006). 
miRNA genes have been found within introns of protein coding genes and in introns and 
exons of longer ncRNAs, located in sense and anti-sense orientation (Rodriguez et al., 2004; 
Zeng, 2006). Furthermore they can be transcribed from their own promoter, promoters from 
nearby genes or be regulated together with their host genes. Usually miRNAs are transcribed 
by RNA polymerase II as part of longer primary constructs (pri-miRNA) including a 5’ cap 
structure and 3’ poly(A) tail (Bartel, 2004; Fig. 2). Those pri-miRNAs fold into a hairpin 
structures and are processed in the nucleus by a microprocessor complex, which consists of 
the RNase III type endonuclease Drosha and its partner DGCR8 (Denli et al., 2004). The 
resulting 65-85 nucleotide stem loop termed precursor miRNA (pre-miRNA) is actively 
transported into the cytoplasm by Exportin-5 and its cofactor RAN-GTP (Lund et al., 2004). 
Final processing is carried out by the RNase II type endonuclease Dicer in association with 
TAR RNA-binding protein (TRBP or TARBP2; Hammond, 2005). Usually one strand of the 
resulting 20-25 nucleotide mature miRNA duplex is degraded, while the mature miRNA is 
loaded into the RNA-inducing silencing complex (RISC) containing Argonaute (Ago) proteins 
(Gregory et al., 2005). Within the RISC complex, the miRNA guides target selection, resulting 
in mainly negative regulation of target mRNAs by different mechanism (Carthew and 
Sontheimer, 2009). Aside from this linear miRNA processing pathway, various miRNA 
specific differences have been described such as transcription by RNA polymerase III or 
RNA editing, allowing for multiple regulatory options to express and process individual 
miRNAs differentially (Winter et al., 2009). The importance of certain factors involved in 
miRNA biogenesis and function have been demonstrated by mouse models of Dicer 
(Bernstein et al., 2003), Dgcr8 (Wang et al., 2007) or Ago2 (Liu et al., 2004) knockout that 
displayed embryonic lethality.  
 
The main mechanisms causing gene silencing influence mRNA cleavage, stability and 
translational repression of the target gene. The choice of mechanism depends in part upon 
the degree of complementarity between a miRNA and its target (Hutvagner and Zamore, 
2002; Zeng et al., 2003). Perfect or near perfect base pairing promotes cleavage of the 
mRNA, a rare event in animals that depends on the slicer activity of Ago2 (Yekta et al., 2004; 
Liu et al., 2004; Meister et al., 2004). In vertebrates, miRNA base pairing is usually imperfect 
and is thought to cause inhibition of translation of the target mRNA, followed by a variable 
degree of mRNA degradation (Pillai et al., 2005). Several mechanisms of translational 
repression by miRNAs have been suggested, including blocking of both initiation and post-
initiation steps and sequestrations of the mRNA targets together with miRNAs and Ago 
proteins into P-bodies, specialized cytoplasm compartments where translational repression 
and mRNA turnover takes place (Pillai et al., 2007). This miRNA mediated repression and 
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P-body localization of mRNAs seems to be reversible in response to certain environmental or 
developmental cues (Bhattacharyya et al., 2006; Pillai et al., 2007). Destabilization has been 
shown to occur by mRNA deadenylation, followed by decapping and subsequent 5’-3’ 
exonucleolytic degradation (Wu et al., 2006; Behm-Ansmant et al., 2006; Chekulaeva and 
Filipowicz, 2009). A recent study combined ribosome and mRNA profiling analyses and it is 
claimed that >84% of the miRNA dependent decrease in protein production is caused by 
destabilization of target mRNAs while the influence on translational efficiency is modest (Guo 
et al., 2010).  
In a few cases activation of gene expression was reported involving different circumstances. 
One group reported that miRNAs act as translational activators only in cells arrested in 
G0/G1 involving Ago2 and FXR1 proteins (Vasudevan and Steitz, 2007; Vasudevan et al., 
2007). In another case, miR-10a enhanced translation by targeting the 5’UTR of ribosomal 
protein mRNAs (Orom et al., 2008). miR-122 stimulated translation of hepatitis C virus if 
bound to the 5’UTR, while binding to the 3’UTR of a reporter resulted in downregulation of its 
activity (Jopling et al., 2005; Jopling et al., 2008; Henke et al., 2008). 
The RNA interference (RNAi) process triggered by small RNAs was thought to silence gene 
expression at the posttranscriptional level. Over the past few years, components of the RNAi 
machinery have also been identified to function in the nucleus. Transcriptional gene silencing 
in mammals was discovered by the use of promoter-directed, synthetic, small interfering 
RNAs (siRNAs; Morris et al., 2004; Ting et al., 2005) and shown to be accompanied by 
dimethylation of lysine 9 (H3K9) and trimethylation of lysine 27 (H3K27) in histone H3 (Ting 
et al., 2005; Kim et al., 2006; Weinberg et al., 2006; Han et al., 2007). Ago1 and Ago2 
proteins are recruited to the promoter and involved in the formation of silent chromatin 
domains (Janowski et al., 2006; Kim et al., 2006). More recently, such synthetic, promoter-
directed antigene RNAs (agRNAs) were also described to activate gene expression in 
human cancer cell lines (Li et al., 2006a; Janowski et al., 2007). Transcriptional activation is 
associated with demethylation of H3K9 (Li et al., 2006a) and increased di- and trimethylation 
of H3K4 (Janowski et al., 2007). Both, gene activation and inactivation by agRNAs is 
sequence specific, but no position dependent rules could be identified that cause gene 
silencing versus activation (Li et al., 2006a; Janowski et al., 2007). Recently, it has been 
reported that for both inhibition and activation, agRNAs recruit Ago proteins to antisense 
transcripts of the promoter and mediate formation of complexes with proteins and 
chromosomal DNA (Schwartz et al., 2008).  
Currently, there are only a few reports in mammals providing evidence of miRNAs 
modulating gene expression by promoter recognition. In one study an epigenetic mechanism 
of miRNA directed transcriptional gene silencing has been suggested (Kim et al., 2008). 
They found that miR-320 targets the promoter location of the POLR3D gene from which it is 
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transcribed in antisense direction and showed that expression of this miRNA and protein 
coding gene, are anti-correlated. Another study reported the activating effect of miR-373 and 
pre-miR-373 in the presence of Dicer on E-cadherin and cold-shock domain-containing 
protein C2 (CSDC2), which was associated with an enrichment of RNA polymerase II at both 
promoters (Place et al., 2008). Activation was specific to the miR-373 sequence and 
dependent on the predicted target site within the promoter sequences.  
 
Not all protein coding genes are regulated by miRNAs. Some genes that are involved in 
basic cellular processes seem to even avoid miRNA regulation due to short 3’UTRs that are 
specifically depleted of miRNA binding sites (Stark et al., 2005). However, about 30% of 
protein coding genes are estimated to be regulated by miRNAs (Lewis et al., 2005) with a 
high probability for transcription factors (John et al., 2004). Several target prediction 
programs have been developed to predict miRNA binding sites (John et al., 2004; Krek et al., 
2005; Grimson et al., 2007). However, accurate prediction is made difficult since target 
sequences are very short and base pairing is mostly imperfect between the miRNA and 
regulated mRNAs. Perfect complementarily of the seven nucleotides between positions two 
to eight (seed sequence) of the miRNA and its target mRNA have been shown to be crucial 
in various cases, resulting in perfect seed sequences as a prerequisite in the majority of 
search algorithms (Lewis et al., 2005). Other features include thermodynamically stability of 
the duplex miRNA-mRNA, phylogenetic conservation, position within the 3’UTR, multiple 
target sites in a single mRNA by the same or different miRNAs and absence of stable 
secondary structures (Grimson et al., 2007). In contrast to the majority of programs available, 
RNA22 can upload and analyze a specific target sequence and miRNAs of interest and does 
not rely upon cross-species conservation (Miranda et al., 2006). Although many miRNA 
genes have been identified and potential targets have been bioinformatically predicted, the 
challenge is to provide experimental evidence of miRNA-mRNA interactions and identify their 
biological relevance (Kuhn et al., 2008). 
Because miRNAs are important regulators of gene expression, misregulation or mutations of 
miRNAs seem to play key roles in several diseases including many types of cancer, genetic 
disorders and viral infections (Croce and Calin, 2005; Garofalo et al., 2008). They can 
function as oncogenes (e.g., miR-21 regulating the tumor-suppressor tropomyosin 1 (TPM1; 
Zhu et al., 2008)) or tumor suppressors (e.g., let-7 regulating RAS oncongene mRNAs; 
Johnson et al., 2005) and affect various steps of tumor formation from initiation to metastasis 
(Hanahan and Weinberg, 2000; Kent and Mendell, 2006; Shenouda and Alahari, 2009; 
Ventura and Jacks, 2009; Croce, 2009). Interestingly, dual oncogenic and tumor-suppressive 
roles are reported for several miRNAs, depending on the cell type and pattern of gene 
expression (Fabbri et al., 2007).  
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4 Objective of this study 
HNF4A2 overexpression results in a significant decrease in cell proliferation. The aim of the 
first part of this project is to narrow down the number of potential HNF4A target genes to 
those crucial for proliferation control. For this purpose, a HNF4A isoform with no impact on 
cell proliferation decrease is sought. A cell line conditionally expressing this isoform will be 
established to subsequently determine its target genes by microarray analyses. Any 
identified gene is likely irrelevant for proliferation control and can thus be eliminated from the 
numerous potential HNF4A2 target genes identified previously. Detailed analyses, by means 
of qRT-PCR, RNAi and generation of inducible cell lines, of promising HNF4A target genes 
will be conducted to corroborate the impact on cell proliferation control.  
 
The second part of this project addresses the transcriptional regulation of HNF4A itself. The 
impact of mutations identified within the P2 promoter, active in the pancreas, of patients with 
clinical signs of MODY1, will be analyzed in reporter gene studies. The aim is to link novel 
mutations in the regulatory sequences of HNF4A to MODY1.  
In addition, evidence for the potential regulation of the HNF4A P1 and P2 promoter by 
miRNAs will be investigated. Considering an activating effect of miRNAs on gene promoters, 
downregulation of miRNAs in RCC or diabetes might contribute to the downregulation of 
HNF4A in those diseases due to dysfunction of the P1 and P2 promoter, respectively. To 
approach this hypothesis, the impact of miRNA depletion on both HNF4A promoters as well 
as truncated constructs will be investigated with reporter analyses in a cell system allowing 
for the conditional knock-down of Dicer.  
 
The third part of this project will elucidate the previously unrecognized posttranscriptional 
regulation of HNF4A. Initially, the predicted as well as possible alternative HNF4A 3’UTRs 
will be assessed and their mode of regulation evaluated in reporter assays. Due to the 
impressive length of the 3’UTR, shortened constructs will be generated to facilitate the 
identification of crucial elements targeted by regulatory factors. To specifically investigate 
3’UTR regulation by any miRNA present in the cell, the conditional Dicer knock-down assay 
will be applied. In the case of evidence of miRNA regulation, selected miRNAs upregulated in 
RCC should be gathered from different profiling studies. Due to the repressive effect of 
miRNAs on 3’UTRs, overexpression of a specific miRNA targeting the 3’UTR should result in 
the downregulation of HNF4A. Such an effect measured by luciferase assays should be 
abolished upon destruction of the potential target sites in the mRNA.   
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B Materials and Methods 
The following procedures were taken from the methods collection of Sambrook et al. (1989), 
unless other sources are given as reference.  
1 Chemicals, enzymes and solutions 
Chemicals and enzymes were purchased from Aldrich, Amersham Biosciences, Bio-Rad, 
Boehringer Mannheim, Fluka, Gibco, Invitrogen, Merck, New England Biolabs, Pharmacia, 
Roche, Roth, Serva and Sigma in pro analysis quality, unless stated otherwise. Cell culture 
materials were purchased from TTP and Nunc. Oligonucleotides were obtained from 
Invitrogen. 
2 General DNA and RNA procedures 
Standard procedures such as gel electrophoresis, restriction digests, ligations, as wells as 
preparation of competent cells and bacterial transformation were carried out according to 
standard protocols (Sambrook et al., 1989). The “QIAquick PCR Purification Kit” (Qiagen) 
was used to purify DNA after enzymatic reactions. For mini-preparations of plasmid DNA up 
to 20 µg a method based on alkaline lyses was used. Large quantities of plasmid DNA up to 
500 µg were extracted with the „Nucleobond PC500 AX Kit“ (Machery und Nagel).  
Sequence analyses were carried out by the group of Prof. Küppers of the Institute of Cell 
Biology or by the sequencing service of the Institute of Human Genetics of the University 
Clinic Essen.  
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3 Oligonucleotides 
Primers used for esiRNA generation: 
Primer name  Primer sequence (5’-3’) 
T7      TAATACGACTCACTATAGGGA  
T3   TAATACGACTCACTATAGGGAAATTAACCCTCACTAAAGGGA  
HNF4A2 U  TAATACGACTCACTATAGGGAACCTGTTGC 
HNF4A2 L  TAATACGACTCACTATAGGGAACTTCCTGC   
 
Primers used for qRT-PCR: 
Primer name  Primer sequence (5’-3’) 
GAPDH U  GTCAGTGGTGGACCTGAC 
GAPDH L  ACCTGGTGCTCAGTGTAG 
hCIDEB-E6 U  AGTACTTTCTTTGGGCCAAGTC 
hCIDEB-E6 L  CCAAGCACAGCAAGGACAT 
mCideb-E6 U  CAAAACACAGCAAGGACAT 
mCideb-E6 L  AGTACTCTTTTAGGGCCAACTC 
 
Primers used for Cideb cloning: 
Primer name  Primer sequence (5’-3’) 
mCideb-cDNA U CCGGAATTCAATGGAGTACCTTTCAGCCTTCA 
mCideb-cDNA L CCGCTCGAGTTAGGAGTGGAGGTGTCTCTGC  
Underlined are the EcoRI and XhoI restriction sites.   
 
Primers used for 3’ RACE PCRs: 
Primer name  Primer sequence (5’-3’) 
Oligo-dT-adapter GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT 
Adapter AS  CCACGCGTCGACTAGTACTTT 
Proximal PA S CGGGATCCGGCTGCACTAAAATTCACTTAGGGTCG 
Distal PA S  CGGGATCCTTCTTACTCTTCTGTGTTTTAACAAAA 
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Primers used to amplify the HNF4A 3’UTR: 
The upper primers used to amplify parts of the HNF4A 3’UTR are always listed first and the 
lower primers second. The upper primers are either flanked by a SpeI (bold) or XbaI (bold 
and italics) restriction site, while the lower primers contain a NotI (underlined) site for ligation 
into the XbaI/NotI sites downstream of the renilla luciferase into the RL-Con plasmid. 
 
HNF4A 3’UTR (nt) Primer (5’-3’) 
      1 - 3180  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCTTAGAAAACATATGCGCCATTT 
1 - 2769  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCTGTCCCCCCAGCAAC 
1 - 2573  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCCTCCAGAAAGGGGTAGATTC 
      1 - 1746  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCGAGAAAAGCTGTCAAGAGTCATGA 
1 -   630  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCCCTGCCTGGTGCCT 
1 -   449  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCCGGCCGCTGCCCCAAGTGCCAC 
1 -   386  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCTAGGAGAGGAGAAGCACCAGG 
1 -   378  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCGAGAAGCACCAGGCTAGGG 
1 -   264  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCTGAAGGCAGTGGCTTCAAC 
1 -   258  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCAGTGGCTTCAACATGAGAAAA 
1 -   249  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCAACATGAGAAAGTTGTCCAAG 
1 -   241  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCGAAAAGTTGTCCAAGGCAGTAGA 
1 -   204  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCAAAGTCTTGTTATCCAGAGCAGG 
1 -   196  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCGTTATCCAGAGCAGGGCGT 
1 -   159  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCGTGGCCCTTAGGCCATG 
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1 -   151  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCTAGGCCATGTTCTCGGG 
1 -   134  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCCCTTCATCCTTCCCATTC 
1 -   126  GGACTAGTTAGCAAGCCGCTGGG 
   GCATGCGGCCGCCCTTCCCATTCCTGCTCTG 
  423 -   875  GGACTAGTCTGGGTCCAATTGTGGCA 
   GCATGCGGCCGCTCCCATCTCACCTGCTCTACC 
  850 -   899  GCTCTAGATGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCTGGCTCAGGCTGTTCTTTG  
  850 - 1013  GCTCTAGATGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCCTCAGCCTGGTGTTCCAGA  
  850 - 1167  GCTCTAGATGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCGTCCTCTCCAGCCCCAAG 
  850 - 1207  GCTCTAGATGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCCCTCCTGATGTCACTCTGAT 
  850 - 1259  GCTCTAGATGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCAGACAGTGCCTGGGAGTAAGG 
  850 - 1313  GGACTAGTTGGCTGGTAGAGCAGGTGA 
   GCATGCGGCCGCGGTTAATAGGGAGGAAGGGAGG 
  900 - 1013  GCTCTAGAAGGCCTAGTGGTAGTAAGAATCTAGC  
    GCATGCGGCCGCCTCAGCCTGGTGTTCCAGA  
  900 - 1167  GCTCTAGAAGGCCTAGTGGTAGTAAGAATCTAGC  
   GCATGCGGCCGCGTCCTCTCCAGCCCCAAG 
  900 - 1207  GCTCTAGAAGGCCTAGTGGTAGTAAGAATCTAGC  
   GCATGCGGCCGCCCTCCTGATGTCACTCTGAT 
1014 - 1167  GCTCTAGAGTCCTGATCAGCTTCAAGGAGT  
   GCATGCGGCCGCGTCCTCTCCAGCCCCAAG 
1014 - 1207  GCTCTAGAGTCCTGATCAGCTTCAAGGAGT 
   GCATGCGGCCGCCCTCCTGATGTCACTCTGAT 
1127 - 1207  GCTCTAGATAATGCGGGTGAGAGTAATGAG 
   GCATGCGGCCGCCCTCCTGATGTCACTCTGAT 
1208 - 1313  GCTCTAGAAATAAGCTCCCAGGGCCTG 
   GCATGCGGCCGCGGTTAATAGGGAGGAAGGGAGG 
1288 - 1460  GCTCTAGATAATCCTCCCTTCCTCCCTATT 
   GCATGCGGCCGCCTTCCTAGTTGTGTGAGTTTCAGAA 
1288 - 1513  GCTCTAGATAATCCTCCCTTCCTCCCTATT 
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   GCATGCGGCCGCAAGAGCTCCTGTTCTGATCCAG 
1288 - 1597  GCTCTAGATAATCCTCCCTTCCTCCCTATT 
   GCATGCGGCCGCTGTAGAAGGGAGCCGGAAG  
1288 - 1666  GCTCTAGATAATCCTCCCTTCCTCCCTATT   
   GCATGCGGCCGCCAGCCTCAGGCCAATCTT  
1288 - 1746  GGACTAGTTAATCCTCCCTTCCTCCCTATT 
   GCATGCGGCCGCGAGAAAAGCTGTCAAGAGTCATGA 
1336 - 1746  GCTCTAGATTCTCCTCCTCCCTCCCC  
   GCATGCGGCCGCGAGAAAAGCTGTCAAGAGTCATGA 
1392 - 1513  GCTCTAGATTACAGAAGCTGAAATTGCGTTC 
   GCATGCGGCCGCAAGAGCTCCTGTTCTGATCCAG 
1392 - 1746  GCTCTAGATTACAGAAGCTGAAATTGCGTTC 
   GCATGCGGCCGCGAGAAAAGCTGTCAAGAGTCATGA 
1461 - 1746  GCTCTAGATGGCTGAGTCAGGACTTGAA 
   GCATGCGGCCGCGAGAAAAGCTGTCAAGAGTCATGA 
1725 - 2573  GGACTAGTATGACTCTTGACAGCTTTTCTCTCT 
   GCATGCGGCCGCCCTCCAGAAAGGGGTAGATTC 
2574 - 3180  GGACTAGTAGAAACCCATTCCACCTTAATAAC 
   GCATGCGGCCGCTTAGAAAACATATGCGCCATTT 
2771 - 3180  GGACTAGTAGCGTGGGCACAATTTC 
   GCATGCGGCCGCTTAGAAAACATATGCGCCATTT 
 
SV40 PA   GCTCTAGATTCCCTTTAGTGAGGGTTAATGC 
   GGACTAGTATCACCCTAATCAAGTTTTTTGGG 
4 Plasmid constructions 
The pcDNA5/FRT/TO expression vector (Invitrogen) was used to generate the Flp-In T-Rex 
293 cell lines of interest. When co-transfected with the Flp recombinase expression plasmid 
pCSFLPe1 (Werdien et al., 2001) into the Flp-In host cell line, the pcDNA5/FRT/TO vector 
containing the gene of interest (GOI) is integrated in a Flp recombinase-dependent manner 
into the genome. Generation of pcDNA5/FRT/TO containing the myc-tagged open reading 
frame (ORF) of HNF4A8 was described previously (Erdmann et al., 2007).  
For Cideb, a full-length mouse cDNA clone was obtained from RZPD (IRAVp968B0424D6) 
and the ORF was amplified by PCR using primers (2.4 Oligonucleotides) containing 
restriction sites for EcoRI and XhoI. The digested PCR product was first cloned into the 
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EcoRI and XhoI sites of the pCS2+MT plasmid (Rupp et al., 1994) to add a myc-tag to the 
sequence and verified by sequencing. The myc-tagged Cideb was excised with BamHI and 
XhoI and cloned into the same sites of pcDNA5/FRT/TO.  
 
The HNF4A P2 promoter luciferase constructs were generated previously by introducing 
different PCR fragments of the P2 promoter sequence into XhoI and HindIII restriction sites 
of the pGL3-BasicII vector (Promega; Thomas et al., 2001). 
The QuikChange II Site-Directed Mutagenesis Kit (Stratagene) was used to introduce point 
mutations into P2/-285 and obtain P2/-285(-136A>G), P2/-285(-169-C>T) and P2/-285 
(-192C>G) (Wirsing et al., 2010). 
To obtain HNF4A P1 promoter fragments upstream of the firefly ORF in the pGL3 Basic 
plasmid (Promega), P1 promoter fragments were excised from hHNF4-luc plasmid that was 
generated previously (Thomas et al., 2002). P1/-1114 was restricted with KpnI and HindIII, 
P1/-590 with BamHI and HindIII, P1/-281 with XmaI and HindIII and P1/-132 with BglII and 
HindIII and all fragments were ligated to corresponding sites within the pGL3 basic plasmid.  
The CMV promoter was excised from the pCSGFP2 plasmid (Wild et al., 2000) with SalI and 
HindIII and cloned into the XhoI and HindIII sites of pGL3 basic.  
 
The HNF4A 3’UTR was amplified using a human BAC clone (RPCIB753B08466Q; 
imaGenes) as a template and primers containing flanking SpeI or XbaI and NotI sites (2.3 
Oligonucleotides). The restricted HNF4A 3’UTR and all shortened fragments were cloned 
into XbaI/NotI sites of pRL-Con (Schmitter et al., 2006) and subsequently sequenced.  
The sequence 631-3180 of the corresponding construct was excised from construct 1-3180 
with XbaI/NotI and ligated into the same sites of the RL-Con plasmid. To delete the 
sequence containing negative element A and B and obtain constructs 1-844+1720-3180 and 
631-844+1720-3180, two EcoRI sites present in the HNF4A 3’UTR sequence were used. 
The latter construct was also used to generate construct 631-849+1718-850+1719-3180, by 
re-introducing the excised EcoRI-fragment and selecting for clones containing this sequence 
in 3’-5’ direction. To get constructs 1-636+850-1207 and 1-636+1288-1666, a construct 
containing the 5’ 843 nt of the HNF4A 3’UTR was cut with XbaI/NotI and ligated into the 
XbaI/NotI restricted PCR products from 850-1207 and 1288-1666. To determine if negative 
element A and B function on RNA level, a XbaI/SpeI cleaved PCR product containing the 
SV40 PAS was introduced into the XbaI site upstream of negative element A and B 
constructs. Both orientations of the insert were identified by sequencing, resulting in 
construct 5’-3’ PAS + 850-1207, 3’-5’ PAS + 850-1207, 5’-3’ PAS + 1288-1666 and 3’-5’ PAS 
+ 1288-1666.  
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5 Cell culture 
All procedures with eukaryotic cells were performed under sterile conditions at a laminar flow 
hood.  
5.1 Growth and maintenance of cell cultures  
All cell lines were grown in DMEM or RPMI-1640 medium (Gibco-BRL) supplemented with 
10% heat inactivated fetal calf serum (FCS), penicillin/streptomycin (100 U/ml) and 2 mM 
glutamine at 37°C under 8% CO2 atmosphere and a relative humidity of 95%.  
The host cell line Flp-In T-Rex 293 was cultured in DMEM supplemented with 15 µg/ml 
blasticidin and 100 µg/ml zeocin. In case of the stable cell lines derived from the host cell 
line, zeocin was substituted with 50 µg/ml hygromycin B. Dicer-kd/2b2 cells (Schmitter et al., 
2006) were grown in DMEM supplemented with 10 µg/ml blasticidin and 50 µg/ml zeocin 
(Invitrogen). Expression of an anti-Dicer short hairpin was induced with 1 µg/ml of 
doxycycline (dox). HEPG2 cells were maintained in DMEM and HK120 cells (Stilla Frede, 
Institute of Physiology, University clinic Essen) were grown in RPMI-1640 medium. The 
INS-1 #5.3-19 cell line and INS-1 (HNF1B #1A) (Thomas et al., 2004) cells were cultured in 
RPMI-1640 medium supplemented with 1 mM sodium pyruvate, 10 mM HEPES, 50 µM 
mercaptoethanol, 10 µg/ml blasticidin and 200 µg/ml zeocin.  
All cells were routinely passaged at approximately 80% confluence. The culture medium was 
removed, cells washed with 10 ml PBS and detached by incubation in 1 ml Trypsin/EDTA for 
2-3 minutes in the incubator. Trypsin was inactivated by addition of 9 ml culture medium. 
Cells were diluted about 1:10 in fresh medium.  
5.2 Cryoconservation  
For long term storage, cell pellets were resuspended in 2 ml of cold freezing medium (culture 
medium without antibiotics and additional 10% FCS and 10% DMSO) after centrifugation for 
5 minutes at 900 rpm. 1 ml aliquots were transferred into cryo tubes (1.8 ml). After cooling 
down to -80°C for 24-48 hours, the cells were stored in liquid nitrogen (-196°C).  
Cell cultures were replaced from frozen stocks after 20-30 passages. Cells were thawed in a 
water bath at 37°C and then diluted with 9 ml cold medium. After centrifugation for 5 minutes 
at 900 rpm, the cell pellet was resuspended in fresh medium. After 24 hours medium was 
exchanged and antibiotics were added.  
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5.3 Cell counting  
To determine the number of cells per unit volume of a suspension, a counting chamber 
(hemocytometer) was used. Prior to counting, cells were trypsinized and resuspended in 
fresh medium. Cells were counted in each of the four corner squares. The average was 
multiplied with 1 x 104 to obtain the cell number per milliliter cell suspension.  
6 Generation of cell lines with the Flp-In T-Rex system 
6.1 Flp-In T-Rex 293 cells  
The Flp-In T-Rex 293 host cell line (Invitrogen) contains a single integrated FRT site which is 
recognized by the Flp-recombinase and stably expresses the tetracycline repressor. To 
obtain a cell line conditionally expressing the GOI, the host cell line was co-transfected 1:1 
with the pcDNA5/FRT/TO plasmid containing the GOI and a hygromycin resistance gene and 
the Flp recombinase expression vector pCSFLPe1 (Werdien et al., 2001). 3 x 105 cells were 
seeded in 6- wells and transfected the next day with a total of 1.6 µg plasmid DNA. 100 µl of 
lipofectamine (Invitrogen) were diluted 1:17.5 in Optimem (Invitrogen) in a polystyrene (PS) 
tube. The DNA was diluted in Optimem as well and added to the tube drop-by-drop. While 
incubating for 15 minutes at room temperature, the cell culture medium was exchanged with 
1.5 ml Optimem. The transfection mix was added to the cells and after four hours in the 
incubator, the medium was replaced with fresh DMEM including blasticidin, but no zeocin.   
One day after the transfection, the cells were trypsinized and transferred to a 10 cm dish. To 
select for cells including the GOI, 24 hours later, fresh medium including hygromycin (and 
blasticidin) was added. After 10-14 days the selection process was completed. The 
hygromycin resistant cell colonies were pooled and expanded to obtain a polyclonal cell line. 
As soon as the cells reached confluence, aliquots of the new cell lines were stored in liquid 
nitrogen.  
To verify that the GOI had integrated into the FRT site, each cell line was tested for the lack 
of β-galactosidase activity due to disruption of the functional lacZ-zeocin fusion gene. Cells 
expressing β-galactosidase cleave the substrate X-gal and transform it into a blue product 
easily visible by microscopy, while cells lacking that enzyme remain clear. The generated cell 
lines were seeded in 6-well dishes, washed 24 hours later with PBS and fixed in PBS 
containing 1% formaldehyde and 0.2% glutaraldehyde. Cells were washed in PBS again and 
incubated at 37°C for 1-24 hours with PBS containing 5 mM potassium ferricyanide, 5 mM 
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potassium ferrocyanide, 2 µM MgCl2 and 1 mg/ml X-Gal (5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside). After the incubation period, the cells were analyzed by light microscopy. 
Each cell line was only used for further experiments when containing less than 5% of blue 
cells.  
6.2 Induction of cell lines with doxycycline  
To induce expression of the stably integrated GOI, cells were cultivated with medium 
containing doxycycline (1 µg/ml). Doxycycline was used instead of tetracycline due to its 
longer half time of 48 hours versus 24 hours. Since doxycycline is dissolved in ethanol, 
control cells were treated with ethanol. If incubation times exceeded two days, medium 
including fresh doxycycline was exchanged regularly.  
7 Analyzing cell morphology and cell proliferation 
In the course of the experiments, cell morphology was monitored daily using a phase 
contrast microscope (Diavert, Leitz). Phenotypical changes of the cells were documented 
with digital fotography (Nikon Coolpix 4500).  
 
The MTS assay (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega) was 
used to analyze cell proliferation. This colometric method is based on the metabolic activity 
of cells and thus determines the number of viable cells in proliferation. The tetrazolium 
compound MTS is bioreduced into the aqueous soluble formazan by dehydrogenase 
enzymes found in metabolically active cells, in the presence of the electron coupling reagent 
PMS. The absorbance of the formazan product is measured at 490 nm in a photometer and 
is directly proportional to the number of living cells in culture.  
Cells were seeded in a 96-well plate at a density of 2-10x103 cells in 100 µl medium per well. 
Doxycycline or ethanol was added after 24 hours and the cells were incubated for 3-6 days. 
20 µl MTS reagent was added to each well. After 60 minutes incubation at 37°C, OD490 was 
measured with a microplate photometer (Bio-Rad, Model 550). The measured values from 
the wells just containing medium, were used to determine the background. Each experiment 
was performed in triplicate. 
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8 Immunofluorescence microscopy 
Immunofluorescence microscopy was used to visualize the presence and localization of 
target proteins in the cell. 1 x 105 to 3 x 105 cells were seeded per well in a 6-well dish on top 
of cover glasses. For fixation, cells were washed with PBS, fixed with methanol for 10 
minutes at room temperature and washed again twice with PBS. To block unspecific binding 
of the antibody, the cells were incubated with PBS/10% goat serum for 60 minutes at 4°C. 
The primary antibody targeting the myc-tag (9E10 monoclonal) was diluted 1:4 in DMEM and 
incubated for 60 minutes at room temperature. The secondary antibody (anti-mouse Cy3; 
Jackson ImmunoResearch) was diluted 1:200 in PBS/10% goat serum for 60 minutes at 4°C 
protected from light. To visualize the nuclei, cells were incubated for 5 minutes at room 
temperature with Hoechst A 33342 (1:1000 in H2O, Sigma) to stain the DNA and 
subsequently mounted with Vectashield (Vector-Laboratories). The preparations were 
analyzed with a fluorescence microscope (DM IRE2, Leica) and documented with an 
attached digital camera (DC 500, Leica) and the image analysis software Qfluoro.  
9 Proteins 
9.1 Total cell protein extract and quantification  
To obtain whole cell protein extracts, the cells were detached from the petri dish by using 
trypsin and centrifuged for 5 minutes at 900 rpm at room temperature. The pellet was 
washed with 1 ml icecold PBS and transferred into a 1.5 ml microcentrifuge tube. After 
additional centrifugation (14,000 rpm, 1 min, 4°C) the cells were resuspended in icecold 
RIPA buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 0.1% SDS, 1% Natriumdeoxycholat, 1% 
Triton X-100) containing protease inhibitors (Sigma; P8340 1:500) and lysed 30 minutes on 
ice. Cell debris was separated by centrifugation (50,000 rpm, 10 min, 2°C) and the 
supernatant containing the whole cell protein extract was stored at -80°C. 
 
The Bradford assay (Bradford, 1976) is based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 
595 nm when binding to protein occurs. The concentration of whole cell protein extracts was 
determined using the Bio-Rad Protein-Assay reagent. 2-10 µl protein solution were diluted in 
1600 µl H2O in a cuvette and mixed with 400 µl Bio-Rad Protein-Assay reagent. After 
incubation for 5 minutes at room temperature, the solution was measured in a 
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Spectrophotometer (S2000 WPA) at OD595. The OD595 of each sample was compared to a 
standard curve prepared with BSA (2-20 µg). RIPA buffer, in which the proteins were diluted, 
served as a control.  
9.2 Discontinuous SDS polyacrylamide gel electrophoresis (SDS-
Page)  
Protein samples were separated electrophoretically on a denaturing SDS-polyacrylamide gel 
according to Laemmli (1970). Depending on the size of the proteins, a 7.5% or 10% resolving 
gel was used in combination with a 5% stacking gel in a vertical Mini-Protean Gel chamber 
(Bio-Rad). 2x Laemmli buffer (Tris-HCL pH 6.8, 4% SDS, 20% glycerol, 0.2% bromphenol 
blue, 10% β-mercaptoethanol) was added to each sample in appropriate volumes and 
samples were denatured at 95°C for 5 minutes before application to gel slot. Electrophoresis 
was performed in 1x SDS running buffer under 100 V. The prestained protein ladder 
“Precision Plus protein Standards, Dual color” (Bio-Rad) was used as a standard.  
9.3 Western blot and protein detection  
A semi-dry blotting chamber was used to transfer the separated proteins from the 
polyacrylamide gel to a nitrocellulose membrane. All components were soaked in 1x transfer 
buffer (8 mM Tris, 40 mM glycine, 0.0375% SDS, 20% methanol) for 2 minutes before 
stacking them between the anode and cathode plate of the blotting chamber (Trans-Blot SD 
Semi-Dry Transfer Cell, Bio-Rad) in the following order: five Whatman papers, nylon 
membrane, gel, five Whatman papers. The transfer was performed for one hour at 2 mA/cm2. 
After the transfer, the membrane was blocked to prevent non-specific binding of antibodies to 
the membrane by incubating with blocking agent (Amersham) diluted 1:20 in blocking buffer 
(150 mM NaCl pH7.5, 100 mM Tris) for one hour at room temperature. The membrane was 
further incubated over night at 4°C with the mouse monoclonal primary antibody against the 
myc-tag (9E10, lab specific) at a dilution of 1:5 in PBS-T (PBS, 0.1% Tween-20). After the 
primary antibody, the membrane was incubated with the horseradish-peroxidase-conjugated 
anti-mouse secondary antibody (NXA 931, Amersham) at a dilution of 1:5000 in PBS-T for 
one hour at room temperature. After each incubation, the membrane was washed three 
times with PBS-T at room temperature. Immunoreactivity was detected using the ECL Kit 
(Amersham Bioscience) according to manufacturer´s instructions. The membrane was 
wrapped in a plastic film and put in a cassette for exposure of the film (HyperfilmTM ECLTM, 
Amersham Bioscience) for 5 sec to 50 min, depending on signal intensity.  
Materials and Methods 
 
39
10 Microarray analysis 
Microarray analyses were performed in collaboration with PD Dr. Ludger Klein-Hitpass 
(BioChip Lab, Institute of Cell Biology, University Clinic Essen). 
10.1 Microarray chips  
The Affymetrix Genechip HG_U133_2.0_Plus is a high density oligonucleotide microarray 
which detects 54,000 probe sets representing about 38,500 genes. Oligonucleotides, usually 
25-mers, are directly synthesized onto a glass wafer by a combination of photolithography 
and solid phase chemical synthesis technology. Each gene sequence is represented by 
eleven pairs of oligonucleotide probes, present in millions of copies. A pair consists of a 
perfect match (PM) probe that is entirely complementary to the gene sequence and a 
corresponding mismatch (MM) probe that contains a single base substitution in the middle of 
the sequence, reducing binding of the corresponding transcript. This setup helps to 
determine the background and nonspecific hybridization that contributes to the signal 
measured for the PM probe. To obtain the absolute or specific intensity value for each 
probes set, the hybridization intensities of the MM probes are substracted from those of the 
PM oligonucleotides.  
10.2 RNA isolation for microarray analysis  
Total RNA was extracted from induced (+dox) and uninduced (-dox) HEK293 HNF4A8# 11 
and HNF4A8 #14 cells using peqGold RNAPure (PeqLab) according to the manufacturer’s 
instructions. For a 10 cm dish, 3 ml peqGOLD RNA pure were used and the isolated RNA 
was dissolved in 30 µl RNase-free water. The RNA was further purified using the RNeasy 
Mini Kit (Qiagen) according to the standard protocol including on column DNase digestion 
with the RNase-free DNase set (Qiagen). After determining the concentration in a ND-1000 
Spectrophotometer (NanoDrop Technologies), the RNA was stored at -80°C.   
10.3 Synthesis of cDNA, marking and hybridization  
mRNA, comprising about 0.2-0.4% of total RNA was reverse transcribed into single-stranded 
cDNA using a T7-d(T)21 primer. The complementary cDNA strand was synthesized by DNA 
polymerase I, DNA ligase and RNase H. Using the T7 RNA polymerase recognizing the 
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introduced T7 promoter sequence, the double-stranded cDNA was used as a template to 
synthesize biotinylated antisense cRNA by in vitro transcription. Labeled cRNA was purified, 
fragmented and hybridized to the chip. Non-complementary cRNAs were removed by 
washing and the arrays were stained. Fluorescence intensity emitted by labeled cRNA/cDNA 
upon laser treatment was measured and quantified using a GeneArray Scanner (25000, 
Agilent). All steps were carried out according to the Affymetrix Gene Expression Analysis 
Technical Manual.  
10.4 Data analyses  
The Affymetrix Microarray Suite Version 5.0 software was used to process array images and 
determine signal intensities and detection calls, which are defined as present (P), absent (A) 
or marginal (M) for each probe set. To compensate for variations in the amount and quality of 
the cRNA samples and other experimental variables of non-biological origin, scaling across 
all probe sets of a given array to an average intensity of 1000 was conducted. Differentially 
expressed genes between induced and uninduced cells were determined by comparing the 
values of each probe set in a pairwise manner using the Affymetrix Microarray Suite 5.0 
software, which calculates the significance (change P-value) of each change in gene 
expression based on a Wilcoxon ranking test. To identify target genes, the data was filtered 
by applying specified cut-offs using the Affymetrix Data Mining Tool 3.0 Software.  
11 Quantitative real-time PCR 
11.1 RNA isolation and cDNA synthesis for qRT-PCR  
Total RNA was isolated from cells using peqGold RNAPure (PeqLab) according to the 
manufacturer’s instructions. To prevent false results due to DNA contamination, the RNA 
samples were digested with DNase using the RNase-free DNase Set (Qiagen). The RNA 
concentration was determined in a ND-1000 Spectrophotometer (NanoDrop Technologies) 
and aliquots were frozen at -80°C. cDNA was synthesized using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) including random hexamers.  
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11.2 qRT-PCR  
To obtain relative expression data of several genes, qRT-PCR was performed using the 
POWER SYBR Green PCR Master Mix from Applied Biosystems. This dye binds to dsDNA 
during amplification and upon excitation emits light. As PCR product accumulates, 
fluorescence increases. A dissociation curve stage after the PCR amplification was included 
to make sure only one sharp peak is detected at the melting temperature of the amplicon and 
no primer dimers are detected. The gene specific primers used are listed in section 2.3. Each 
reaction of 20 µl included the SYBR Green Master Mix, primers at a concentration of 0.3 µM 
and 2-4 ng cDNA. A 10 minute incubation period at 95°C was followed by 40 cycles 
comprised of 15 s at 95°C (denaturation) and 60 s at 60°C (annealing-extensions). 
Amplification and detection of the cDNA was carried out with the 7900HT Sequence 
Detection System (Applied Biosystems) and the corresponding software.  
Gene expression was relatively quantified with the 2-∆∆Ct method (2 power of [(Ct target - Ct 
reference) of calibrator - (Ct target - Ct reference) of sample] (Livak and Schmittgen, 2001). 
Hence, the averaged values of the reference gene (GAPDH) were substracted from the 
averaged values of the target gene to obtain ∆Ct. To calculate ∆∆Ct the ∆Ct values of the 
cells treated with doxycycline were substracted from the ∆Ct of the control cells (-dox) that 
served as the calibrator. Each cDNA was measured at least twice in one approach and 
control reactions without reverse transcriptase were included. 
12 Gene inactivation using RNAi 
RNAi is used to silence gene expression by using small RNAs complementary to target 
mRNAs (Echeverri and Perrimon, 2006). In this study the cost-efficient endonuclease-
prepared short interfering RNA (esiRNA) method was applied (Kittler and Buchholz, 2003; 
Kittler et al., 2004; Kittler et al., 2007).  
12.1 esiRNA generation  
An esiWay silencer was used to generate CIDEB specific esiRNAs (p3000E01609, RZPD). 
The CIDEB sequence within the esiWay silencer plasmid (about 550 bp) is flanked by T7 and 
T3 promoter sequences for amplification by PCR. The T7 sequence was attached to the T3 
primer used together with the T7 primer for the PCR reaction to be able to perform the in 
vitro transcription later on. The same primers were used to amplify the tomato sequence, 
coding for a red fluorescent protein, which had been cloned into the pBluescript II SK+ vector 
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in our lab previously (Roose et al., 2009). The HNF4A sequence was amplified using the 
pcDNA5/FRT/TO HNF4A2 vector as a template and gene specific primers linked to the T7 
sequence. All primers are listed in section 2.3. PCR reaction was performed in volumes of 
50 µl with the Pwo-DNA polymerase (Peqlab) in a Gene AmpPCR System 2400 
thermocycler (Perkin Elmer). An aliquot of 4 µl was used to confirm the expected size of the 
amplicon on a gel.  
 
The in vitro transcription was performed using the MEGAscript Kit (Ambion) according to 
manufacturer´s instructions, but in half the recommended volume. The reaction including 4 µl 
of the PCR product was incubated over night at 37°C. The RNA was annealed after an initial 
denaturation step at 95°C for 3 minutes and slowly cooled down to room temperature. The 
dsRNAs were digested for 30 minutes at 37°C, using the ShortCut RNase III (Biolabs) to 
restrict long dsRNAs to small RNAs, 18-25 bp of size. This digestion step was a modification 
to the original protocol (Kittler and Buchholz, 2003) as well as the following purification step 
using the RNeasy Kit (Qiagen) as described by Byrd and Watzl (Lab Times online, Lab 
Trick4: Money saving siRNA purification: http://www.labtimes.org/tricks/ index.html). The 
correct sizes of the RNA fragments were confirmed on gels after the in vitro transcription, 
RNA digestion and purification step. For the last two cases, a 5% gel for small fragments 
(Roth) was used. The esiRNA concentration was determined in a ND-1000 Spectro-
photometer (NanoDrop Technologies). 
12.2 esiRNA dependent cell proliferation assays  
24 hours before transfection, 2 x 103 HNF4A2 #4 (Lucas et al., 2005) cells were seeded in a 
96-well plate in DMEM medium without antibiotics. Transient transfections were carried out 
using ExtemeGene transfection reagent (Roche) according to manufacturer´s instructions. A 
reaction mix contained 0.1 µg esiRNA and 1µl transfection reagent. Four hours after the 
transfection process antibiotics were added to the cells as well as 1 µg/ml doxycycline for 
induction of HNF4A2 expression or an equal amount of ethanol. After three days the medium 
was exchanged and after four days cell proliferation rate was determined using the MTS 
assay (Promega).  
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13 3’ RACE PCRs 
Total RNA was isolated from HEPG2 and HK120 cells as described above (11.1 RNA 
isolation and cDNA synthesis for qRT-PCR). cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) together with an oligo-dT-adapter 
primer (2.3 Oligonucleotides).  
PCR was performed (FailSafe PCR System, EPICENTRE) using a sense gene specific 
primer for the proximal and distal PA of HNF4A together with an antisense adapter primer 
(2.3 Oligonucleotides). PCR products were analyzed on an agarose gel and then cloned into 
pBluescript and sequenced or sequenced directly.  
SYBR-Green real time PCR was performed as described above (11.2 qRT-PCR). Templates 
were determined in triplicate and the housekeeping gene GAPDH served as a reference. To 
check for DNA contamination, control reactions without reverse transcriptase were 
performed. The primers used were the same as for the standard PCR. To determine the 
abundance of different HNF4A 3’UTRs, 2-∆Ct was calculated using GAPDH as a reference. 
14 Transient transfections and luciferase assays 
For each assay, 1 x 104 to 2.5 x 104 cells were seeded into a 96-well plate in 100 µl DMEM 
medium without antibiotics, 24 hours before transfection. The transfection mix was prepared 
in PS tubes and included a total of 40 ng DNA and 0.2 µl FuGene HD (Roche) diluted in 5 µl 
OptiMEM per well. The DNA mix was comprised of renilla reporter plasmids and firefly 
plasmids used for normalization of transfection efficiencies or firefly was used as a reporter 
and the renilla plasmid RL-Con served to control for transfection efficiency. The total amount 
of DNA was adjusted to 40 ng with Rc/CMV (Invitrogen) if necessary. After a 15 minute 
incubation period at room temperature, the mix was carefully added to the cell medium. 
24 hours after transfection, cells were lysed by addition of 25 µl 1x lysis buffer (Promega) per 
well followed by incubation at room temperature with continual rocking for 15 minutes. A 
5-15 µl sample of the lysate was transferred into a white 96-well plate to avoid crossover 
luminescence from neighboring wells. Firefly and renilla luciferase activities were measured 
sequentially with a luminometry (Centro LB 960, Berthold) using the Dual-Luciferase 
Reporter Assay Kit (Promega) according to the manuals instruction, but adding only 50 µl of 
the reagents. Specifics and alterations to this procedure are described below.  
 
For HNF4A P2 promoter mutation analyses, HEK293 (HNF1B) (Senkel et al., 2005) and 
INS-1 (HNF1B #1a) (Thomas et al., 2004) cell lines, both containing a tetracycline inducible 
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HNF1B transgene were used. 30 ng of the P2 specific firefly promoter constructs were 
co-transfected with 0.01 ng pRL-Con for normalization of transfection efficiencies. Four hours 
after transfection, HNF1B expression was induced by the addition of 1 µg/ml tetracycline.   
 
For Dicer knock-down experiments, expression of the short hairpin targeting Dicer (Schmitter 
et al., 2006) was induced with 1 µg/ml of doxycycline in total for three or seven days. To 
determine regulation of the HNF4A promoters by miRNAs, 8 ng of firefly promoter constructs 
were co-transfected with 0.01 ng pRL-Con. For miRNA dependent HNF4A 3’UTR analyses, 
transfection assays were performed using 0.08 ng of renilla reporter plasmids and 0.02 ng of 
the firefly construct. Four hours after transfection, addition of doxycycline was repeated and 
48 hours after transfection, luciferase activities were determined. The normalized values for 
each construct obtained for uninduced cells, treated with ethanol, were always set to 100% 
and used for standardization.  
 
In case of transfecting different 3’UTR fragments, the DNA mix was comprised of 
0.05-0.08 ng RL reporter plasmid to obtain equal molar amounts and 0.02 ng firefly luciferase 
construct (pGL3). Normalized renilla activities in cells transfected with pRL-Con was always 
set to 100% and used for standardization.  
 
To determine the impact of specific miRNAs on the HNF4A 3’UTR, 0.08 ng of the renilla 
reporter plasmids were co-transfected with 0.02 ng of the firefly construct and 50 ng of 
miRNA expression plasmids (pSM-122 (Lin et al., 2008), pCMV-miR-21 (Zhu et al., 2007) or 
pri-miR-34a (Lodygin et al., 2008)). As a negative control 50 ng Rc/CMV or 50 ng pSM-155 
(Du et al., 2006) were used instead of the miRNA expression plasmid and the obtained 
normalized values were used for standardization (100%).  
15 miRNA expression profile 
RNA was isolated from HEK293 cells by using the mirVanaTM RNA isolation Kit (Ambion) 
according to the manufacturer’s instructions. RNA samples (20 ng) were reverse transcribed 
(TaqMan MicroRNA RT Kit, Applied Biosystems) using eight different 48plex stem-loop RT 
primer pools. The cDNAs were quantified by real-time PCR using the corresponding 8x48 
individual miRNA Taqman Assays in duplicate reactions (10 µl) containing 0.1 ng of cDNA, 
1x Universal Master Mix and 1x assay. Data were analyzed by the ∆CT method using 
RNU48 as a normalization control. Microarray analyses were performed in collaboration with 
PD Dr. Ludger Klein-Hitpass (BioChip Lab, Institute of Cell Biology, University Clinic Essen). 
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16 In silico analyses 
Target sites for 20 miRNAs (Table 2) were predicted within the 3180 nt HNF4A 3’UTR with 
RNA22 (Miranda et al., 2006) using 1, 7, 14 and -20 for unpaired bases, seed/nucleus in 
nucleotides, minimum number of paired-up bases and maximum folding energy in 
heteroduplex, respectively. The proximal miR-34a target site in the 5’ 449 nt of the HNF4A 
3’UTR was predicted with TargetScan (Lewis et al., 2003). The UTRdb database (Grillo et 
al., 2009) was used to identify regulatory motifs within the HNF4A 3’UTR. MIRb and MIRc 
were predicted using the RepeatMasker function from the UCSC Genome Browser of Human 
Feb. 2009 Assembly (http://www.genome.ucsc.edu/cgi-bin/hgGateway).  
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C Results 
1 Search for proliferation relevant target genes 
regulated by HNF4A  
Overexpression of HNF4A2 causes a decrease in cell proliferation and morphological 
changes. An approach to narrow down the large number of predicted target genes of HNF4A 
involved in various processes, to those responsible for the proliferation decrease is based on 
a microarray analysis with an HNF4A isoform that has no impact on cell proliferation. All 
genes regulated by this isoform should not be relevant for the cell proliferation decrease and 
could thus be eliminated from the numerous HNF4A2 target genes determined by previous 
microarray analyses in HEK293 cells (Lucas et al., 2005; Grigo et al., 2008). 
1.1 Generation and characterization of HEK293 cells conditionally 
expressing HNF4A8 
HNF4A8, expressed from the P2 promoter is the alternative isoform to P1 specific HNF4A2 
and thus lacks the N-terminal activation domain (Sladek and Seidel, 2001). To analyze the 
effect of HNF4A8 on cell proliferation in HEK293 cells, a cell line conditionally expressing 
HNF4A8 was generated. Using the Flp-In T-Rex 293 cell system (Invitrogen) and the 
pcDNA5/FRT/TO plasmid containing the myc-tagged HNF4A8 sequence (Erdmann et al., 
2007), three independent cell lines, HNF4A8 #9, HNF4A8 #11 and HNF4A8 #14, were 
generated. All three HNF4A8 cell lines are fully functional and show a comparable 
expression pattern to other established HNF4A cell lines as determined by the following 
assays. Insertion of the cassette containing the GOI into the FRT site disrupts the functional 
lacZ-Zeocin transcriptional unit. Lack of β-galactosidase activity, validated the integration of 
HNF4A8 at the right locus (data not shown). To test for proper HNF4A8 expression upon 
addition of doxycycline, western blot analyses and immunofluorescence microscopy using a 
myc-specific antibody were performed. After induction with doxycycline for 24 hours, 
HNF4A8 was expressed in all three cell lines to a similar amount, while no protein was 
detected in uninduced cells (Fig. 3A). Loading two different amounts of protein lysate for 
each induced cell line resulted in a correspondent change in signal detection. 
Immunofluorescence analysis validated the doxycycline dependent expression of HNF4A8 in 
about 99% of the cells in all three cell lines and also confirmed the location of this 
transcription factor in the nucleus (Fig. 3B).  
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Figure 3: Establishment of HEK293 cells conditionally expressing HNF4A8.  
Cells were treated with 1 µg/ml doxycycline (+) or ethanol (-) and expression of the different HNF4A 
isoforms was detected using the monoclonal antibody 9E10 that recognizes the myc-tag. (A) The 
upper part of the western blot image compares HNF4A expression of cells treated with doxycycline or 
ethanol for three days, while in the lower part two different amounts of protein extract of cells induced 
for 24 hours were probed. The artificial HNF4A mutant C106R has a point mutation in the second zinc-
finger of the DNA-binding domain and acts as a loss-of-function mutation with a weak dominant 
negative effect (Taylor et al., 1996). (B) Hoechst staining and immunofluorescence are given for three 
independent HNF4A8 cell lines treated with doxycycline or ethanol for 24 hours. 
 
To determine if HNF4A8 regulates cell proliferation as known for HNF4A2, the proliferation of 
induced (+dox) and uninduced (-dox) cells was compared by measuring the metabolic 
activity using the MTS assay (Fig. 4A). For each cell line the values of the untreated cells 
were used for standardization (100%). Overexpression of HNF4A2, used as a positive 
control, clearly reduced cell proliferation after three and even more pronounced after six 
days. Induction of HNF4A8 #9 inhibited growth as well, but just after six days and only to 
about 90%. The metabolic activity of the other two HNF4A8 cell lines was highly comparable 
to the artificial mutant C106R and resulted in part in a minor increase in activity which was 
significant for C106R and HNF4A8 #14 after three days of induction.  
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Figure 4: Expression of HNF4A8 has no impact on cell proliferation rate and morphology.  
The cell line HNF4A2 #4 and mutant C106R served as positive and negative control, respectively. (A) 
Proliferation of cell lines induced with 1 µg/ml doxycycline for three and six days to express the given 
HNF4A isoform was determined using the MTS assay (Promega). The values were standardized to 
untreated cells grown under the same conditions. The results are means±SD of three independent 
experiments performed in triplicate. P values were determined using a one-sample t test. P values of 
< 0.05 and of < 0.01 are indicated by * or **, respectively. (B) Cells were analyzed by phase-contrast 
microscopy after treatment with 1 µg/ml doxycycline (+) or ethanol (-) for three and six days.  
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Overexpression of HNF4A2 has been shown to change morphology in HEK293 cells (Lucas 
et al., 2005). While uninduced cells exhibit a small, polygonal-shaped morphology and form a 
closely packed monolayer at confluence, induced cells change to a rounded phenotype, 
clump together building aggregates and fail to grow in an epithelium-like monolayer. 
Comparable to the negative control C106R, cell morphology was not altered in the three 
HNF4A8 cell lines upon HNF4A8 expression as assessed by phase-contrast microscopy 
after three and six days of treatment with doxycycline or ethanol (Fig. 4B).  
1.2 Comparing microarray analyses of HNF4A8 with HNF4A2 
In contrast to HNF4A2, HNF4A8 is clearly not affecting cell proliferation or morphology upon 
overexpression in the two HEK293 cell lines HNF4A8 #11 and #14. To exclude target genes 
of HNF4A not involved in proliferation control, the expression profile upon HNF4A8 
overexpression was determined using the Affymetrix GeneChip HGU 133_Plus_2.0 that 
probes approximately 38,500 human protein coding genes (54,000 probe sets). RNA isolated 
from uninduced cells and cells treated with doxycycline for 24 hours was compared from the 
two HNF4A8 cell lines. Target probe sets were identified using the following filter conditions. 
The probe sets had to be induced (I) or decreased (D), the candidates had to score a change 
p-value < 0.0045 for induced probe sets or p > 0.9955 for decreased probe sets and had to 
include at least one present call in the uninduced versus induced sample pair.  
 
 
 
Figure 5: HNF4A8 regulates only few target genes in comparison to HNF4A2.  
Microarray analyses were performed with the two independent HNF4A8 cell lines #11 and #14. The 
expression profile of cells treated with 1 µg/ml doxycycline for 24 hours was compared to untreated 
cells (ethanol). The 199 probe sets consistently regulated by HNF4A8 were compared to the 1781 
probe sets determined in two HNF4A2 cell lines (Grigo et al., 2008). 119 probe sets were regulated by 
both HNF4A isoforms. All microarrays were performed with the Affymetrix HGU 133_Plus_2.0 
GeneChip using the same filter conditions (increase: p < 0.0045; decrease: p > 0.9955). 
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Microarray analysis revealed 956 and 730 differentially expressed probe sets for 
HNF4A8 #11 and HNF4A8 #14, respectively and 199 probe sets were collectively regulated 
by HNF4A8 (Fig. 5). An overlap of 1781 probe sets was determined between target genes 
regulated by HNF4A2 #1 (3820 probe sets) and HNF4A2 #4 (3819 probe sets) by previous 
microarray analyses under the same conditions (Grigo et al., 2008). In conclusion, 119 probe 
sets were consistently regulated by both HNF4A isoforms, HNF4A2 and HNF4A8. Since 
some genes are represented by several probe sets on the chip, 119 probe sets correspond 
to 111 genes. Several differences were observed between the HNF4A8 and HNF4A2 
dependent microarray analyses. While about two-thirds of the genes were upregulated (126 
versus 55) by HNF4A8, the number of genes downregulated (628) upon HNF4A2 expression 
was almost as high as the increased (783) gene number. Even more striking is the four to 
five times higher number of target genes identified for HNF4A2 in comparison to HNF4A8 in 
the individual cell lines. The overlap of targets between HNF4A2 #1 and HNF4A2 #4 of 
almost 50% is clearly greater than for the two HNF4A8 cell lines with about 25%. This 
difference is quite remarkable considering that the two cell lines were established using the 
same host cell line at the same time, should have HNF4A8 integrated at a defined locus and 
had a highly similar phenotype in the conducted assays. Despite the low number of 
collectively regulated genes by the two HNF4A8 cell lines, the overlap of genes regulated by 
both isoforms is relatively high with over 60% of genes regulated by HNF4A8. However, only 
111 of 1411 HNF4A2 target genes were ruled out to have a significant impact on cell 
proliferation control or morphology using this approach. Although still left with 1300 potential 
HNF4A target genes involved in proliferation control, one gene (CIDEB) seemed worthwhile 
to pursue in more detail.  
1.3 CIDEB is involved in the HNF4A2 dependent decrease in cell 
proliferation 
CIDEB, a gene described to induce apoptosis, was highly upregulated in the two HNF4A2 
cell lines as determined in two independent microarray analyses (Lucas, 2005; Grigo, 2007). 
The HNF4A2 dependent upregulation of CIDEB could previously not be validated by 
qRT-PCR using the TaqMan Low Density Array (Applied Biosystems) and CIDEB was thus 
neglected (Lucas, 2005; Grigo, 2007). Interestingly, CIDEB expression as determined in the 
present microarray analyses was not altered by overexpression of HNF4A8 or the HNF4A 
mutants C106R and R154X, which do not decrease cell proliferation (Fig. 6). Since it is 
possible, that the primer pair used to detect CIDEB in the low density array was not 
functional, new primers were generated. qRT-PCR using the same RNA as for the 
expression profile, validated the microarray data for the HNF4A isoform specific regulation of 
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CIDEB (Fig. 6). Some differences in transcript detection between the two methods are likely 
based on the higher sensitivity of qRT-PCR. In contrast to the qRT-PCR data, in the 
microarray analyses CIDEB expression was absent in the HNF4A mutants, uninduced 
HNF4A2 #1 cells and both HNF4A8 cell lines. Upregulation of CIDEB upon HNF4A2 
expression in both cell lines was higher in the microarray analyses than in the qRT-PCR 
data. However, comparing the expression level of CIDEB in the induced HNF4A2 #1 and 
HNF4A2 #4 cell lines for each method, CIDEB showed a higher upregulation upon HNF4A2 
expression in HNF4A2 #1 cells by microarray analyses and in HNF4A2 #4 cells by qRT-PCR 
analyses. This observation is likely based on the absent call of CIDEB in uninduced 
HNF4A2 #1 cells in the microarray data, since the fold induction from an absent call is not as 
precise as from a present call. 
 
 
 
Figure 6: CIDEB is upregulated upon HNF4A2 expression.  
CIDEB induction was compared between cells induced with 1 µg/ml doxycycline or ethanol for 24 
hours in cell lines expressing the different types of HNF4A as indicated. The HNF4A mutant cell line 
R154X expresses a truncated HNF4A protein that lacks most of the ligand binding domain (Lausen et 
al., 2000; Laine et al., 2000). The fold induction from the microarray analyses for CIDEB is given in the 
bottom row. Values obtained in qRT-PCR were normalized to the house keeping gene GAPDH. The 
results are means±SD of one experiments performed at least in duplicate. 
 
RNA interference was used to determine if CIDEB is not only a target gene of HNF4A2, but 
also involved in the HNF4A2 dependent proliferation control. The endoribonuclease-prepared 
short interfering RNA (esiRNA) method was used to generate a pool of specific esiRNAs 
targeting various parts of the target mRNA to inhibit its expression (Kittler et al., 2004). 
According to the hypothesis that CIDEB is involved in the proliferation decrease triggered 
upon HNF4A2 overexpression, inhibiting CIDEB with esiRNAs should interrupt the signal 
cascade, resulting in an increased proliferation rate. Transfection of untreated cells not 
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expressing HNF4A (-dox) with negative control esiRNA lacking a human gene target 
(tomato) or with HNF4A esiRNA did not affect proliferation (Fig. 7). Thus, esiRNAs lacking 
endogenous target mRNAs do not exhibit any side effects. In contrast to the uninduced cells, 
transfection of cells expressing HNF4A (+dox) with tomato or HNF4A esiRNA resulted in a 
significant difference in cell proliferation decrease. Although this rescue effect was 
significant, the decrease in cell proliferation was not entirely abolished upon transfection of 
HNF4A esiRNA. Possibly not all cells were transfected and/or the esiRNAs were not active 
over the entire four day time period. However, this technique has been extensively used in a 
different study and the effect was highly reproducible (Grigo et al., 2008). Application of 
esiRNA targeting CIDEB rescued the inhibition of cell proliferation triggered by induction of 
HN4A2 expression for four days to a comparable degree as detected for the HNF4A esiRNA 
itself. Hence, CIDEB seems to be part of the signal cascade triggered by HNF4A2 
overexpression, resulting in a decrease in cell proliferation.  
 
 
 
Figure 7: CIDEB is involved in the HNF4A2 dependent decrease in cell proliferation.  
Cells were transfected with the indicated esiRNAs, four hours before addition of ethanol or 1 µg/ml 
doxycycline to induce HNF4A2 expression. As controls, esiRNA targeting tomato or HNF4A were 
used. Cell proliferation was assayed after four days using the MTS assay (Promega). The value given 
by adding tomato esiRNA and ethanol was used for standardization. The standardized value of cells 
transfected with tomato esiRNA and expressing HNF4A2 (+) was used to determine the rescue effect 
caused by HNF4A and CIDEB esiRNA in induced cells. The results are means±SD of one experiment 
run in triplicate with one exception. For CIDEB the results are means±SD of three experiments run in 
triplicate involving three independent esiRNA preparations. 
1.4 CIDEB only functions within a network of HNF4A2 target 
genes 
To determine if CIDEB is a key player in the proliferation decrease mediated by HNF4A2 and 
sufficient to cause a decrease in cell proliferation independently of HNF4A2 expression, a 
HEK293 cell line expressing Cideb upon demand was generated using the Flp-In technology. 
To be able to differentiate between the endogenous human CIDEB and the stable integrated 
Results 
 
53
Cideb, an expression construct encoding the mouse sequence including a myc-tag at the 
N-terminus was introduced into the cells. The two independent cell lines Cideb #1 and 
Cideb #2 lacked β-galactosidase activity (data not shown) and expressed Cideb upon 
addition of doxycycline for 24 hours as determined by western blot analysis using a 
myc-specific antibody (Fig. 8A).  
 
 
 
 
 
Figure 8: Establishment of HEK293 cells conditionally expressing Cideb.  
Expression of Cideb or HNF4A was detected with the monoclonal antibody 9E10 targeting the 
attached myc-tag. Cells were treated with 1 µg/ml doxycycline (+) or ethanol (-) for 24 hours. HNF4A 
served as a positive control. (A) Two different amounts of protein extract were probed on the gel for 
the induced cells in the western blot analysis. (B) The images obtained after Hoechst staining and 
immunofluorescence analyses are given for the two Cideb cell lines.  
 
As visualized by immunofluorescence analysis, all cells expressed Cideb in the two cell lines 
after doxycycline treatment for 24 hours, while uninduced cells lacked Cideb expression. 
Furthermore, the localization of Cideb in cytosolic corpuscles was clearly visible in contrast to 
HNF4A being detected in the nucleus (Fig. 8B). Mitochondria localization of CIDEB has been 
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described to be essential for induction of apoptosis (Chen et al., 2000). However, 
morphological analysis of stained nuclei (Hoechst) of cells overexpressing Cideb in 
comparison to uninduced cells, showed no signs of apoptosis (data not shown).  
 
 
 
 
 
Figure 9: Expression of Cideb does not decrease cell proliferation or changes morphology.  
The cell line HNF4A2 #4 and mutant C106R served as positive and negative control, respectively. (A) 
Proliferation was measured using the MTS assay (Promega). Gene expression was induced by 
addition of 1 µg/ml doxycycline for three and six days. Cells treated with ethanol and grown under the 
same conditions were used for standardization. The results are means±SD of two independent 
experiments performed in triplicate. P values were determined using a one-sample t test. P values of 
< 0.05 and of < 0.01 are indicated by * or **, respectively. (B) Morphology of cells treated with 1 µg/ml 
doxycycline (+) or ethanol (-) for three and six days were analyzed by phase-contrast microscopy. 
 
The MTS assay was used to determine the effect of Cideb overexpression on cell 
proliferation in the two Cideb cell lines. The metabolic activity of cells treated with 
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doxycycline for three or six days was standardized to the values obtained for the uninduced 
cells of each cell line (100%). In each assay HNF4A2 and the mutant C106R were included 
as positive and negative control, respectively. Similar to the negative control, overexpression 
of Cideb in the two cell lines for three or six days resulted in a minor in part significant 
increase in cell proliferation (Fig. 9A).  
In agreement with the proliferation data, overexpression of Cideb did not change cell 
morphology after three or six days of induction in comparison to untreated cells (Fig. 9B). 
HNF4A2 #4 and the mutant C106R were included as positive and negative control, 
respectively. Hence, expression of Cideb, independent of HNF4A2 expression, does not 
decrease cell proliferation.  
 
The expression level of Cideb might not be sufficient to cause an effect in the two Cideb cell 
lines. Due to the lack of a functional CIDEB specific antibody targeting both, the mouse and 
human sequence, comparing the exogenous Cideb expression level in the Cideb cell lines 
with the endogenous CIDEB expression triggered by HNF4A2 overexpession on protein level 
was not possible.  
 
 
 
Figure 10: Relative expression level of CIDEB.  
CIDEB expression was determined by qRT-PCR in Cideb and HNF4A2 #4 cells treated for one or 
three days with doxycycline (+) or ethanol (-). The values were normalized to the house keeping gene 
GAPDH. Two different primer pairs were used to distinguish between the endogenous CIDEB (human, 
HEK293 cell derived) and exogenous Cideb (mouse, transfected) introduced into the Cideb cell lines. 
The results are means±SD of one experiment performed in duplicate involving Cideb #2 and 
doxycycline or ethanol treatment for 1 day. Values determined after three days of incubation include 
results performed in duplicate with Cideb #1 and #2 cells. mCideb, primer targeting the mouse 
sequence; hCIDEB, primer targeting the human sequence.  
 
To approach this issue at least on RNA level, qRT-PCR was performed (Fig. 10). Primers 
targeting the mouse Cideb sequence introduced into the Cideb cell lines were used to 
analyze the transgene. No transcripts were detected in the HNF4A2 #4, HNF4A8 and C106R 
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cell lines with those primers, proofing that they do not target the endogenous human CIDEB, 
but are specific for the mouse sequence (data not shown). Addition of doxycycline to the 
Cideb cell line for one and three days resulted in a six to seven fold increase in transgene 
Cideb expression. Using primers targeting the human sequence, endogenous CIDEB was 
shown to be present at a relative abundance of about 2% compared to the house keeping 
gene GAPDH in Cideb and untreated HNF4A2 #4 cells. Upon addition of doxycycline, 
endogenous CIDEB expression remained at the same level in Cideb cells, but increased in 
HNF4A2 #4 cells. Thus, induced expression of the Cideb transgene does not seem to 
influence endogenous CIDEB expression. The relative abundance of exogenous Cideb in the 
Cideb cell lines was more than twice as high as the endogenous CIDEB level upon 
overexpression of HNF4A2. Hence, at least the RNA expression level of Cideb is not too low 
to cause an effect in the Cideb cell lines. 
2 Transcriptional regulation of HNF4A via the P2 and P1 
promoter  
The regulation of HNF4A itself is crucial for proper function. At the transcriptional level, 
regulation of HNF4A is imparted by two promoters, P2 and P1, which mediate cell-specific 
activity (Thomas et al., 2001). The transcriptional regulation of both promoters was 
investigated with regards to dysregulation leading to human diseases.  
2.1 Mutations in the P2 promoter impair the function of the 
promoter in vitro and co-segregate with diabetes 
The -192C>G mutation in the HNF4A P2 promoter was linked to diabetes in several families 
by two independent studies, but an impact of the mutation on the promoter activity could not 
be confirmed by luciferase assays (Ek et al., 2006; Raeder et al., 2006a). From our 
colleagues in Exeter, Bratislava and Auckland we learned of two additional mutations in the 
P2 promoter of the HNF4A gene including a -136A>G mutation in a Slovak family and a 
-169C>T mutation in a New Zealand family. These mutations were not identified in >800 
control chromosomes (500 of which were of European Caucasian origin). The -136A>G 
mutation co-segregated with diabetes in two family members with normal body mass index 
and early diabetes onset (Fig. 11A). The -169C>T mutation co-segregated with diabetes in 
all but one family member (maternal aunt) who has features of T2DM (Fig. 11B). Details of 
clinical data have been published recently (Wirsing et al., 2010). 
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(A)   P2/-136A>G                     (B)                               P2/-169C>T  
 
 
Figure 11: Pedigrees of the families with P2/-136A>G (A) and P2/-169C>T mutations (B). 
Squares represent male; circles represent female; open symbols are normal glucose tolerant; and 
filled symbols are diabetic. Probands are indicated by an arrow. The text beside each individual 
represents: mutation carrier status (NM, HNF4A P2 mutation positive; NN, wild-type; and n.t., not 
tested); age at diagnosis if diabetic/current age, current diabetes treatment (diet; Met, metformin; SU, 
sulfonylurea; OAD, oral antidiabetic drug – type unknown; INS, insulin); body mass index; and 
birthweight standard deviation score. n.a., not available. Data as given in Figure 1 of Wirsing et al. 
(2010).  
 
The -136A>G mutation affects the region identified as the HNF6/OC2 binding site in the 
murine promoter (Briancon et al., 2004) and -169C>T mutates the HNF1 binding site of the 
P2 promoter (Thomas et al., 2001; Hansen et al., 2002). The latter site can be targeted by 
HNF1A and HNF1B since the DNA binding sequence specificity is almost identical for both 
transcription factors (Tronche and Yaniv, 1992). The previously described mutation -192C>G 
affects binding of an unknown factor enriched in human pancreatic islets and rat INS-1 cells 
(Ek et al., 2006). All three mutations alter nucleotides that are conserved from human to 
platypus (Fig. 12). To reveal the functional importance of these alterations, mutations for 
-136A>G, -169C>T and -192C>G were introduced into a firefly luciferase reporter construct 
containing the highly conserved P2 promoter region from -285 to -1 upstream of the 
translational start site (P2/-285; Fig. 12). Their effects were analyzed in transient transfection 
experiments in the HEK293 (HNF1B) cell line (Senkel et al., 2005) and INS-1 (HNF1B) cells 
(Thomas et al., 2004) allowing for homogenous induction of HNF1B expression. While 
HEK293 cells lack endogenous HNF1A and HNF1B expression (Lucas et al., 2005), 
endogenous HNF1A expression is higher than HNF1B in the INS-1 cell line (Thomas et al., 
2004). 
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Figure 12: Schematic representation of the P2 promoter region of the human HNF4A gene.  
The screen shot taken from the UCSC Genome Browser (assembly March 2006) displays the genome 
position from 42417570 to 42417866 of chromosome 20 and the degree of conservation across 28 
species indicated by black areas. The bracket locates the region included in the P2/-285 promoter 
luciferase construct from -285 to -1 relative to the ATG located in exon 1D (Thomas et al., 2001). The 
nucleotide sequence alignment of a highly conserved region and the position of the novel mutations 
-136A>G and -169C>T and the late-onset diabetes mutation -192C>G (Ek et al., 2006; Raeder et al., 
2006a) is shown below. The binding sites for HNF1A/HNF1B (Thomas et al., 2001; Hansen et al., 
2002), IPF1 (Thomas et al., 2001) and HNF6/OC2 (taken from the mouse data (Briancon et al., 2004)) 
are boxed. Data published in Wirsing et al. (2010). 
 
In HEK293 cells the basal activity of the P2/-285(-136A>G) and P2/-285(-169C>T) mutated 
constructs was significantly lower than the basal activity of the wild-type promoter construct 
P2/-285 (Fig. 13, upper part). Induction of HNF1B expression resulted in a fourfold activation 
of the wild-type promoter, but all three mutated constructs were activated at a significantly 
lower level. Mutation of the HNF1 binding site (-169C>T) resulted in the lowest 
transactivation by HNF1B. Comparing the activity in the presence of HNF1B, all three 
mutated constructs revealed a lower activity, although the effect of the -192C>G mutation 
was marginal. In INS-1 cells, the constructs P2/-285(-169C>T) and P2/-285(-192C>G) had 
significantly impaired basal activity compared with the wild-type promoter (Fig. 13, lower 
part). Following tetracycline induction of HNF1B expression, the activity of all of the 
constructs except P2/-285(-169C>T) decreased to about 50% of their uninduced activity. 
Comparing the activity in the presence of HNF1B, all three mutated promoter constructs had 
reduced activity compared to the wild-type promoter.  
In conclusion the two novel mutations, -136A>G and -169C>T and the previously identified 
late-onset diabetes mutation, -192C>G are linked to diabetes and impair the function of the 
HNF4A P2 promoter in vitro.  
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Figure 13: In vitro analyses of mutations in the P2 promoter of the HNF4A gene. 
The results of transient transfection assays in HEK293 and INS-1 cells are shown. The activity of the 
wild-type promoter was about threefold and fiftyfold higher than the value obtained from pGL3-Basic in 
HEK293 and in INS-1 cells, respectively. For each construct, eight transfection assays were 
performed involving four independent plasmid preparations. Each luciferase assay was performed in 
triplicate and a CMV driven renilla luciferase was used to control for transfection efficiency. The 
activity of the wild-type construct was used to standardize the basal activity (no HNF1B). The 
activation by HNF1B reflects the activation of the constructs by the induction of HNF1B. The activity 
with HNF1B compares the activity of the mutants with the wild-type in the presence of induced 
HNF1B. P values were determined using a one-sample t test for basal activity as well as for activity 
with HNF1B and an independent-samples t test for activation by HNF1B. P values of < 0.05, of < 0.01 
and of < 0.001 are indicated by *, ** or ***, respectively. 
2.2 The P1 and P2 promoter might be regulated by miRNAs 
In addition to transcription factors regulating the activity of promoters, few studies have 
described an activating effect of agRNAs (Li et al., 2006a; Janowski et al., 2007) and 
miRNAs on promoters (Place et al., 2008; Majid et al., 2010). Hence, miRNAs that are 
downregulated in diabetes and RCC might contribute to the downregulation of HNF4A in 
these diseases due to the loss of activation of the P2 and P1 promoter, respectively. 
Numerous potential miRNA binding sites were predicted within the HNF4A P2 and P1 
promoter using the RNA22 program (Miranda et al., 2006). To experimentally evaluate the 
possibility of any miRNA targeting the P2 and P1 promoter, a HEK293 cell line was used in 
which the Dicer protein can be conditionally knocked-down by doxycycline (Schmitter et al., 
2006). Since Dicer is required for miRNA biogenesis, its inhibition results in a lack of 
miRNAs. In the case of miRNAs targeting and activating a promoter, addition of doxycycline 
attenuates the activating effect. A reporter plasmid (pGL3 basic) containing the P2 promoter 
sequence extending from -2200 bp to the nucleotide preceding the translation initiation site 
(position -1) upstream of the firefly luciferase was transfected into cells depleted of Dicer. In 
comparison to uninduced cells, luciferase activity was decreased by about 25%, indicating a 
potential regulation of the HNF4A P2 promoter by miRNAs present in HEK293 cells 
(Fig. 14A). To locate the area of crucial miRNA binding sites, luciferase activity of various 5’ 
deletions constructs was assessed upon Dicer knock-down. However, even deleting the 
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promoter sequence up to position -135 bp upstream of the ATG codon (transcription start site 
at position -103 and TATA box starting at -136) still resulted in a highly similar decrease in 
luciferase activity upon miRNA depletion as for all other P2 constructs. To ensure that the 
observed effect was promoter specific, the impact of miRNA depletion was analyzed on the 
CMV promoter, resulting in no decreased activity (Fig. 14A). 
 
 
 
Figure 14: Dicer knock-down experiments to determine whether the HNF4A P2 (A) and P1 (B) 
promoters are regulated by miRNAs.  
The P2 and P1 promoter fragments are all cloned into the pGL3 basic plasmid. The longest P2 
promoter fragment contains 2200 base pairs upstream of the translation initiation site (excluding the 
ATG codon). The P1 promoter fragment of 1114 base pairs extends from nucleotides -998 to +117 
from the transcription start site. Dicer knock-down was triggered by addition of doxycycline to the 
Dicer-kd/2b2 cell line (Schmitter et al., 2006) for three and seven days. Firelfly reporter constructs 
were transiently transfected two days before luciferase activity was measured. At least three 
transfection assays were performed for each construct, involving two independent plasmid 
preparations, except for P1/-132 for which just one construct was available. Each assay was 
performed in triplicate and a CMV-driven renilla luciferase was used to control for transfection 
efficiency. The values obtained for each construct determined in the presence of Dicer (ethanol 
added) were used for standardization (100%) and are not shown. The P values were determined 
between the promoter constructs and pGL3 basic in induced cells using an independent-samples t 
test. P values of < 0.05 are indicated by *. 
 
Analyses of the 1114 bp P1 promoter revealed a highly reduced luciferase activity to 35% 
upon Dicer knock-down, suggesting an activating effect of miRNAs on the HNF4A P1 
promoter (Fig. 14B). Further 5’ deletion of this promoter, even up to -132 bp still conferred a 
reduced activity to 56% in comparison to cells expressing mature miRNAs. Although no 
effect had been detected using the CMV promoter, the activity of the CMV promoter was 
severalfold higher than the P1 and P2 activity. To rule out possible side effects from the 
residual sequence of the pGL3 reporter plasmid, which might be masked by the high activity 
of the CMV promoter in the corresponding construct, the Dicer dependent activity was 
determined for the pGL3 basic plasmid. Although this plasmid does not contain a promoter 
sequence, it was slightly active and also conferred a reduced activity upon Dicer knock-
down. However, upon miRNA depletion the activity of the P1 constructs containing 1114 bp 
and 282 bp was significantly reduced by about 50% in comparison to pGL3 basic. Although 
there is little knowledge about the regulation of promoters by miRNAs and adequate positive 
and negative controls are missing, the present data including the measurements of the pGL3 
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basic plasmid make the regulation of the HNF4A P2 promoter by miRNAs unlikely, but 
provides evidence for an activating effect of miRNAs on the P1 promoter.  
3 Posttranscriptional regulation of HNF4A via the 3’UTR 
While transcriptional regulation of HNF4A has been extensively studied, the 
posttranscriptional regulation has been entirely neglected to date. The evident role of 3’UTRs 
in translation, localization and stability of mRNAs and its impact on various diseases, has 
proven that it is essential to gain knowledge of the posttranscriptional regulation (Chatterjee 
and Pal, 2009; Thomas et al., 2010). To obtain a comprehensive understanding of HNF4A, 
the 3’UTR and its regulation was investigated.  
3.1 HNF4A expresses two alternative 3’UTRs 
The RefSeq sequences NM_000457.3 and NM_178849.1 of the human HNF4A mRNA 
encode a 3’UTR of 1724 bp that contains the non-canonical PAS GATAAA 15 nt upstream of 
the 3’ end (Fig. 15A). However, this PAS and the surrounding sequence are conserved in 
primates only, but not among other mammals. In contrast, the 3’UTR of the murine Hnf4a 
mRNA is 2816 nt in length (RefSeq NM_008261.2) and encompasses the canonical PAS 
AATAAA (Fig. 15A). This PAS and the surrounding sequence are highly conserved among 
different mammals including human. To determine which polyadenylation site is functional in 
human cells, 3’ RACE was performed with HNF4A mRNA isolated from the hepatoma cell 
line HEPG2 and the kidney cell line HK120. Sequence analyses of the cDNA revealed that in 
both cell lines the proximal as well as the distal PAS are used, resulting in cleavage of the 
mRNA 15 nt and 19 nt downstream of the PAS at position 1724 nt and 3180 nt, respectively.  
To determine the abundance of the short and long 3’UTR in the human HNF4A RNA of the 
HEPG2 and HK120 cell lines, qRT-PCR was performed using GAPDH as a reference. The 
amount of the HNF4A 3’UTR was about two-fold higher in HEPG2 than in HK120 cells 
(Fig. 15B). In both cell lines the distal PAS generating the long 3’UTR was used 
predominantly, representing about 75% and 60% of the HNF4A transcripts in the hepatoma 
and kidney cell line, respectively. These data reveal that in human cells in addition to the 
predicted HNF4A 3’UTR of 1724 nt, a much longer 3’UTR of 3180 nt is expressed.  
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Figure 15: Two distinct PAS in the human HNF4A mRNA.  
(A) Schematic representation of the HNF4A 3’UTR. The screen shot taken from the UCSC Genome 
Browser (assembly March 2006) depicts the known human HNF4A 3’UTR with the RefSeq sequences 
NM_000457.3 and NM_178849.1 and the genome position from 42,491,540 to 42,494,950 of 
chromosome 20. The degree of conservation across 17 species is indicated by black areas. The 
nucleotide sequence alignment of the region surrounding the proximal and distal PAS is shown below. 
Non-conserved nucleotides in comparison to the human sequence are given for the different species, 
while dots represent conserved nucleotides. The proximal and distal PAS are boxed and the 
corresponding cleavage sites, as determined by 3’ RACE and subsequent sequencing, are indicated 
by a vertical line. The last nucleotide of the short and long 3’UTR is marked at position 1724 and 3180, 
respectively. (B) The relative abundance of the short and long HNF4A 3’UTRs was determined in 
comparison to the house keeping gene GAPDH. Two independent RNA samples were prepared from 
each cell line and the qRT-PCR was performed in triplicates. Each column thus represents the 
mean±SD of six measurements.  
3.2 Both 3’UTRs confer a repressive effect 
To gain insight into the mode of regulation of HNF4A via its 3’UTR, the short and long 3’UTR 
was cloned downstream of the renilla luciferase ORF into the reporter plasmid RL-Con 
(Schmitter et al., 2006). The effect was analyzed in HEK293 cells using a firefly luciferase 
reporter as reference (Fig. 16, middle panel). The renilla luciferase activity was significantly 
reduced to about 60% by insertion of the long (1-3180) or short (1-1746) 3’UTR implying the 
existence of elements conferring a repressive effect.  
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Figure 16: Systematic reporter analyses of the human HNF4A 3’UTR.  
The results of luciferase assays 24 hours after transient transfections into HEK293 and INS-1 cells are 
shown. The numbers of the construct names refer to the nucleotide position in the HNF4A 3’UTR with 
1 being the first nucleotide after the stop codon. Each 3’UTR fragment was cloned downstream of the 
renilla luciferase ORF into the RL-Con plasmid. At least three transfection assays were performed for 
each construct, involving two independent plasmid preparations. Each assay was performed in 
triplicate and a CMV-driven firefly luciferase was used to control for transfection efficiency. The activity 
of the RL-Con plasmid was used for standardization to 100%. P values were determined using a one-
sample t test. P values of < 0.05 and of < 0.01 are indicated by * or **, respectively. 
 
To get an indication which cis-elements mediate the effect, an in silico search was 
performed. Only few potential cis-elements of RNA-binding proteins were found (Tab. 1). The 
sex-lethal (SXL) binding site consists of a polyuridine tract of eight or more residues and is 
bound by the SXL RNA-binding protein (Samuels et al., 1994). In Drosophila melanogaster 
this female specific protein functions as the master regulator of somatic sex determination 
and X-chromosome dosage compensation. It modulates splicing and translation of target 
pre-mRNAs (Johnson et al., 2010). The K-box (cTGTGATa) has been identified in the 
3’UTRs of many Notch pathway target genes in Drosophila melanogaster (Lai et al., 1998). 
Regulation by K-box is spatially and temporally ubiquitous and mediates negative 
posttranscriptional regulation, mainly causing decreased transcript levels. The Musashi 
binding element (MBE) is critical for early translational activation in Xenopus by interaction 
with the Musashi binding protein (Arumugam et al., 2010). In mammalian somatic cells, MBE 
seems to mediate repression of mRNAs at the translational level (Imai et al., 2001). 
Furthermore, the distal, but not the little conserved proximal PAS was found. Considering the 
large size of the 3180 nt long HNF4A 3’UTR, this raised the question if various other 
functional binding elements are missing. miRNA binding site prediction in turn revealed 
several hundred possible target sites. Depending on which miRNA prediction program and 
setting was applied, potential target sites for various miRNAs varied substantially. To 
address this issue of uncertain regulatory element prediction, functional assays were used to 
initially locate the area of crucial regulatory elements. 
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Table 1: Regulatory sites in the long 3’UTR of HNF4A. 
Binding sites identified by UTRdb (http://utrdb.ba.itb.cnr.it/; Grillo et al., 2009).  
 
Binding site Position Sequence 
SXL binding site 2680-2695 TTTTTTTTTTTTTTT 
K-box 2940-2947 CTGTGATC 
Musashi binding element 910-914  GTAGT 
Musashi binding element 2152-2157 ATTAGT 
Polyadenylation signal 3156-3180 AATAAATGGCGCATATGTTTTCTAA 
 
In a comprehensive systematic approach, the 3’UTR was dissected and a repressive activity 
was found in the 5’ part (1-630), whereas the 3’ part (2770-3180) had no influence (Fig. 16). 
Furthermore, a distinct activity located in fragment 631-3180 was observed that surprisingly 
had a much higher repressive effect, while a construct containing the sequence from 1-2769 
resulted in a decrease in luciferase activity similar to the one observed for the long 3’UTR. To 
pin down the area within the HNF4A 3’UTR which confers the strong repressive effect, short, 
mainly overlapping constructs were generated covering the entire 3180 nt of the 3’UTR. 
Whereas the majority of 3’UTR-fragments showed no or only minor effects, the two 
constructs comprising the 3’UTR sequences A (850-1313) and B (1288-1746) repressed 
luciferase activity down to 27% and 21%, respectively. Since in HEK293 cells the HNF4A 
gene is silent (Lucas et al., 2005), the activity of the same 3’UTR fragments was measured in 
the INS-1 cells expressing HNF4A (Thomas et al., 2004). In this cell line similar repressive 
activities were seen that were even more pronounced (Fig. 16, right panel). Taken together, 
the HNF4A 3’UTR contains several elements that negatively influence luciferase reporter 
activity.  
3.3 Identification of two novel negative elements within the 
HNF4A 3’UTR 
Using UCSC Genome Browser the “mammalian interspersed repetitive elements” MIRb and 
MIRc were identified within sequence A (850-1313) and B (1288-1746), respectively (Fig. 17, 
left panel). MIRs are tRNA-derived SINEs found in all mammalian genomes, including 
marsupials (Smit and Riggs, 1995) and have a trend for PAS association (Lee et al., 2008). 
However, it was excluded that these repetitive elements mediate the repressive effects, as 
fragments retaining the sequence for MIRb (1208-1313) or MIRc (1392-1513) did not affect 
luciferase reporter activity in HEK293 and INS-1 cells (Fig. 17, middle and right panel).  
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Figure 17: Locating negative elements within sequence A and B of the HNF4A 3’UTR.   
The results of luciferase assays were derived and evaluated as in Figure 16. The grey boxes in the left 
panel indicate negative element A or B. The white box illustrates the mammalian interspersed 
repetitive elements (MIRb or MIRc) as predicted by the USCS Genome Browser.  
 
To locate the functional elements, the sequences were gradually trimmed from the 3’ and 5’ 
end. Shortening sequence A on the 3’ end to position 1259 and even to 1207 amplified the 
repressive effect in HEK293 cells to 16% and 15%, respectively. Further constriction on 
either side revealed a gradual release of the repressive effect, ruling out an essential role of 
the Musashi element (910-914) on the HNF4A 3’UTR (Tab. 1). Instead, the fragment 
extending from 850-1207 was defined as negative element A. Similarly, shortening sequence 
B on the 3’ and 5’ end, negative element B (1288-1666) was defined, as it mediates the 
highest repressive function and any truncation leads to a partial or even total loss of the 
repressor activity. A corresponding analysis in INS-1 cells gave similar result (Fig. 17, right 
panel).  
Taken together, two previously unknown elements were located within the HNF4A 3’UTR 
that are separated by about 80 bp. Their size of approximately 400 nt (357 nt and 378 nt) is 
quite large and based on their position they are present in the short as well as the long 
3’UTR of the HNF4A mRNA.  
 
The strong activity of negative element A and B was only observed when these elements 
were excised from the 3‘UTR (Fig. 16). Deleting a sequence containing both negative 
elements from the construct containing the long HNF4A 3’UTR did not change the luciferase 
activity in comparison to the entire 3’UTR (Fig. 18). In contrast, the high repressive effect of 
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construct 631-3180, was abolished upon deletion or inversion of the sequence containing 
negative element A and B. This implied a counteracting element in the 5’ part of the 3’UTR 
(1-630). Indeed, insertion of the sequence 1-630 nt upstream of element A or B largely 
abolished the repressive effect of the negative element A or B. The observation that the 
repressive effect of element A and B is lost upon inversion is consistent with a regulatory 
element functioning on the RNA level. To obtain further evidence, the SV40 3’UTR with its 
PAS was inserted upstream of negative element A or B. In both cases the repressive effect 
was lost, as expected if the transcript is polyadenylated at the SV40 PAS and thus does not 
include negative element A or B. However, the abolishment of the repressive effect was not 
seen, if the SV40 3’UTR was inserted in opposite direction leading to a PAS on the 
noncoding DNA. Additionally, this experiment excluded the possibility that any sequence 
introduced upstream of element A or B would abrogate the effect. All described effects were 
highly similar in HEK293 and INS-1 cells.  
 
 
 
Figure 18: Counteracting the two negative elements.  
The negative elements A and B are indicated by grey boxes, the deletion of the negative elements is 
illustrated by a broken line, whereas the inversion of this element is marked by backwards arrows. The 
insertion of the SV40 termination signal in sense and antisense is marked. The results of luciferase 
assays were derived and evaluated as in Figure 16. P values were determined between two columns 
as indicated by brackets. Non-significant changes are marked by ns and refer to p values > 0.01.  
3.4 The HNF4A 3’UTR is regulated by miRNAs 
To address the question experimentally whether HNF4A is regulated by miRNAs, initially a 
general approach was applied using the HEK293 cell line in which the Dicer protein can be 
conditionally knocked-down by doxycycline (Schmitter et al., 2006). Since Dicer is required 
for miRNA biogenesis, the repressive effect of miRNAs is relieved, if Dicer is downregulated. 
Using the renilla luciferase reporter with the entire 3180 nt HNF4A 3’UTR, depletion of Dicer 
resulted in an increase in luciferase reporter activity by 21% (Fig. 19A). The effect was not as 
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pronounced as for the RL-Perf reporter containing one perfect let-7a binding site or the 
RL-3xBulgeB reporter construct containing three bulged let-7a sites (Schmitter et al 2006), 
that mediated in the present study an increase of 55% and 89%, respectively. However, the 
significant increase indicated that miRNAs regulate the HNF4A 3’UTR. 
 
 
 
Figure 19: Dicer knock-down indicates that the HNF4A 3’UTR is regulated by miRNAs.  
To knock-down the Dicer protein, doxycycline was added to the Dicer-kd/2b2 cell line (Schmitter et al 
2006) for three or seven days. Two days before luciferase activity was measured, the cells were 
transiently transfected with reporter constructs. The nomenclature of the constructs is as in Figure 16. 
At least three transfection assays were performed for each construct, involving at least two 
independent plasmid preparations. Each assay was performed in triplicate and a CMV-driven firefly 
luciferase was used to control for transfection efficiency. The activity of each construct measured in 
the presence of Dicer (ethanol added) was used for standardization (100%) and is not shown. The 
3xBulgeB and RL-Con reporter (Schmitter et al 2006) harboring three bulged binding sites for let-7a 
and lack any binding sites, respectively, were included as a positive and negative control in each 
experiment (not shown). The P values were determined using an independent-samples t test. P values 
of < 0.05 and of < 0.01 are indicated by * or **, respectively. 
 
Several miRNAs misregulated in RCC have been identified, while no miRNA expression 
profiles for diabetic β-cells exist. To determine if HNF4A is regulated by miRNAs with regards 
to a physiological significance, binding sites for miRNAs that are upregulated in RCC were 
predicted. 20 miRNAs were selected due to the following criteria (Tab. 2). Each miRNA had 
to be upregulated in RCC according to at least one of the six studies (Gottardo et al., 2007; 
Kort et al., 2008; Nakada et al., 2008; Jung et al., 2009; Chow et al., 2010; Juan et al., 2010). 
One site with a perfect seed sequence was required within the 3180 nt of the HNF4A 3’UTR, 
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unless the miRNA was identified in more than four of six studies with a potential target site 
lacking a perfect seed sequence. The RNA22 program was used to search for binding sites 
for those 20 miRNAs, since it allows to specifically predict binding sites for miRNAs of 
interest within the queried 3’UTR sequence (Miranda et al., 2006). Despite the restriction to 
20 miRNAs overexpressed in RCC, still 140 potential binding sites for miRNAs were 
retrieved within the HNF4A 3’UTR.  
 
Table 2: Set of miRNAs upregulated in RCC.  
The 20 selected miRNAs upregulated in RCC are listed. For each miRNA the studies reporting an 
increase are given as indicated by 1-6 (1: Gottardo et al., 2007; 2: Kort et al., 2008; 3: Nakada et al., 
2008; 4: Jung et al., 2009; 5: Chow et al., 2010; 6:Juan et al., 2010). Eric J. Kort provided the original 
data on miRNA expression profiling (Kort et al., 2008). The average fold change for a miRNA is used 
when identified in more than one study. The predicted number of target sites by RNA22 (Miranda et 
al., 2006) including perfect seed sequences is given with the perfect seed sites also listed in brackets. 
The CT values were determined in HEK293 cells by qRT-PCR using 384 TaqMan human miRNA 
assays from Applied Biosystems and a multiplex RT protocol comprising eight different pools of stem-
loop RT primers. In cases only the opposite stem loop of the corresponding miRNA was on the 
TaqMan Array this is indicated. miRNAs not analyzed are marked as not determined (n.d.).  
 
 
Hence, to locate the area of crucial miRNA binding sites within the HNF4A 3’UTR, several 
fragments of the 3’UTR were analyzed. Transfection of the 5’ end of the 3’UTR (1-630) 
conferred a significantly increased luciferase reporter activity upon Dicer depletion, but the 
increase was even more pronounced for a construct containing the remaining sequence from 
631-3180 (Fig. 19, upper part). Therefore, the focus was set on the previously described 
miRNA References Fold induction N of target sites  
(seed) 
CT 
miR-7 1   1.25   8 (1)    33.4 
miR-18a* 2, 6   4.05 12 (1)     33.1 (miR-18a) 
miR-21 2, 4, 5, 6   3.50   7 (0)    34.3 
miR-27a 4   1.85 13 (1)    35.3 
miR-34a 2, 5, 6   2.95 14 (2)    34.2 
miR-106b* 4   2.30   9 (2)    29.8 (miR-106b) 
miR-122 2, 3, 4, 6 28.16   9 (0) > 40 
miR-140-5p 4 10.63   4 (2)    31.7 
miR-146b 2   1.70   2 (1)     35.0 
miR-155 2, 3, 5, 6   5.66   2 (0)    36.6 
miR-193a-3p 6   2.20   1 (1)    35.6 (miR-193a-5p) 
miR-210 2, 3, 4, 5, 6 11.85   9 (0)    33.1 
miR-224 2, 3, 4, 5, 6   7.05   2 (0) > 40 
miR-340* 4   2.41   9 (1)    34.1 (miR-340) 
miR-342-3p 4   2.35   4 (1)    29.5 
miR-342-5p 2   2.30 10 (1)    29.5 (miR-342-3p) 
miR-452* 2, 3, 6   8.50   2 (1) > 40    (miR-452) 
miR-584 4   2.91 14 (1)    n.d. 
miR-592 5   4.95   4 (1)    n.d. 
miR-1271 4   3.86   5 (1)    n.d. 
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fragments spanning the entire 3180 nt. Whereas miRNAs did not seem to target the 3’ end of 
the 3’UTR (2574-3180), the remaining fragments mediated a slight increase in reporter 
activity upon Dicer knock-down. However, only the 5’ fragment 1-449 nt showed a highly 
significant effect. To locate the area of crucial miRNA binding sites even further and possibly 
identify the exact location by loss of the effect, 12 gradually shortened constructs were 
analyzed within the 5’ 449 nt (Fig. 19, lower part). The significant increase upon miRNA 
depletion was still present in over 50% of the constructs, but lost for constructs containing 
196 or less nucleotides from the 5’ end. Hence, miRNA target sites significant for HNF4A 
regulation seem to be located within nucleotides 204-449. No significant loss of effect 
between two consecutive constructs was observed, possibly reflecting several miRNAs 
targeting this area with a similar effect. In that case depleting all miRNAs is useful to locate 
an area of crucial miRNA binding, but a more specific method is needed to pinpoint single 
miRNA binding sites. In conclusion, the data reveal potential functional miRNA target sites 
distributed within 2.6 kb of the 3.2 kb 3’UTR. 
3.4.1 miR-122 and miR-21 are not key regulators of the HNF4A 3’UTR 
To experimentally verify miRNAs upregulated in RCC that potentially target the HNF4A 
3’UTR (Tab. 2), miRNAs were specifically mimicked. miR-122 shows the highest fold 
induction in RCC and has nine potential binding sites predicted within the 3180 nt HNF4A 
3’UTR including one located within nucleotides 204-449 at position 249-270 according to 
RNA22. To ensure optimal experimental conditions, the miR-122 dependent downregulation 
of the validated reporter plasmid psi-CCNG1 was reproduced (Fig. 20A) using the expression 
plasmid pSM-122 (Lin et al., 2008). Transfection of the reporter plasmid containing the long 
HNF4A 3’UTR or fragment 631-3180, resulted in a similar significant decrease as obtained 
for psi-CCNG1, indicating the regulation by miR-122 (Fig. 20A). Further analysis of various 
shortened constructs including fragment 1-449, revealed a slightly inhibited activity, but no 
significant effect upon miR-122 expression in most of the cases. Deleting the remaining 
potential miR-122 binding site in construct 1-249, still caused the same decrease. Hence, to 
rule out side effects from the residual sequence of the reporter plasmid as observed in the 
promoter studies, the effect of miR-122 was determined on the RL-Con plasmid. Indeed, a 
significant decrease was observed, making the regulation of the HNF4A 3’UTR by miR-122 
unlikely. Furthermore, no regulation of the HNF4A 3’UTR by miR-122 was detected in INS-1 
cells (Senkel et al., unpublished data). 
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Figure 20: Reporter analyses of miR-122 (A) and miR-21 (B) sites in the HNF4A 3’UTR.  
HEK293 cells were co-transfected with reporter plasmids and miRNA expression vectors (pSM-122; 
Lin et al., 2008 and pCMV-miR-21; Zhu et al., 2007) 24 hours before cell collection. At least one 
transfection assay was performed for each construct, involving two independent plasmid preparations 
in case of two or more assays. Each assay was performed in triplicate and a CMV-driven firefly 
luciferase was used to control for transfection efficiency. The activity of each construct in the absence 
of the miRNA expression plasmid (replaced by pSM-155; Du et al., 2006 or Rc/CMV) was used for 
standardization (100%) and is not shown. psi-CCNG1 (Lin et al., 2008) and TPM1 (Luc-TPM1-V1-
UTR; Zhu et al., 2007) served as positive controls for miR-122 and miR-21, respectively, while TPM1 
mut (Luc-TPM1-V1-UTR-d; Zhu et al., 2007) was used as a negative control for miR-21. The firefly 
activity used to control for transfection efficiency was expressed from the same plasmid as the renilla 
activity in case of psiCCNG1. The positive and negative control for miR-21 expressed firefly luciferase 
so that the RL-Con plasmid was used to control for transfection efficiency. The grey boxes indicate 
potential miRNA target sites without a perfect seed sequence and the number of target sites is given 
underneath the box in case of more than one site. A black cross in the grey box illustrates a destroyed 
target site. P values were determined using a one-sample t test. P values of < 0.05 are indicated by *. 
 
While miR-122 is usually highly liver specific (Lagos-Quintana et al., 2002), miR-21 
expression is conserved in the kidney and data indicates it is involved in kidney disease and 
functions as an oncogene (Zhu et al., 2007; Saal and Harvey, 2009). Hence, miR-21 shows a 
moderate expression in HEK293 cells. The upregulation in RCC is less pronounced but 
frequently detected (Tab. 2). To ensure that miR-21 expression effects target genes despite 
the moderate endogenous miR-21 level, the decrease of the reporter construct Luc-TPM1-
V1-UTR was confirmed in the present study upon miR-21 expression (pCMV-miR-21), while 
no effect was detected for the TPM1 mutant (Luc-TPM1-V1-UTR-d) in which the miR-21 
bindings site is deleted (Zhu et al., 2007; Fig. 20B). Furthermore, an impact of miR-21 on 
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RL-Con was ruled out. Transfection of the 3180 nt HNF4A 3’UTR and the construct 
631-3180 resulted in a similarly small but significant decrease (Fig. 20B). Hence, the 
potential binding site at position 621-642 does not seem to be functional. Analyses of 
shortened constructs containing at least one potential binding site did not cause a decreased 
luciferase activity upon miR-21 expression. Thus, miR-21 seems to only have a slight impact 
on the HNF4A 3’UTR by targeting several sites simultaneously.  
3.4.2 miR-34a downregulates HNF4A by targeting several sites in the 3’UTR 
miR-34a has one of the highest numbers of potential target sites (14) within the HNF4A 
3UTR (Tab. 2). Two sites include a perfect seed sequence and one of them is located within 
the 5’ sequence of 1-449 nt of the HNF4A 3’UTR (RNA22). Although miR-34a is moderately 
expressed in HEK293 cells (Tab. 2), overexpression of pri-miR-34a downregulated the 
validated miR-34a reporter plasmid pGL3-CDK6-BS2 (Fig. 21A) containing one miR-34a 
target site (Lodygin et al., 2008). A similar effect was seen in INS-1 cells. An even more 
pronounced decrease by miR-34a was observed by using reporters including the 5’ end 
construct 1-449 or 1-378 of the HNF4A 3’UTR. Destroying the target sequence of the 
predicted miR-34a binding site in construct 1-249 clearly diminished the decrease, but did 
not entirely abrogate the effect. Therefore, additional miR-34a binding sites were searched 
for within the 5’ 249 nt and another potential site containing a perfect seed sequence was 
identified using TargetScan (Lewis et al., 2003). Transfection of constructs 1-159 and 1-151 
which both lack the seed sequence of the proximal miR-34a target site (Fig. 21B), resulted in 
loss of effect in HEK293 and INS-1 cells. Taken together, it is evident that the proximal and 
distal miR-34a binding site within the 5’ 449 nt are functional and their effect is additive.  
Examination of the entire 3180 nt 3’UTR revealed 13 additional potential miR-34a binding 
sites (Fig. 21C). Overexpression of miR-34a with the long 3’UTR luciferase reporter led to a 
decreased luciferase activity in HEK293 and INS-1 cells similar to the one observed for 
pGL3-CDK6-BS2 reporter construct. It was ruled out that this decrease was based entirely 
on the two identified miR-34a binding sites within the 5’ 449 nt fragment, as a miR-34a 
dependent drop in luciferase activity was measured with a construct (631-3180) lacking the 
5’ sequence. Therefore, several shortened constructs of the HNF4A 3’UTR were tested, 
each containing at least one potential miR-34a binding site. Since the construct 1288-1746 
was affected by miR-34a overexpression, it is assumed that this region contains several 
cooperating miR-34a sites.  
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Figure 21: Reporter analyses of miR-34a binding sites in the HNF4A 3’UTR.  
(A) Reporter plasmids and pri-miR-34a expression plasmids were co-transfected 24 hours before cell 
collection, into HEK293 (upper dark grey columns) and INS-1 cells (lower light grey columns). At least 
one transfection assay was performed for each construct, involving two independent plasmid 
preparations in the case of two or more assays. Each assay was performed in triplicate and a CMV-
driven firefly luciferase was used to control for transfection efficiency. The activity of each construct in 
the absence of pri-miR-34a (replaced by Rc/CMV) was used for standardization (100%) and is not 
shown. pGL3-CDK6-BS2 (Lodygin et al., 2008) and RL-Con served as positive and negative controls, 
respectively. Since pGL3-CDK6-BS2 expresses the firefly luciferase, the RL-Con plasmid was used to 
control for transfection efficiency. The black boxes indicate miR-34a target sites including a perfect 
seed sequence. A grey cross in the black box displays a partially destroyed target site. P values were 
determined using a one-sample t test. Values of HEK293 and INS-1 cells were combined for each 
construct. P values are < 0.05 (*) and < 0.01 (**). (B) Schematic diagram of the two potential miR-34a 
binding sites within the 5’ 449 nt of the HNF4A 3’UTR. The numbering refers to the first nucleotide 
after the stop codon as 1. The distal site located at 239-261 nt was predicted by RNA22 and 
TargetScan and is highly conserved among vertebrates. The proximal site extending from 149-171 nt 
was only predicted by TargetScan and is little conserved. The two perfect seed matches are indicated 
by vertical lines between the HNF4A 3’UTR and miR-34a sequence. The arrows at position 151, 159 
and 249 mark the last nucleotide of the HNF4A 3’UTR in the corresponding constructs.  (C) Analyzing 
miR-34a binding sites in the long HNF4A 3’UTR performed as in panel A. The grey and black boxes 
indicate miR-34a target sites with and without a perfect seed sequence, respectively. The number of 
target sites indicated by a box is given underneath the target site in case of more than one site.  
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D Discussion 
1 Search for proliferation relevant target genes 
regulated by HNF4A 
The transcription factor HNF4A is dysregulated in various diseases such as diabetes and 
cancer. Overexpression of HNF4A2 results in a clear decrease in cell proliferation and 
morphological changes in different tissues in contrast to the HNF4A mutant C106R (Lucas et 
al., 2005; Erdmann et al., 2007; Grigo et al., 2008). These facts together with the finding that 
C106R cannot bind to DNA, but contains the full protein sequence (Taylor et al., 1996), 
suggests that the effects are mediated by target genes transcriptionally regulated by HNF4A. 
Previous microarray analyses identified 1411 potential target genes of HNF4A2 in HEK293 
cells (Grigo et al., 2008). While in microarray experiments differentially expressed genes are 
revealed simultaneously among tens of thousands of genes with relative ease, the challenge 
is to retrieve direct target genes involved in the process of interest. Considering the 
numerous tissues and biological processes HNF4A is involved in (Bolotin et al., 2009), a 
significant amount of the potential 1411 HNF4A2 target genes are likely involved in 
mechanisms other than proliferation control and morphological changes. Selecting genes 
due to ontological analyses is associated with various limitations such as bias toward well 
annotated biological processes (Khatri and Draghici, 2005). To circumvent these issues, an 
expression profile of an HNF4A isoform, such as HNF4A8, with possibly no impact on 
proliferation control was sought for, to narrow down the 1411 HNF4A2 target genes to a 
reasonable number of proliferation relevant genes.  
1.1 Target genes of HNF4A8 which have no impact on cell 
proliferation 
HNF4A8 only differs in the first exon from HNF4A2 due to differential promoter usage and 
hence lacks the activation function AF-1 (Nakhei et al., 1998). Such a difference has been 
shown to be sufficient to cause functional distinction as reported for example for Hnf4a1 
versus Hnf4a7 (Briancon and Weiss, 2006) and is likely based on the distinct capacities of 
AF-1 and AF-2 to interact with cofactors (Wang et al., 1998; Sladek et al., 1999; Eeckhoute 
et al., 2003). In contrast to HNF4A2, it could be shown in the present study that cell lines 
conditionally expressing HNF4A8 have no impact on cell proliferation or morphology in 
HEK293 cells (Fig. 4A). Even though a single copy of the gene-of-interest is supposed to be 
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integrated at a defined locus in the Flp-In system, slight functional differences have been 
observed in the resulting cell lines (Lucas et al., 2005; Grigo et al., 2008). While 
overexpression in the cell line HNF4A8 #9 caused a small decrease in cell proliferation after 
six days of induction with doxycycline, a transient increase was observed for HNF4A8 #11 
and HNF4A8 #14 after three days (Fig. 4A). The same phenomenon was reported for 
HNF4A8 expression in INS-1 cells and seems to be based on an initial increase in metabolic 
activity measured by MTS assay, as no increase in cell number was detected by cell 
counting (Erdmann et al., 2007). In INS-1 cells, overexpression of HNF4A8 reduces cell 
proliferation and changes morphology, although cell reduction has a later onset and is not as 
pronounced as for HNF4A2 and cell morphology changes are distinct (Erdmann et al., 2007). 
Those differences in INS-1 cells, which express endogenous Hnf4a (Huang et al., 2008) in 
contrast to HEK293 cells (Jiang et al., 2003) are likely based on a distinct cofactor 
environment and subsequently on a diverse set of target gene. This assumption of tissue-
specific functioning is supported by a very limited overlap of HNF4A target genes determined 
by microarray analyses in hepatocytes (Naiki et al., 2002), insulinoma cells (Thomas et al., 
2004) and HEK293 cells (Lucas et al., 2005).  
In this study, microarray analyses revealed about 25% of consistently regulated target genes 
in both HNF4A8 #11 and HNF4A8 #14 cell lines (Fig. 5). A limited number of concordantly 
regulated genes of about 30% (Lucas, 2005) and about 50% (Grigo, 2007) has been 
previously observed for two independent HNF4A2 cell lines. Hence, the slight functional 
differences of the independent Flp-In cell lines containing the same GOI seem to be reflected 
by, in part, a distinct set of target genes. The amount of 181 consistently regulated target 
genes by HNF4A8 identified in this study is about eight times smaller than 1411 genes 
regulated by HNF4A2 in HEK293 cells (Grigo et al., 2008). This is in accordance with 
previous findings in INS-1 cells, identifying about three times less target genes for HNF48 in 
comparison to HNF4A2, although the difference is not as pronounced (Erdmann et al., 2007). 
Those data can be explained by the findings that HNF4A8 is a weaker transactivator than 
HNF4A2 due to the lack of AF-1 in the former isoform (Nakhei et al., 1998; Torres-Padilla et 
al., 2002; Eeckhoute et al., 2003; Ihara et al., 2005) and is supported by the identification of 
AF-1 dependent target genes (Briancon and Weiss, 2006). The majority of HNF4A8 target 
genes identified in this study are upregulated (~70%) in HEK293 cells, supporting the 
assumption of HNF4A as a mainly positive regulator due to the following data published 
previously. About 90% (Lucas et al., 2005) and 55% (Grigo et al., 2008) of genes were 
upregulated by HNF4A2 in HEK293 cells. In INS-1 cells about 70% of upregulated genes 
were detected upon HNF4A2 expression (Thomas et al., 2004). Another study using INS-1 
cells detected about 80% and 90% positive regulation for target genes upon HNF4A2 and 
HNF4A8 expression, respectively (Erdmann et al., 2007). Microarray analyses of human 
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hepatoma cells (HuH-7) additionally transfected with rat Hnf4a2 cDNA identified the majority 
of target genes (~90%) to be upregulated as well (Naiki et al., 2002).  
Similar to the 70% overlap of HNF4A8 target genes with HNF4A2 regulated genes in INS-1 
cells (Erdmann et al., 2007), about 60% of genes identified for HNF4A8 in the present study 
were also regulated by HNF4A2 in HEK293 cells (Fig. 5). But in contrast to INS-1 cells, 
where both isoforms cause a decrease in cell proliferation and morphological changes, in 
HEK293 these genes are assumed to have no impact on cell proliferation decrease or 
morphology. However, the elaborate approach to narrow down the number of 1411 potential 
HNF4A2 target genes to a reasonable number of proliferation relevant genes failed to do so 
in this study. Of only 181 target genes identified for HNF4A8, 111 genes were also regulated 
by HNF4A2 and thus deemed not to be relevant for proliferation, still leaving 1300 potential 
HNF4A target genes involved in proliferation control.  
1.2 The multifaceted target gene CIDEB 
Despite the vast amount of potential target genes, CIDEB was analyzed in more detail. Out 
of all tested isoforms and HNF4A mutants it was exclusively upregulated upon HNF4A2 
expression (Fig. 6) which has a strong impact on proliferation decrease. Furthermore, it has 
been shown in HEK293 cells that HNF4A targets the internal CIDEB promoter and enhances 
its activity (Da et al., 2006). CIDEB is a member of the cell death-inducing DNA 
fragmentation factor-α-like effector (CIDE) family that contain an evolutionary conserved 
CIDE-N domain sharing sequence similarity with DNA fragment factor 40/45 (DFF40/45; 
Inohara et al., 1998). Hence, all initial publications described a cell death-inducing activity for 
CIDEB (Inohara et al., 1998; Lugovskoy et al., 1999; Chen et al., 2000; Erdtmann et al., 
2003; Reed et al., 2004). In previous experiments HNF4A2 was ruled out to induce apoptosis 
in HEK293 cells by propidium iodine staining in FACS, annexin staining and measuring 
caspase 3/7 activity (Lucas et al., 2005). This is in contrast to INS-1 cells where 
overexpression of HNF4A induced apoptosis (Erdmann et al., 2007). However, apoptosis 
triggered by Cideb in mammalian cells could not be inhibited by caspase inhibitors, 
suggesting a caspase independent mechanism (Inohara et al., 1998). This potentially 
provides an alternative mechanism via CIDEB causing a decrease in cell number upon 
HNF4A2 expression that would not be contradictory to the lack of HNF4A2 induced 
caspase 3/7 activity in HEK293 cells (Lucas et al., 2005). qRT-PCR validated the HNF4A2  
dependent increase in CIDEB expression in the present study (Fig. 6). This method is known 
to be more sensitive than microarray analysis and thus only qRT-PCR revealed constitutive 
expression of CIDEB in HEK293 cells independent of HNF4A expression. This is in contrast 
to previous data detecting no CIDEB mRNA in HEK293 cells likely due to application of less 
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sensitive northern blot analyses (Inohara et al., 1998). The short 1.3 kb CIDEB transcript that 
is activated by HNF4A is the major transcript and expressed at high levels in adult and fetal 
liver and at lower levels in various tissues including kidney (Inohara et al., 1998; Liang et al., 
2002). However, the primer pair used in this study targeted exon six and thus did not 
differentiate between the short and long transcript.  
RNAi experiments performed in the present study indicated that CIDEB has an impact on the 
HNF4A2 dependent decrease in cell proliferation (Fig. 7). The cost-efficient esiRNA method 
has been shown to be comparable to optimized siRNAs in its silencing effect (Kittler and 
Buchholz, 2003). The advantage lies in the pool of esiRNAs used for one target gene, since 
the individual concentration of each esiRNA is believed to be too low to cause off-target 
effects, but the sum of many esiRNAs targeting the same gene is high enough for efficient 
genet silencing (Kittler et al., 2007; Mathey-Prevot and Perrimon, 2007). Although, in the 
present study, the rescue effect was only partial using HNF4A and CIDEB specific esiRNAs, 
it was highly reproducible even with different sets of esiRNAs. The reliability of this assay is 
supported by a previous report in which only about 20% of selected, upregulated HNF4A2 
target genes showed a highly significant rescue effect (p>0.01) including p21 (CDKN1A) that 
was sufficient to cause a decrease in cell proliferation independent of HNF4A2 expression 
(Grigo et al., 2008).  
 
Flp-In cell lines conditionally expressing Cideb (Fig. 8) confirmed the previously reported 
location of this protein in cytosolic corpuscles (Liang et al., 2002). A more detailed study 
reported that Cideb is localized to the endoplasmic reticulum and lipid droplets (Ye et al., 
2009), while mitochondria localization as well as dimerization seems to be required for 
CIDEB induced apoptosis (Chen et al., 2000). Indeed, the observed corpuscular distribution 
of Cideb in the cytoplasm in the present study could reflect mitochondria location, but no 
signs of apoptosis such a chromatin condensation were observed in the Cideb cell lines upon 
induction (data not shown), in contrast to previous transient transfection studies (Inohara et 
al., 1998; Chen et al., 2000; Liang et al., 2002; Erdtmann et al., 2003). Notably, Cidea, 
initially recognized for its ability to trigger apoptosis just like Cideb (Inohara et al., 1998) does 
not induce cell death in liver of mice (Viswakarma et al., 2007) and no difference in apoptosis 
was observed in brown adipocytes between wild-type and Cidea-deficient mice (Gong et al., 
2009).   
In the present study, overexpression of Cideb in the two cell lines did not decrease cell 
proliferation as observed for HNF4A2, but instead resulted in a small increase after three 
days of induction which diminished after six days (Fig. 9A). This might be due to an initial 
increase in metabolic activity as described for HNF4A8 in INS-1 cells (Erdmann et al., 2007), 
but the cell number was not counted to confirm this hypothesis for Cideb. Possibly, cell line 
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dependent factors are responsible for the insufficiency of to cause a decrease in cell 
proliferation. For example, CIDEB induced apoptosis has been shown to be dose-dependent 
(Inohara et al., 1998; Liang et al., 2002). However, qRT-PCR ruled out that insufficient Cideb 
expression is the limiting factor, since the transgene is expressed more than twice as high as 
the endogenous CIDEB gene upon HNF4A2 expression (Fig. 10). Notably, the RNA level 
does not necessarily correlate with the protein amount due to posttranscriptional regulation. 
Endogenous and exogenous CIDEB protein level could not be compared, as commercially 
available antibodies were not specific enough to detect the protein unambiguously.  
In contrast to the lack of Cideb protein in untreated cells as determined by western blot and 
immunofluorescence analyses using a myc-tag antibody, Cideb RNA was detected by 
qRT-PCR even in uninduced Cideb cells. The two protein specific methods are less sensitive 
than qRT-PCR, although it cannot be ruled out that the RNA is not efficiently translated into 
protein. Obviously, the two Cideb cell lines are leaky, an issue of the Flp-In system which has 
been recently reported (Senkel et al., 2009). If increased expression levels of CIDEB trigger 
apoptosis and the system is leaky, no such cell line could be generated. Possibly the 
established Cideb cells have acquired genetic traits during the selection process to cope with 
elevated Cideb expression levels, which makes them insensitive to increased Cideb 
expression.  
 
Figure 22 summarizes some of the HNF4A dependent effects on cell function mediated by 
targets genes with emphasis on CIDEB as determined in the present and previous studies. 
While HNF4A8 has no impact on cell proliferation in HEK293 cells as demonstrated in this 
study, HNF4A2 mainly activates target genes resulting in a decrease in cell proliferation 
(Grigo et al., 2008). p21 is sufficient to inhibit cell proliferation independent of HNF4A2 
expression. CIDEB, extensively analyzed in this study, only contributes to the proliferation 
decrease in cooperation with other factors within the signal cascade triggered by HNF4A2. 
The same conclusion was already drawn in previous experiments for ANK3, ALDH6A1, 
BPHL, DSC2, EFHD1, EPHX2, NELL2, MME, PROS1, SEPP1, TGFA and THEM2 (Grigo et 
al., 2008). It is noteworthy that SEPP1, NELL2 and even p21 are activated by HNF4A8 to a 
highly similar extent as by HNF4A2. Hence, it is not possible to conclude that all target genes 
of HNF4A8 have no impact on cell proliferation due to the observation that HNF4A8 does not 
influence proliferation. Those findings further corroborate the assumption that not a single 
gene, but the complex interplay of numerous factors determines the overall function. For 
example, p21 was implicated as a target gene of HNF4A2 relevant for proliferation decrease 
(Grigo et al., 2008). Another study revealed a dichotomy between differentiation and 
proliferation due to interactions between Sp1, HNF4A1 and c-Myc proteins and the p21 
promoter (Hwang-Verslues and Sladek, 2008). In the absence of c-Myc, HNF4A1 activates 
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p21 by interaction with Sp1, causing a block in cell cycle and decreased cell proliferation. In 
the presence of c-Myc, activation of p21 by HNF4A1 is reduced due to several mechanism 
such as displacement of HNF4A1 from Sp1, resulting in increased proliferation.    
 
 
 
Figure 22: Impact of HNF4A via target genes such as CIDEB on various cell functions. 
Overexpression of HNF4A2, but not HNF4A8 inhibits cell proliferation in HEK293 cells mediated by 
several target genes. Most target genes including CIDEB are only functional within the HNF4A2 
dependent network, while p21 is sufficient to cause a decrease in cell proliferation. Genes depicted in 
grey were identified previously (Grigo et al., 2008). Genes activated by HNF4A8 as well are indicated 
by an asterix. In the liver, Cideb has been shown to influence metabolic processes (Gong et al., 2009; 
Li et al., 2010).  
 
In accordance with one gene mediating multiple functions under different circumstances, 
CIDE proteins including CIDEA, CIDEB and Fsp27 (CIDEC) have been recently associated 
in the development of metabolic disorders such as diabetes, liver steatosis and obesity. 
Cideb knock-out mice are lean and resistant to diet-induced obesity and liver steatosis. This 
phenotype is caused by increased insulin sensitivity despite lower levels of plasma insulin 
and reduced serum triacylglycerol (TAG) due to decreased hepatic lipogenesis and 
increased fatty acid β-oxidation (Li et al., 2007b; Gong et al., 2009; Fig. 22). Furthermore, a 
recent report observed decreased cholesterol biosynthesis in Cideb knock-out mice that 
showed increased hepatic cholesterol uptake and storage upon high cholersterol diet (Li et 
al., 2010; Fig. 22). The essential function of HNF4A in the liver has been thoroughly 
investigated and includes the regulation of genes involved in the control of lipid homeostasis 
(Li et al., 2000; Hayhurst et al., 2001; Naiki et al., 2005). HNF4A regulates the majority of 
apolipoproteins and is thus assumed to play a role in atherosclerosis (Li et al., 2000; Bolotin 
et al., 2010). Cideb was shown to interact with apoB (Ye et al., 2009) and is suggested to 
contribute to atherosclerosis as well (Li et al., 2010). HNF4A2, which upregulates CIDEB, is 
the main isoform in the adult liver, while expression of HNF4A8, which has no impact on 
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CIDEB expression as shown in this study, is absent (Torres-Padilla et al., 2001). A recent 
report used an integrated approach of genome-wide techniques, in silico predictions and 
functional assays to identify direct target genes of HNF4A and confirmed CIDEB as an 
HNF4A target gene in the liver (Bolotin et al., 2009). Taken together, CIDEB seems to be a 
crucial target gene of P1 specific HNF4A isoforms due to its involvement in proliferation 
control and energy homeostasis in a cell type dependent manner (Fig. 22).   
2 Transcriptional regulation of HNF4A via the P2 and P1 
promoter 
2.1 Impact of mutations in the P2 promoter on gene expression 
An overview of the regulation of HNF4A as determined mainly in this study and its implication 
on diabetes and cancer is given in Figure 23. Transcriptional regulation is mediated by 
transcription factors and miRNAs targeting the HNF4A P2 and P1 promoter, respectively. 
The posttranscriptional control is achieved via binding sites for miRNAs and regulatory 
factors within the two 3’UTRs identified for HNF4A.  
 
 
 
Figure 23: Transcriptional and posttranscriptional regulation of HNF4A.  
Mutations identified within the HNF4A P2 promoter that are linked to diabetes and impair the P2 
promoter activity in vitro as indicated by an arrow pointing downwards, are depicted. P2/-136 and 
P2/-169 were characterized in the present study (Fig. 13). P2/-146 (Thomas et al., 2001), P2/-181 
(Hansen et al., 2002) and P2/-192 (Ek et al., 2006; Raeder et al., 2006a) were reported previously, but 
the latter mutation was shown to reduce promoter activity in this study (Fig. 13). miRNAs potentially 
activate the HNF4A P1 promoter as displayed by an upwards pointing arrow. Downregulation of those 
miRNAs might contribute to the dysregulation of HNF4A in cancer such as RCC. Both 3’UTRs with a 
length of 1724 bp and 3180 bp confer a negative posttranscriptional regulation of HNF4A mediated by 
at least two binding sites for miR-34a and negative element A and B. Downwards pointing arrows 
describe the negative effects of miR-34a and factors targeting negative element A and B on HNF4A 
regulation. Upregulation of miR-34a, as detected in RCC for example or/and other factors likely cause 
downregulation of HNF4A relevant for cancer or diabetes progression. 
 
The families presented in Figure 11 are consistent with HNF4A associated diabetes, 
including either neonatal hypoglycaemia (-136A>G) or increased birth weight (-169C>T). 
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Diabetes was generally adequately controlled by sulphonylurea (SU) or diet alone. Mutations 
affecting the P2 promoter or P2-derived isoforms are typically diagnosed later (median age, 
31 years) compared with mutations that affect all isoforms of HNF4A (median age, 24 years; 
Harries et al., 2008). Most of the P2 promoter mutation carriers presented in this study were 
diagnosed before 25 years of age, suggesting that these mutations are relatively severe or, 
alternatively, this could represent case-finding bias leading to mutation suspicion and testing 
only in younger affected individuals. In contrast, the -192C>G mutation is linked to a later age 
of onset (mean age of diagnosis, 45 years) and few carriers were diagnosed before 25 years 
of age (Ek et al., 2006; Raeder et al., 2006a).  
Both novel HNF4A P2 promoter mutations, -136A>G and -169C>T, decrease the basal 
activity of the promoter in transient transfection assays in HEK293 cells (Fig. 13). Based on 
gene expression profiling, HEK293 cells do not express HNF1A, HNF1B, HNF6 or OC2 
(Lucas et al., 2005), implying that the mutations at -136 and -169 affect the binding of 
additional factors (Fig. 12). In contrast, -192C>G does not affect the basal activity in HEK293 
cells, but decreases the basal activity in INS-1 cells (Fig. 13), supporting previous evidence 
that this mutation affects binding of a cell-specific factor enriched in INS-1 cells (Ek et al., 
2006). All three mutations have decreased activity in the presence of HNF1B compared with 
the wild-type promoter in both kidney and β-cell lines. The -169C>T mutation, affecting the 
consensus sequence of the HNF1 binding site, shows the most marked reduction in activity 
with HNF1B. Since the other mutations are unlikely to affect binding of HNF1B directly, it is 
most likely that the reduced activity with HNF1B reflects a co-operative action of transcription 
factors at the HNF4A P2 promoter. An interplay of various tissue-specific transcription factors 
has also been assumed in previous P2 promoter analyses, since transactivation by CDX-2 is 
reduced for the mutated P2/-146T>C site, although it does not seem to interact directly with it 
(Thomas et al., 2001). In the present study in INS-1 cells, a consistent decrease in promoter 
activity was observed upon HNF1B induction for all of the constructs except 
P2/-285(-169C>T), which has a mutated HNF1 binding site. The decrease in activity is as 
expected, since the HNF1 binding site is recognized by HNF1A and HNF1B, but INS-1 cells 
express more HNF1A than HNF1B (Thomas et al., 2004). Thus endogenous HNF1A is 
outcompeted by the weaker transactivator HNF1B (Ryffel, 2010). A mutation upstream in the 
same HNF1 binding site at position -181G>A has been analyzed in more detail previously 
and revealed a decreased activation due to a reduced affinity for HNF1A (Hansen et al., 
2002). However, regulation by HNF1B was not determined. It is most likely that -169C>T 
affects binding of HNF1A in the same way.  
Previous experiments by two independent groups failed to show an impaired performance of 
the HNF4A P2 promoter mutation -192C>G in transfection assays in the MIN6 cell line and in 
CaCo2 cells (Ek et al., 2006), but also in INS-1 cells (Ek et al., 2006; Raeder et al., 2006a). 
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While promoter variants are known to affect promoter activity in a cell-specific manner as 
reported for the -146T>C mutation that caused a decreased activity in INS-1 cells but not in 
hepatoma cells (FT0-2B; Thomas et al., 2001), the lack of effect in INS-1 cells requires 
another explanation. Possibly, the use of a renilla luciferase construct as an internal control 
in the present experiments may have facilitated the detection of small changes. In addition, it 
is likely that the use of cell lines containing HNF1B as a stably integrated conditional 
transgene mimics the in vivo situation more efficiently.  
The present data establish that three HNF4A P2 promoter point mutations co-segregating 
with diabetes affect highly conserved nucleotide positions and, more importantly, impair the 
function of the mutated promoters in transfected cells. This makes it most likely that these 
mutations cause the diabetic phenotype. Taking into account the -146T>C (Thomas et al., 
2001) and -181G>A mutations (Hansen et al., 2002), there are now five mutations known in 
the P2 promoter that affect the performance of HNF4A in pancreatic β-cells and result in 
diabetes (Fig. 23). 
2.2 Impact of miRNAs on the P2 and P1 promoter 
So far it could only be assumed that binding of miRNAs to promoter regions follows the same 
guidelines as established for miRNAs targeting 3’UTRs, since corresponding data is lacking. 
A recent study examined computational methods for predicting miRNA binding sites within 
promoter sequences and indicates that those regulatory sequences are as good candidates 
for miRNA regulation as 3’UTRs (Younger et al., 2009). On average they identified about 30 
miRNA seed matches per promoter sequence analyzed (-200 to -1 relative to transcription 
start site) and suggest that minimum free energy as well as high complementarity between 
the miRNA and target sequence are useful criteria to prioritize miRNA target predictions 
within promoters, similar as known for 3’UTRs. In silico prediction using the online RegRNA 
software (available at http://regrna.mbc.nctu.edu.tw; Huang et al., 2006) revealed numerous 
potential miRNA binding sites within the HNF4A P2 promoter. Although this software was 
designed to predict regulatory motifs and miRNAs in RNA sequences, it predicted the 
miR-373 binding site within the E-cadherin and CSDC2 promoters. For both promoters the 
activating function was experimentally validated (Place et al., 2008). However, it is not 
possible to upload any miRNA sequences in order to obtain a specific map of potential 
miRNA binding sites for miRNAs of interest within the sequence analyzed. Using RNA22 
(Miranda et al., 2006), various potential binding sites were predicted within the HNF4A 
promoter regions for miRNAs that are downregulated in RCC.  
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An interplay of ubiquitous and cell-specific factors targeting various regulatory elements 
within promoter sequences as well as the chromatin context, regulate the activity of gene 
promoters and influence experimental procedures (Maston et al., 2006). While promoter 
regulation by transcription factors has been studied extensively, knowledge about promoter 
modulation by miRNAs and inevitable experimental limitations are scarce. Certainly, various 
properties for promoter regulation by transcription factors and miRNAs apply to both. In 
accordance with that, the effect of miR-373 on E-cadherin and CSDC2 is cell type specific 
(Place et al., 2008) as described for many transcription factors for example on the HNF4A 
promoters (Bailly et al., 2009). In contrast to transcription factors, small dsRNAs 
complementary to gene promoters have been shown to modulate transcription of target 
genes by recruiting members of the Ago family to RNA transcripts that originate from the 
target promoter in either sense or antisense direction (Janowski et al., 2006; Kim et al., 2006; 
Han et al., 2007; Schwartz et al., 2008). So far it is only assumed that miRNAs might 
regulate gene promoters by targeting such transcripts as well (Kim et al., 2008; Younger et 
al., 2009). In that case, generation of promoter transcripts might be disrupted by introducing 
only parts of the promoter sequences into a reporter plasmid. Induction of gene promoters by 
miR-373 was identified by analyzing the effect of this miRNA on the endogenous target gene 
and not by reporter analyses (Place et al., 2008). However, a recent study claims the 
regulation of the interleukin genes IL24 and IL32 by miR-205 via targeting specific sites in the 
promoter sequences (Majid et al., 2010). Besides demonstrating the miR-205 dependent 
regulation of the endogenous genes, they observed an activating effect of miR-205 on a 
co-transfected vector containing the 2.2 kb IL24 promoter sequence in luciferase assays. 
Hence, it seems to be possible to address miRNA regulation on at least large promoter 
fragments in transient transfection assays. Notably, this experiment was just shown for IL24, 
but not for IL32 and even more importantly, the predicted miR-205 binding sites within the 
promoter sequences were not mutated to confirm the sequence specific effect of miR-205 on 
the IL24 and IL32 promoters. Despite promising data, indirect effects of miR-205 on IL24 and 
IL32 promoter activation cannot be entirely excluded. The experimental limitations might 
explain the lack of research in this field. However, a recent study analyzed conserved short 
sequence (< 8 nt) located within 100 bp up- and downstream of the transcription start site. 
They postulate that the majority of the common sequences are frequently found within 
mature miRNAs and stem-loop sequences (Putta and Mitra, 2010) and hence provide further 
evidence of a possible widespread impact of miRNAs on promoter sequences.  
Due to the high degree of uncertainty in this field, in this study a general approach was 
applied by knocking down Dicer, to evaluate regulation of the two HNF4A promoters by any 
miRNA. Deletion of Dicer decreases or abrogates the production of mature miRNAs 
(Hutvagner et al., 2001; Grishok et al., 2001). Although depletion of the Dicer protein is not 
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complete in the cell line after addition of doxycycline (Schmitter et al., 2006), a significant 
relief of reporter constructs containing binding sites for let-7a in the 3’UTRs (RL-Perf, 
RL-3xBulge) was verified in contrast to RL-Con, lacking any binding site (data not shown). 
This data confirmed the miRNA specific functionality of the assay, but was restricted to 
3’UTR sequences, since positive controls for promoter sequences are lacking.  
The activity measured in this study for the gradually shortened HNF4A P2 and P1 promoter 
fragments in uninduced cells was differential, likely due to interruption of transcription factor 
binding sites as described previously for the P2 promoter (Thomas et al., 2001). However, in 
the current analyses the focus was set only on miRNA regulation by comparing activities 
between cells in the presence and absence of miRNAs for each construct. The decrease in 
activity of the P2 promoter upon Dicer knock-down (Fig. 14A), implies depletion of a miRNA 
functioning as an activator. However, this finding is controversial, since the decrease is not 
significant in comparison to the empty control vector pGL3 basic and is not abolished upon 
gradual deletion of the promoter sequence even up to constructs P2/-135 which essentially 
removes the promoter (transcription start site at -103) and mainly consists of 5’UTR 
sequence (~100 bp). In contrast, the CMV-promoter was not affected by miRNA depletion, 
which suggests a promoter specific effect. However, its activity is several hundred-fold higher 
in comparison to the P2 promoter and small alterations in its activity would thus be lost in 
detection due to the high expression. A potential influence of miRNAs on the P2 promoter 
mutations described in the previous section was not analyzed. Even in case of P2 regulation 
by miRNAs, the present data would indicate that miRNA targeting takes place downstream of 
-135 relative to the translational start site, but the identified P2 promoter mutations were all 
located upstream from this position.   
In general, the P1 promoter was more active than the P2 promoter. The former promoter 
seems to be predominantly active in the embryonic kidney and P1 specific Hnf4a1 was 
detected at a higher level in comparison to Hnf4a7 in murine kidney (Kanazawa et al., 2009). 
Regulation of the P1 promoter by miRNAs as determined in this study seems more likely 
since the effect varies to some extent with different fragments and is significantly reduced in 
comparison to pGL3 basic in case of P1/-1114 and P1/-281 (Fig. 14B). Interestingly, the 
activity of those two constructs in uninduced cells is comparable and higher than for P1/-590 
and P1/-132. However, since no preferential miRNA targeting was observed for any area 
within the 200 bp upstream of the transcription start site of promoters surveyed (Younger et 
al., 2009), any predicted miRNA within the P1/-281 construct (117 bp are 5’UTR sequence) 
is a potential candidate.  
 
Data obtained in this study by specifically mimicking or inhibiting certain miRNAs as 
described in this section is not shown. miR-187, miR-199b-5p and miR-200c are 
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downregulated in RCC according to at least two different studies (Kort et al., 2008; Nakada 
et al., 2008) and were predicted to have 5(2), 8(5) and 3(1) target sites within the sense 
strand of the HNF4A P1/-1114 (P1/-281) promoter as determined by RNA22. The approach 
to specifically inhibit certain miRNAs by using chemically synthesized, single-stranded, 
modified RNAs (Qiagen), was successfully established as inhibiting let-7a resulted in a 
significant increase in luciferase activity for the reporter constructs containing binding sites 
for let-7a in the 3’UTRs (RL-Perf, RL-3xBulge). No changes in activity were observed for 
RL-Con serving as a negative control. However, positive and negative controls specific for 
miRNA promoter analyses were lacking. Inhibiting miR-187, miR-199b-5p and miR-200c did 
result in a pronounced decrease in luciferase activity as expected if abolishing their activating 
effect on the promoter. However, the decreased activity was gradually lost with increasing 
inhibitor concentrations ranging from 50 nM to 250 nM and even turned into an increased 
activity at high concentrations. Notably, the same phenomenon was observed for miR-20a 
which is not predicted to target the P1/-281 promoter fragment and thus seems to be an 
unspecific effect. Mimicking miR-200c, using chemically synthesized, dsRNAs from Qiagen 
at concentration ranging from 1 nM to 100 nM had no effect on P1/-281 expression. 
Generating and transfecting a pre-miR-200c expression plasmid, the decrease on the 
validated pMIR-REPORT vector containing parts of the zinc-finger E-box binding homeobox 
1 (ZEB1) 3’UTR could be reproduced (Burk et al., 2008). One of the three potential miR-200c 
binding sites located upstream of position -281 in the P1 promoter exhibits high 
complementarity to the miRNA sequence including just four mismatches. Since high 
complementarity has been suggested to be a promising criteria for miRNA binding sites 
within promoter sequences (Younger et al., 2009), the effect of the pre-miR-200c expression 
plasmid was also tested on the P1/-590 and P1/-1114 constructs. For all three P1 promoter 
constructs a decrease in luciferase activity was observed, disagreeing with an activating 
function of miR-200c on the HNF4A P1 promoter. Taken together, the attempt to specifically 
inhibit or mimic certain miRNAs potentially targeting the HNF4A promoter failed due to 
ambiguous results under different conditions and the lack of reliable controls. 
 
Taken together, a tumor-suppressive role has been suggested for P1 driven HNF4A 
(Lazarevich et al., 2004; Lucas et al., 2005; Tanaka et al., 2006; Niehof and Borlak, 2008). 
Cancer dependent downregulation of specific miRNAs usually targeting and activating the 
HNF4A P1 promoter as indicated in Figure 23, potentially decreases HNF4A expression and 
thus contributes to the progression of certain cancers. This hypothesis would explain why so 
far no mutations in the ORF have been identified causing the downregulation of HNF4A 
function in RCC (Lausen et al., 2000; Dalgliesh et al., 2010). Such a mechanism has most 
recently been described involving loss of transcriptional activation of the interleukin tumor 
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suppressor genes IL24 and IL32 in prostate cancer due to silencing of miR-205 targeting 
specific sites in their promoter sequences (Majid et al., 2010). 
3 Posttranscriptional regulation of HNF4A via 3’UTRs  
In addition to HNF4A gene regulation involving complex networks of cis-acting elements and 
trans-acting factors that work on the transcriptional level, Figure 23 summarizes the negative 
posttranscriptional regulation via two HNF4A 3’UTRs mediated by cis-elements targeted by 
miRNAs and other regulatory factors as determined in this study. Whereas on the 
transcriptional level promoter and enhancer elements with their corresponding DNA binding 
proteins have been well characterized (Mitchell and Tjian, 1989; Kadonaga, 2004), 
posttranscriptional control involving the 3’UTR of mRNAs has been largely neglected. This 
ignorance is quite surprising, as in many cases the 3’UTR of a given mRNA exceeds the 
length of the ORF substantially (Mignone et al., 2002) as exemplified also by HNF4A 
(Fig. 15A). Furthermore, only 39 motifs recognized by RNA-binding proteins are deposited in 
the database UTRdb (Grillo et al., 2009), whereas 457 transcription factor binding sites are 
available in JASPAR 2010 (Portales-Casamar et al., 2010).  
3.1 Posttranscriptional regulation by RNA-binding proteins 
Investigating the 3’UTR of human HNF4A for its regulatory potential, a non-canonical and 
canonical PAS was detected leading to a short (1.7 kb) and long (3.2 kb) 3’UTR, respectively 
(Fig. 15A). About 29% of mRNAs contain more than one PAS and the distal PAS tend to be 
canonical signals (Beaudoing et al., 2000). Using in silico predictions (Tab. 1) only the highly 
conserved, distal PAS was identified. In accordance with data showing that non-canonical 
signals are processed less efficiently than the canonical PAS (Beaudoing et al., 2000), the 
long 3’UTR is generated predominantly in HEPG2 and HK120 cells (Fig. 15B). 
In the present study, a systematic analysis of both 3’UTRs by reporter assays, significantly 
reduced luciferase reporter activity in HEK293 and INS-1 cells (Fig. 16), as described for 
other 3’UTRs in previous studies (Cok and Morrison, 2001; Mawji et al., 2004; Johnson et al., 
2005; Moncini et al., 2007; Sun et al., 2010). Only few potential cis-acting elements could be 
identified in the HNF4A 3’UTR by in silico studies (Tab. 1). The SXL-binding site is targeted 
by a sex-lethal (SXL) female-specific RNA-binding protein identified in Drosophila 
melanogaster (Kelley et al., 1995). In addition to its function, it is not likely to impact the 
HNF4A 3’UTR since no significant difference was observed between constructs 2574-3180 
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including the element and 2771-3180 lacking it. A K-box element was predicted at the 3’ end 
of the HNF4A 3’UTR (2940-2947). Constructs comprising this area show the highest 
luciferase activity of all constructs tested in HEK293 cells and also higher activities than the 
majorities of constructs in INS-1 cells (Fig. 16), but K-box is described to mediate negative 
regulation (Lai et al., 1998). Furthermore, this element was found to be complementary to the 
5’ end of many miRNAs (Lai, 2002). In Dicer knock-down experiments, construct 2574-3180 
including the potential K-box element showed no sign of regulation by miRNAs (Fig. 19). 
Taken together, it is very unlikely that the K-box element is functional in HNF4A. Using the 
UCSC browser, two elements named MIRb and MIRc were located right within sequence A 
and B, respectively (Fig. 17). However, those elements were not conserved in the mouse 
sequence, did not decrease luciferase activity as reported for sequence A and B and are 
thus unlikely to function as destabilizing elements. Instead, by deletion analyses, the two 
novel elements A and B were identified, conferring the highest repressive effect in both cell 
lines (Fig. 17). The Musashi binding element located within negative element A (910-914) 
might be functional, but is unlikely to be a crucial element, since the large size of negative 
element A cannot be restricted on either side without diminishing the effect (Fig. 17). Taken 
together, none of the predicted regulatory elements seems to be essential for 
posttranscriptional regulation of HNF4A, at least under the present physiological conditions, 
but instead several elements such as negative element A and B and the proximal, non-
canonical PAS are functional, but were not identified by in silico predictions. Those findings 
point out the need for more accurate prediction programs and also the importance of 
functional assays. To exclude that transcriptional elements located in the 3’UTR interfere in 
the assay, elements A and B were shown to act on RNA level, as the antisense sequences 
are not functional and a SV40 transcriptional stop codon upstream of the element destroys 
their function (Fig. 18). The size of elements A and B (~400 nt) is much larger than a binding 
site of a RNA-binding protein or a miRNA. The single-stranded RNA likely adopts a 
secondary structure possibly associated with RNA-binding proteins. Such elements have 
been found for instance in the 3’UTRs of the Vg1 mRNA (Gautreau et al., 1997) and bicoid 
mRNA (Seeger and Kaufman, 1990; Macdonald, 1990), where they are involved in the 
cytoplasmic localization of the mRNA.  
The pronounced negative effect of element A and B is masked within the HNF4A 3’UTRs 
due to an element located within the 5’ sequence 1-630 nt (Fig. 18). Depending on the level 
of transacting proteins that potentially target these distinct elements, the regulation of HNF4A 
via its 3’UTR could be altered. A similar complex regulation mediated by several, distinct 
functioning 3’UTR elements has also been described in Cox-2 (Cok and Morrison, 2001) 
Endothelin-1 (Mawji et al., 2004) and CDK5R1 (Moncini et al., 2007) mRNAs. Interestingly, 
an interaction of two quite large elements (~100 bp and ~300 bp) separated by about 2 kb 
Discussion 
 
87
within the insulin-like growth factor II (IGF-II) 3’UTR has been described. Specific parts of the 
two elements can form a stable stem structure that is involved in the formation of RNA-
protein complexes. Those complexes are dependent on growth conditions and regulate 
IGF II mRNA levels involving endonucleolytic cleavage of the mRNA within downstream 
element II (Scheper et al., 1995; Scheper et al., 1996). It is conceivable that such direct 
or/and indirect interactions through a bridging ribonucleoprotein complex between different 
elements of the HNF4A 3’UTR take place as well. However, due to the very limited number 
of studies addressing the comprehensive interactions of different parts of the 3’UTR, the 
majority of phenomena observed are not clearly understood and a distinct biological function 
remains elusive. Further complexity has been revealed recently by identifying interplays 
between RNA-binding proteins and miRNAs. Binding of those proteins to mRNAs has been 
shown to facilitate or counteract miRNA function on 3’UTRs which is in part dependent on 
the mRNA or cellular context (Krol et al., 2010).  
3.2 Posttranscriptional regulation by miRNAs 
Although several target prediction algorithms are available, the majority of programs such as 
miRanda (John et al., 2004), PicTar (Krek et al., 2005) and TargetScan (Lewis et al., 2003), 
analyze the 3’UTRs and miRNAs contained in their databases. Since the 3180 nt HNF4A 
3’UTR is not included, the program RNA22 was used, which allows for the analyses of 
3’UTRs and miRNAs of interest. Furthermore, this program does not rely on cross species 
site conservation or a perfect seed sequence, but allows for GU pairing (Miranda et al., 
2006). The former two parameters have been shown not to be essential for functional miRNA 
binding sites, while GU pairing is tolerated (Grimson et al., 2007; Baek et al., 2008; Hammell 
et al., 2008; Chi et al., 2009; Wu et al., 2010). Due to the less stringent criteria of RNA22, too 
many potential miRNA targets were found in the HNF4A 3’UTR. Therefore, the analysis was 
restricted to the 20 miRNAs upregulated in RCC (Tab. 2), predicting 140 potential miRNA 
binding sites within the long HNF4A 3’UTR. The false-positive rate of target prediction is 
quite high (Bentwich, 2005; Rajewsky, 2006; Jiang et al., 2009; Wu et al., 2010) and 
therefore potential target sites can only be used as a guide (Sethupathy and Collins, 2008). 
In a recent study for example, out of a pool of 266 miRNAs predicted to target the p21 3’UTR 
by four different prediction programs including TargetScan, PicTar, miRanda and RNA22, 
only 28 miRNAs significantly reduced luciferase activity (Wu et al., 2010). To locate the area 
of crucial miRNA binding within the HNF4A 3’UTR in the present study a HEK293 cell line 
with a conditional Dicer knock-down (Schmitter et al., 2006) was used. Potential miRNA 
targets could be located within the 5’ 449 nt of the HNF4A 3’UTR with a high probability for 
sequence 204-449, since the significant increase upon miRNA depletion was lost for 
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constructs containing 5’ 196 or less nucleotides (Fig. 19). In accordance with findings 
describing the effects of miRNAs on proteins as quite modest (Baek et al., 2008; Selbach et 
al., 2008), derepression upon Dicer knock-down was moderate for the HNF4A 3’UTR, but 
significant. Dicer knock-down is quite elegant and attractive, but it reveals only targets of 
miRNAs present in HEK293 cells and those that are dependent on Dicer (Cifuentes et al., 
2010). In addition, cell death upon long term Dicer knock-down may lead to secondary 
effects. Thus, complementary experiments measuring the effect of specific miRNAs were 
needed.  
 
Regulation of the HNF4A 3’UTR by miR-122 as presented in Figure 20A was excluded, since 
the luciferase activity for HNF4A 3’UTR constructs was not significantly reduced in 
comparison to RL-Con, upon expression of miR-122. The decrease in luciferase activity for 
RL-Con upon miR-122 expression, confirms the importance of including such controls in 
miRNA dependent luciferase assays. miR-122 makes up 70% of all miRNAs in the adult liver 
(Lagos-Quintana et al., 2002; Chang et al., 2004) and has been identified as a significant 
regulator of hepatic lipid metabolism (Esau et al., 2006). mRNAs showed differential 
sensitivities to miR-122 levels and the degree of target mRNA modulation was at the most 
3.5-fold (Esau et al., 2006). The importance of the stoichiometry of target to miR-122 was 
already noted previously (Chang et al., 2004). The reporter expression level had to be 
lowered to observe an effect which then increased with rising levels of miR-122. HNF4A is an 
essential gene in the liver and expressed at a high level (Hayhurst et al., 2001). If HNF4A is 
regulated by miR-122 in the liver, it is likely that HNF4A is only responsive to very high 
miR-122 expression levels. miR-122 is highly overexpressed in RCC (~28-fold). Possibly, the 
level of miR-122 expression reached in the present study was not sufficient to cause an 
effect, considering that miR-122 expression is absent in HEK293 cells (Tab. 2). In a recent 
report Seitz suggested that many predicted miRNA binding sites do not function to repress 
their targets, but are pseudotargets that sequester a miRNA to prevent it binding to the 
authentic target (Seitz, 2009). Potentially HNF4A functions as such a “sponge“ for miR-122 in 
the liver.  
In the present study, miR-21 had a minor, but significant effect on the HNF4A 3’UTR which 
was dependent on several binding sites (Fig. 20B). HNF4A might not be responsive to 
increased, exogenous miR-21 expression levels due to the moderate miR-21 expression in 
HEK293 cells, which might be sufficient for HNF4A regulation. In that case a different 
threshold applies to TPM1 since miR-21 overexpression resulted in a clear decrease in 
luciferase activity (Fig. 20B). However, synergy of miRNA action has been described in 
previous reports (Doench et al., 2003; Chang et al., 2004; Grimson et al., 2007) and 
simultaneous repression of an mRNA by different miRNA species was shown to be additive 
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(Doench and Sharp, 2004). Possibly, miR-21 additionally requires other miRNAs for 
regulating the HNF4A 3’UTR efficiently. miR-21 is a ubiquitious, very well-studied miRNA 
(Krichevsky and Gabriely, 2009). It is one of the most abundant miRNAs in a large variety of 
cancers analyzed, including high expression in most cancer cell lines of various origins, but 
miR-21 is also upregulated in other human proliferative disorders. The oncogenic role is 
supported by several experiments overexpressing and inhibiting miR-21, resulting for 
example in enhanced and decreased cell proliferation, migration and invasion in cultured 
human hepatocellular cancer cells, respectively (Meng et al., 2007). In this specific case, the 
tumor suppressor phosphatase and tensin homolog (PTEN) was identified as a target of 
miR-21 by luciferase assays and contributed to some of the miR-21 effects. Other studies 
confirmed the miR-21 dependent regulation of PTEN in vitro and in vivo by using miR-21 
specific mimics, inhibitors and expression plasmids as analyzed by western blot analyses 
and in part by luciferase assays (Zhang et al., 2009; Roy et al., 2009). The predicted miR-21 
binding site within the PTEN 3’UTR does not contain a perfect seed sequence (Zhang et al., 
2009). Although this miR-21 site was not mutated to confirm the site specific regulation, the 
amount of data by different studies makes the functionality of this seedless miR-21 site quite 
likely. Another gene that is regulated by miR-21 via a seedless target site is RASGRP1 
(Wickramasinghe et al., 2009). The predicted miR-21 site was not mutated either, but the 
luciferase construct contained only the miR-21 site from the RASGRP1 3’UTR and five 
additional nucleotides on each site. Inhibition of miR-21 in MCF-7 cells resulted in increased 
luciferase activity for the RASGRP1 construct. Interestingly, miR-21 regulation of PTEN is 
cell-specific, as it was also detected in a colon cancer cell line (Asangani et al., 2008) and 
vascular smooth muscle cells (VSMCs; Ji et al., 2007), but not in MCF-7 breast cancer 
(Frankel et al., 2008), A549 non-small cell lung cells (Blower et al., 2008) or glioma cells 
(Gabriely et al., 2008). This data provides further evidence, that strong HNF4A regulation by 
miR-21 might require additional factors that are lacking in HEK293 cells. In addition to RCC 
(Tab. 2), miR-21 has been shown to be upregulated in human kidney disease of various 
causes (Saal and Harvey, 2009). In cultured podocytes and tubular epithelial cells apoptosis 
was inhibited by miR-21, while inhibition of miR-21 in TGF-β1 transgenic mice enhanced 
apoptosis in podocytes. Hence, miR-21 is suggested to have a protective role in diabetic 
nephropathy. Proinflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor 
(TNF)-α, cause defective insulin secretion and apoptosis of pancreatic β-cells and hence 
play a role in diabetes development (Donath et al., 2008). miR-21 expression is induced by 
IL-1β and TNF-α in MIN6 cells and human pancreatic islets and elevated miR-21 expression 
levels were also detected in islets of NOD mice, a well-established type 1 diabetes model 
(Giarratana et al., 2007), during development of pre-diabetic insulitis (Roggli et al., 2010). It 
was further shown that inhibiting miR-21 prevented the decrease in glucose-induced insulin 
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secretion triggered by IL-1β. Interestingly, miR-34a was associated with β-cell failure in the 
same fashion (Roggli et al., 2010). Possibly, miR-34a and miR-21 act synergistically to 
regulate the HNF4A 3’UTR, which might play a role in diabetes and cancer. 
In the present study, miR-34a overexpression experiments validated two bindings sites 
including perfect seed sequences within the 5’ 449 nt of the HNF4A 3’UTR as determined in 
HEK293 and INS-1 cells (Fig. 21A). A significant decrease in luciferase activity was also 
observed in HK120 cells for the 5’ 449 nt upon expression of miR-34a (data not shown), 
hence confirming the miR-34a dependent regulation of HNF4A in three different cell lines. 
Although the proximal miR-34a binding site is still present in the construct including the 
5’ 196 nt, the luciferase activity was not significantly reduced upon miR-34a overexpression. 
The accessibility of a target site influenced by flanking sequences and specific RNA- or 
protein-based cofactors seem to be major determinants of 3’UTR responsiveness to a 
miRNA (Bartel, 2009; Sun et al., 2010). Possibly, sequences downstream of the miR-34a site 
at position 149-171 nt that are necessary for miRNA binding and function were deleted in 
construct 1-196 nt or changes in the secondary structure resulted in loss of site accessibility. 
Deleting the 5’ sequence including the two miR-34a sites in construct 631-3180 resulted in 
no significant changes in the Dicer knock-down experiments in which all miRNAs are 
depleted (Fig. 19). This likely reflects the complex regulation of HNF4A by an interaction of 
various miRNAs. Hence, Dicer knock-down experiments seem to be useful to locate areas of 
extensive miRNA regulation, but not for a detailed analysis of specific miRNA binding sites. 
Both miR-34a sites located within the 5’ 449 nt contributed equally to repression, a 
characteristic of independent and noncooperative action termed multiplicative effect 
(Grimson et al., 2007; Fig. 21A). Recently, miR-34a regulation of the HNF4A mRNA has 
been reported independently in HepG2 cells (Takagi et al., 2010). The present data extends 
this report that described only the distal miR-34a binding site of the 3’UTR to be involved in 
repression of HNF4A. A recent paper by Sun and colleagues described that the repression of 
the RhoB 3’UTR by miR-223 varied with the reporter construct used, including either just the 
miRNA binding site, long fragments or the entire 3’UTR (Sun et al., 2010). Hence, it is 
important to validate miRNA function in different constructs including the full-length 3’UTR 
sequence to substantiate that this target site is functional in vivo. In the present study, 
miR-34a dependent repression of the long 3180 nt HNF4A 3’UTR was verified and by 
applying the assay in a renal and pancreatic cell type (Fig. 21C), miR-34a function was 
established in distinct cofactor environments. Since the remaining 13 potential miR-34a 
binding sites were functioning within construct 631-3180 nt and three even in construct 
1288-1746, multiple control elements in the 3’UTR of HNF4A are deduced that are targeted 
by miR-34a. This is further supported by the recent finding of a miR-34a target site within the 
ORF of HNF4A (Takagi et al., 2010).  
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miR-34a has primarily been characterized as a tumor suppressor, as it is inactivated in 
several tumors and transcriptionally activated by p53. In addition, ectopic miR-34a 
expression induces apoptosis, cell cycle arrest or senescence (Medina and Slack, 2008; 
Hermeking, 2010). In contrast, miR-34a is upregulated in RCC (Tab. 2), hepatocellular 
carcinoma (Pineau et al., 2010), breast cancer (Iorio et al., 2005), squamous cell lung 
carcinoma (Gao et al., 2010) and in chronic lymphocytic leukemia (Asslaber et al., 2010). 
Thus, it appears that mir-34a acts as a tumor suppressor or an oncogene, depending on the 
cell type specific targets and regulatory mechanisms. This observation has been established 
for several other miRNAs (Spizzo et al., 2009). In fact, miR-34a was clearly increased in 
stress induced renal carcinogenesis of the rat and inhibition of miR-34a significantly 
decreased cell proliferation in a rat RCC cell line, but also in HeLa and MCF-7 cells (Dutta et 
al., 2007). Furthermore, the oncogenic potential of miR-34a was implied by its upregulation in 
RCC and the correlated decrease of the tumor suppressor SFRP1 whose loss has been 
observed in a majority of RCC (Liu et al., 2010). Noteworthy, functional assays were not 
applied to validate the regulation of SFRP1 by miR-34a experimentally. An experimental link 
of miR-34a and endogenous HNF4A mRNA has been verified in HepG2 cells where 
overexpression decreased HNF4A mRNA (Takagi et al., 2010). Therefore, it can be 
speculated that the upregulation of miR-34a potentially causes the downregulation of HNF4A 
in RCC (Fig. 23), resulting in increased cell proliferation through misregulation of at least 14 
HNF4A target genes involved in proliferation control (Grigo et al., 2008).  
Although few miRNA expression profiles have been performed, for example in murine 
pancreas (Baroukh et al., 2007) and MIN6 cells (Lovis et al., 2008; Tang et al., 2009) under 
different conditions, no profiles from human β-cells exist that might shed some light on the 
contribution of miRNAs to diabetes development. However, elevated levels of plasma free 
fatty acid are believed to be a predisposing factor for the development of T2DM (Prentki and 
Nolan, 2006). Interestingly, miR-34a was increased in the mouse β-cell line MIN6B1 and 
pancreatic islets of rats upon prolonged treatment with palmitate. miR-34a levels were also 
elevated in the islets of diabetic db/db mice and overexpression of miR-34a decreased 
glucose-stimulated insulin secretion (Lovis et al., 2008). In addition, miR-34a was the most 
upregulated miRNA in livers of streptozotocin-induced type 1 diabetic mice and ob/ob mice 
(model of nonalcoholic fatty liver disease (NAFLD) and hyperglycemia) and is suggested to 
be linked to the regulation of glucose metabolism (Li et al., 2009). In a recent report, the 
impact of miR-34a on β-cell failure caused by proinflammatory cytokines was identified in 
MIN6 cells, human pancreatic islets and islets of NOD mice during development of pre-
diabetic insulitis as mentioned above (Roggli et al., 2010). In the present study 
overexpression of miR-34a in INS-1 cells resulted in a negative regulation of the HNF4A 
3’UTR mediated by several sites (Fig. 21). In view of the above mentioned observations, this 
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interaction might contribute to the downregulation of HNF4A linked to type II diabetes 
(Silander et al., 2004; Love-Gregory and Permutt, 2007) and MODY1 (Ryffel, 2001; Gupta 
and Kaestner, 2004; Fig. 23). 
 
Considering the remarkable lengths of the two HNF4A 3’UTRs, other miRNAs likely regulate 
HNF4A. The impact of miR-20a, miR-210 and miR-361-5p on the full-length HNF4A 3’UTR 
as well as shortened constructs was tested using mimics and/or inhibitors (Qiagen), but no 
consistent effects were determined (data not shown). Established target sites were 
introduced into reporter plasmids as positive controls. However, even those positive controls 
were not or only slightly affected by mimicking or inhibiting the corresponding miRNA. One 
explanation might be the lack of sequence surrounding the target site in vivo. The studies in 
which the miRNA binding sites were confirmed used larger 3’UTR fragments. Possibly, 
optimal experimental conditions were failed to achieve as well. Interestingly, pronounced 
effects were obtained for reporter constructs containing target sites completely 
complementary to the entire length of the miRNA for miR-20a, miR-34a and miR-122. 
Furthermore, using mimics (Qiagen, Dharmacon) for miR-34a, decreases in luciferase 
activity were absent or much less pronounced than the ones determined with the miR-34a 
expression plasmid (Fig. 21A, C). A recent study revealed the importance of pre-miRNAs on 
miRNA function, as the pre-miRNA loop nucleotides were responsible for distinct activities of 
miR-181a-1 and miR-181c that only differ in one nucleotide in the mature sequence (Liu et 
al., 2008). Considering the complex regulation of miRNA processing, an influence on the 
function of mature miRNAs is not surprising (Krol et al., 2010). Hence, the method applied to 
mimic or inhibit miRNAs seems to highly influence the outcome of the experiment. In the 
present study the use of primary-miRNA expression plasmids produced more consistent 
results.  
 
In conclusion the experiments show that HNF4A is not only regulated on the transcriptional 
level via its P1 (Hatzis et al., 2006) and P2 (Wirsing et al., 2010) promoters and the enhancer 
(Hatzis et al., 2006), but also on the posttranscriptional level via its two 3’UTRs. Regulation 
of HNF4A expression inevitable influences the numerous target genes and their functions.  
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E Summary 
HNF4A is a susceptibility gene for diabetes and is considered a tumor suppressor in certain 
cancers including RCC. Although several different HNF4A mutations have been linked to 
diabetes, in the majority of cases including RCC the reason for HNF4A dysregulation is 
unknown. In this study, regulation of proliferation relevant target genes of this transcription 
factor as well as transcriptional and posttranscriptional mechanisms that regulate the 
expression of HNF4A itself were investigated with the intention to illuminate how disruption of 
those processes could impact on diabetes and RCC.  
An inducible HNF4A8 expression cell line was established, which in contrast to HNF4A2 has 
no impact on cell proliferation decrease and morphology. To deduce proliferation relevant 
genes from the 1411 potential HNF4A2 target genes identified previously, an HNF4A8 
dependent microarray was performed. 111 from only 191 HNF4A8 target genes deemed to 
be irrelevant for proliferation control were also controlled by HNF4A2 and excluded, leaving 
1300 potential HNF4A2 target genes. qRT-PCR validated that the apoptosis and metabolism 
gene CIDEB is highly upregulated by HNF4A2 in contrast to HNF4A8 and HNF4A mutants. 
The impact of CIDEB on proliferation control was reasoned to be dependent on a network 
triggered by HNF4A2 as determined by RNAi and Cideb inducible cell lines.  
The two novel mutations -136A>G and -169C>T identified in the P2 promoter of patients with 
symptoms of HNF4A monogenic β-cell diabetes together with a previously reported -192C>G 
promoter mutation linked to late-onset diabetes in several families, were shown to impair the 
function of the HNF4A P2 promoter in vitro using a luciferase reporter assay system. 
Furthermore, evidence of miRNAs enhancing gene expression by targeting the HNF4A P1 
promoter was provided by Dicer dependent luciferase reporter assays.  
To elucidate the so far unrecognized posttranscriptional regulation of HNF4A, the predicted 
1.7 kb HNF4A 3’UTR was validated and an additional 3.2 kb long, predominantly used 3’UTR 
was identified. Both 3’UTRs conferred a repressive effect in HEK293 and INS-1 cells, which 
was even more pronounced in two distinct, previously unknown elements of about 400 nt 
located within the 3’UTR as determined by luciferase assays. These negative elements A 
and B were counteracted by an element located within the 5’ 630 nt. Dicer knock-down 
reporter assays inferred negative regulation of the 3’UTRs by miRNAs. More detailed 
overexpression experiments of selected miRNAs upregulated in RCC revealed a modest 
effect of miR-21 dependent on several sites within the HNF4A 3’UTR. miR-34a negatively 
regulated HNF4A by targeting at least two sites located at the 5’ end of both 3’UTRs.  
In conclusion, dysfunction of transcriptional and posttranscriptional regulation of the two 
promoters and 3’UTRs of HNF4A, respectively, mediated by proteins and miRNAs, alters the 
HNF4A dependent network cascade and likely contributes to the development and/or 
progression of diabetes and RCC.  
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